<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     aethlon_10k-033121.htm     <description>      ANNUAL REPORT      <text>       <title>       </title>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-size: 8pt">         <a href="#toc">          Table of Contents         </a>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        UNITED STATES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        SECURITIES AND EXCHANGE COMMISSION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        WASHINGTON, D.C. 20549       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        FORM 10-K       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (MARK ONE)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        ☒     ANNUAL REPORTPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the fiscal year ended March 31, 2021       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        OR       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        ☐     TRANSITION REPORTPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the transition period from ________ to __________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        COMMISSION FILE NUMBER 001-37487       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         AETHLON MEDICAL, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Exact name of registrant as specified in its charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NEVADA           </font>          </td>          <td style="width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13-3632859           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (State or other jurisdiction of           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (I.R.S. Employer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            incorporation or organization)           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Identification No.)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9635 Granite Ridge Drive, Suite 100           </font>          </td>          <td style="width: 50%">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            San Diego, California           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            92123           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Address of principal executive office)           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Zip Code)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        REGISTRANT’S TELEPHONE NUMBER, INCLUDINGAREA CODE: (858) 459-7800       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        SECURITIES REGISTERED PURSUANT TO SECTION 12(b)OF THE EXCHANGE ACT:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 40%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <u>             TITLE OF EACH CLASS            </u>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            COMMON STOCK, $.001 PAR VALUE           </p>          </td>          <td style="width: 20%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <u>             TRADING SYMBOL            </u>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            AEMD           </p>          </td>          <td style="width: 40%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <u>             NAME OF EACH EXCHANGE ON WHICH REGISTERED            </u>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            NASDAQ CAPITAL MARKET           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        SECURITIES REGISTERED UNDER SECTION 12(g) OF THEEXCHANGE ACT:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        NONE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (TITLE OF CLASS)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act. Yes ☐ No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark if the registrant is not required to file reportspursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registrant(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days. Yes ☒  No ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registranthas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒  No ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registrantis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”,and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 20%">          </td>          <td style="width: 42%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large acceleratedfiler  ☐           </font>          </td>          <td style="width: 38%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acceleratedfiler  ☐           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated filer  ☒           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller reporting company ☒           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth company ☐           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the Exchange Act. ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registranthas filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financialreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report. ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Indicate by check mark whether the registrant is a shell company (asdefined in Rule 12b-2 of the Act). Yes ☐  No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate market value of the common stockheld by non-affiliates of the registrant as of September 30, 2020 was approximately $16.2 million, computed by reference to the closingsale price of the common stock of $1.35 per share on the Nasdaq Capital Market on September 30, 2020. Shares of common stock held by eachexecutive officer and director and by each person who owns 10% or more of the outstanding common stock have been excluded in that suchpersons may be deemed to be affiliates. The determination of affiliate status is not necessarily a conclusive determination for otherpurposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The number of shares of the common stock of the registrant outstandingas of June 21, 2021 was 15,365,490.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         DOCUMENTS INCORPORATED BY REFERENCE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Portions of the registrant’s proxy statementto be filed with the Securities and Exchange Commission, or SEC, pursuant to Regulation 14A in connection with the registrant’s2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III ofthis annual report on Form 10-K. Such proxy statement will be filed with the SEC not later than 120 days following the end of the registrant’sfiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="toc">        </a>        TABLE OF CONTENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PAGE           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="7" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k1">             PART I.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="width: 10%">          </td>          <td style="width: 1%">          </td>          <td style="width: 85%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: right">          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1.           </font>          </td>          <td>          </td>          <td>           <a href="#k2">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Description of Business            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1A.           </font>          </td>          <td>          </td>          <td>           <a href="#k3">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Risk Factors            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            16           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 1B.           </font>          </td>          <td>          </td>          <td>           <a href="#k4">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Unresolved Staff Comments            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            43           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 2.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k5">             Properties            </a>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            43           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 3.           </font>          </td>          <td>          </td>          <td>           <a href="#k6">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Legal Proceedings            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            43           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 4.           </font>          </td>          <td>          </td>          <td>           <a href="#k7">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Mine Safety Disclosures            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            43           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="7" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k8">             PART II.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 5.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k9">             Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </a>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            44           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 6.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k10">             Selected Financial Data            </a>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            44           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 7.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k11">             Management’s Discussion and Analysis of Financial Condition and Results of Operations            </a>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            44           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 7A           </font>          </td>          <td>          </td>          <td>           <a href="#k12">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Quantitative and Qualitative Disclosures about Market Risk            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 8.           </font>          </td>          <td>          </td>          <td>           <a href="#k13">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Financial Statements             <font style="color: blue">              <u>               and Supplementary Data              </u>             </font>            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9.           </font>          </td>          <td>          </td>          <td>           <a href="#k14">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Changes in and Disagreements with Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9A.           </font>          </td>          <td>          </td>          <td>           <a href="#k15">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Controls and Procedures            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 9B.           </font>          </td>          <td>          </td>          <td>           <a href="#k16">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Other Information            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            56           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="7" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k17">             PART III.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 10.           </font>          </td>          <td>          </td>          <td>           <a href="#k18">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Directors, Executive Officers and Corporate Governance            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 11.           </font>          </td>          <td>          </td>          <td>           <a href="#k19">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Executive Compensation            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 12.           </font>          </td>          <td>          </td>          <td>           <a href="#k20">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 13.           </font>          </td>          <td>          </td>          <td>           <a href="#k21">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certain Relationships and Related Transactions and Director Independence            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 14.           </font>          </td>          <td>          </td>          <td>           <a href="#k22">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Principal Accounting Fees and Services            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="7" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#k23">             PART IV.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 15.           </font>          </td>          <td>          </td>          <td>           <a href="#k24">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Exhibits and Financial Statement Schedules            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Item 16.           </font>          </td>          <td>          </td>          <td>           <a href="#k25">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Form 10-K Summary            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="3">           <font style="font: 10pt Times New Roman, Times, Serif">            <a href="#k26">             Signatures            </a>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            63           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="3">           <font style="font: 10pt Times New Roman, Times, Serif">            Certifications           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 2 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->            i            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k1">        </a>        <b>         PART I        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This Annual Report on Form10-K, or Form 10-K, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, whichare subject to the safe harbor created by those sections.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may, in some cases, usewords such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”“would” or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identifythese forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-lookingstatements and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, bytheir nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements containedin this Form 10-K relating to our business, business strategy, products and services we may offer in the future, the timing and resultsof future regulatory filings, the timing and results of future clinical trials, and capital outlook. Forward-looking statements are basedon our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward looking statementsrelate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Ouractual results may differ materially from those contemplated by the forward-looking statements. They are neither statement of historicalfact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements.Important factors that could cause actual results to differ materially from those in the forward looking statements include, but are notlimited to, a decline in general economic conditions nationally and internationally; the ability to protect our intellectual propertyrights; competition from other providers and products; risks in product development; inability to raise capital to fund continuing operations;changes in government regulation; the ability to complete capital raising transactions, and other factors (including the risks containedin Item 1A of this Form 10-K under the heading “Risk Factors”) relating to our industry, our operations and results of operationsand any businesses that may be acquired by us. Should one or more of these risks or uncertainties materialize, or should the underlyingassumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended orplanned.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Factors or events that couldcause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them, nor can we assessthe impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differmaterially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue relianceon these forward-looking statements. We cannot guarantee future results, levels of activity, performance or achievements. Except as requiredby applicable law, we undertake no obligation to and do not intend to update any of the forward-looking statements to conform these statementsto actual results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k2">        </a>        <b>         ITEM 1. DESCRIPTION OF BUSINESS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Unless otherwise indicatedor the context otherwise requires, references to the “Company”, “Aethlon”, “we”, “us”and “our” refer to Aethlon Medical, Inc., combined with its majority-owned subsidiary, Exosome Sciences, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Overview and Corporate History        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are a medical technologycompany focused on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier®, or Hemopurifier,is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifieris designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasisand inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier asa “Breakthrough Device” for two independent indications:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of life-threatening viruses that are not addressed with approved therapies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <!-- Field: Page; Sequence: 3 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We believe the Hemopurifiercan be a substantial advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promotethe growth and spread of tumors through multiple mechanisms. We are currently conducting a clinical trial in patients with advanced andmetastatic head and neck cancer. We are initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinalcancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites to navigate and assess theimpact of the COVID-19 global pandemic on our clinical trials and current timelines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On October 4, 2019, the FDAapproved our Investigational Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifierin patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda). The primary endpoint for the EFS,which will enroll 10 to 12 subjects at a single center, will be safety, with secondary endpoints including measures of exosome clearanceand characterization, as well as response and survival rates. This study, which is being conducted at the UPMC Hillman Cancer Center inPittsburgh, PA, has been approved by the Institutional Review Board, or IRB, and is in the process of recruiting and treating patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We also believe the Hemopurifiercan be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressedwith an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat individualsinfected with human immunodeficiency virus, or HIV, hepatitis-C, and Ebola.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Additionally,        <i>         in-vitro        </i>        ,the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplexvirus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and thereconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-governmentresearch institutes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 17, 2020, the FDAapproved a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients withSARS-CoV-2/COVID-19 in a New Feasibility Study.        <font style="background-color: white">         That study is designed to enroll up to 40 subjectsat up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit,or ICU, and will have acute lung injury and/or severe or life threatening disease, among other criteria. Endpoints for this study, inaddition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT # 04595903). The initial sites for thistrial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital – Irvine in Irvine, CA and Loma Linda Hospitalin Loma Linda, CA, have completed clinical trial agreements, and have received IRB approval in the case of the Hoag hospitals, and arepreparing to open for patient enrollment. Under Single Patient Emergency Use regulations, the Company has also treated two patients withCOVID-19 with the Hemopurifier.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are also the majority ownerof Exosome Sciences, Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threateningdiseases. Included among ESI’s activities is the advancement of a TauSome        <sup>         TM        </sup>        biomarker candidate to diagnose chronic traumaticencephalopathy, or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than sameage-group control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for, a number ofcancers. We consolidate ESI’s activities in our consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Successful outcomes of humantrials will also be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of ourpatents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patentapplications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 4 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition to the foregoing,we are monitoring closely the impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the healthand safety of our employees while continuing our operations. Given the level of uncertainty regarding the duration and impact of the COVID-19pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and the resultingCOVID-19 pandemic on our timelines and future access to capital. We are continuing to monitor the spread of COVID-19 and its potentialimpact on our operations. The full extent to which the COVID-19 pandemic will impact our business, results of operations, financial condition,clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to containor treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We were formed on March 10,1999. Our executive offices are located at 9635 Granite Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858)459-7800. Our website address is www.aethlonmedical.com.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The Mechanism of the Hemopurifier        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Hemopurifier is an affinityhemofiltration device designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system.In the United States, the Hemopurifier is classified as a combination product whose regulatory jurisdiction is The Center for Devicesand Radiological Health, or CDRH, the branch of FDA responsible for the premarket approval of all medical devices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In application, our Hemopurifiercan be used on the established infrastructure of continuous renal replacement therapy, or CRRT, and dialysis instruments located in hospitalsand clinics worldwide. It could also potentially be developed as part of a proprietary closed system with its own pump and tubing set,negating the requirement for dialysis infrastructure. Incorporated within the Hemopurifier is a protein called a lectin that binds toa glycosylated, or sugar substituted, membrane, which exosomes and most infectious viruses share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The Hemopurifier - Clinical Trials In Viral Infections        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The initial development ofthe Hemopurifier was focused on viral infections. In non-clinical bench experiments using a laboratory version of the Hemopurifier, performedin Company labs as well as multiple other outside labs including the Centers for Disease Control, or CDC, the United States Army MedicalResearch Institute of Infectious Diseases, or USAMRIID, Battelle Memorial Research Institute and others, we have demonstrated that themini-Hemopurifier can bind and clear multiple different glycosylated, or containing sugar molecules on their membranes, viruses. Theseviruses include HIV, hepatitis C, or HCV, Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, multiple herpes viruses,a MERS-CoV related pseudovirus and others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Initial clinical trials onthe Hemopurifier were conducted overseas on dialysis patients with HCV, with a subsequent Early Feasibility Study conducted in the U.S.under an FDA approved Investigational Device Exemption, or IDE.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On March 13, 2017, we concludedan FDA-approved early feasibility study under an IDE in end stage renal disease patients on dialysis who were infected with HCV. The studywas conducted at DaVita MedCenter Dialysis in Houston, Texas. We reported that there were no device-related adverse events in enrolledsubjects who met the study inclusion-exclusion criteria. We also reported that an average capture of 154 million copies of HCV (in InternationalUnits, I.U.) within the Hemopurifier during four-hour treatments. Prior to this approval, we collected supporting Hemopurifier data throughinvestigational human studies conducted overseas.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         SARS-CoV-2/COVID-19        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        SARS-COV-2, the causativeagent of COVID-19 is a member of the coronavirus family, which includes the original SARS virus, SARS-CoV, and the MERS virus. SARS-CoV-2,like all coronaviruses, is glycosylated. This suggests that the Hemopurifier could potentially clear it from biologic fluids, includingblood.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 5 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 17, 2020, the FDAapproved a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients withSARS-CoV-2/COVID-19 in a New Feasibility Study.        <font style="background-color: white">         That study is designed to enroll up to 40 subjectsat up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit,or ICU, and will have acute lung injury and/or severe or life threatening disease, among other criteria. Endpoints for this study, inaddition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT # 04595903). The initial sites for thistrial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital – Irvine in Irvine, CA and Loma Linda Hospitalin Loma Linda, CA, have completed clinical trial agreements, and have received IRB approval in the case of the Hoag hospitals, and arepreparing to open for patient enrollment.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">         UnderSingle Patient Emergency Use regulations, the Company has also treated two patients with COVID-19 with the Hemopurifier. The Company recentlypublished a manuscript reviewing case studies covering those treatments entitled “Removal of COVID-19 Spike Protein, Whole Virus,Exosomes and Exosomal microRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients with COVID-19 Infection.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">         Themanuscript described the use of the Hemopurifier for a total of nine sessions in two critically ill COVID-19 patients. The first casestudy demonstrated the improvement in the patient who was a SARS-COV-2 positive COVID-19 present at entry to the hospital, with associatedcoagulopathy (CAC), lung injury, inflammation, and tissue injury despite the absence of demonstrable COVID-19 viremia at the start oftreatment at Day 22 and having demonstrated strong viremia earlier in the patient’s disease cycle, suggesting that the significantremoval of exosomes contributed to the patient’s recovery. This patient received eight Hemopurifier treatments without complicationsand eventually was weaned from a ventilator and was discharged from the hospital.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">         Thesecond patient case study demonstrated in vivo removal of SARS-CoV-2 virus from the blood stream of an infected patient. This patientcompleted a six-hour Hemopurifier treatment without complications and subsequently was placed on Continuous Renal Replacement Therapy(CRRT). The patient ultimately expired three hours after being placed on CRRT because of the advanced stage of the patient’s disease.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The Hemopurifier – Clinical Trials Conducted Overseas in ViralInfections        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         EBOLA Virus        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December of 2014, TimeMagazine named the Hemopurifier a “Top 25 Invention” as the result of treating an Ebola-infected physician at Frankfurt UniversityHospital in Germany. The physician was comatose with multiple organ failure at the time of treatment with the Hemopurifier. At the AmericanSociety of Nephrology Annual Meeting, Dr. Helmut Geiger, Chief of Nephrology at Frankfurt University Hospital reported that the patientreceived a single 6.5 hour Hemopurifier treatment. Prior to treatment, viral load was measured at 400,000 copies/ml. Post-treatment viralload reported to be at 1,000 copies/ml. Dr. Geiger also reported that 242 million copies of Ebola virus were captured within the Hemopurifierduring treatment. The patient ultimately made a full recovery. Based on this experience, the Company filed an Expanded Access protocolwith the FDA to treat Ebola virus infected patients in up to ten centers in the U.S. and a corresponding protocol was approved by HealthCanada.These protocols remain open allowing Hemopurifier treatment to be offered to patients presenting for care in both countries. In 2018,we applied for and were granted a Breakthrough Designation by the FDA “… for the treatment of life-threatening viruses thatare not addressed with approved therapies.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Hepatitis C Virus (HCV)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Prior to FDA approval of theIDE feasibility study, we conducted investigational HCV treatment studies at the Apollo Hospital, Fortis Hospital and the Medanta MedicityInstitute in India. In the Medanta Medicity Institute study, twelve HCV-infected individuals were enrolled to receive three six-hour Hemopurifiertreatments during the first three days of a 48-week peginterferon+ribavirin treatment regimen. The study was conducted under the leadershipof Dr. Vijay Kher. Dr. Kher’s staff reported that Hemopurifier therapy was well tolerated and without device-related adverse eventsin the twelve treated patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Of these twelve patients,ten completed the Hemopurifier-peginterferon+ribavirin treatment protocol, including eight genotype-1 patients and two genotype-3 patients.Eight of the ten patients achieved a sustained virologic response, which is the clinical definition of treatment cure and is defined asundetectable HCV in the blood 24 weeks after the completion of the 48-week peginterferon+ribavirin drug regimen. Both genotype-3 patientsachieved a sustained virologic response, while six of the eight genotype-1 patients achieved a sustained virologic response, which definesa cure of the infection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 6 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Hemopurifier - Human Immunodeficiency Virus (HIV)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition to treating Ebolaand HCV-infected individuals, we also conducted a single proof-of-principle treatment study at the Sigma New Life Hospital in an AIDSpatient who was not being administered HIV antiviral drugs. In the study, viral load was reduced by 93% as the result of 12 Hemopurifiertreatments (each four hours in duration) that were administered over the course of one month.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The Hemopurifier in Cancer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        While hepatitis C is no longera major commercial opportunity in developed markets due to the wide availability of curative, oral direct acting anti-viral agents, wecontinue to investigate potential viral targets for the Hemopurifier. Recently, however, our primary focus has been on the evaluationof the Hemopurifier in cancer, where we have shown in non-clinical studies that it is capable of clearing exosomes, which are subcellularparticles that are secreted by both normal and malignant cells. Tumor derived exosomes, have been shown in multiple laboratories to becritical components in the progression of cancers. They can mediate resistance to chemotherapy, resistance to targeted agents such astrastuzumab (Herceptin), metastasis and resistance to the newer immuno-oncology agents, such as pembrolizumab (Keytruda). Based on theseobservations and data, in November 2019 the FDA granted us a second Breakthrough Designation “…for the treatment of individualswith advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types inwhich exosomes have been shown to participate in the development or severity of the disease.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On October 4, 2019, the FDAapproved our IDE application to initiate an EFS of the Hemopurifier in patients with head and neck cancer in combination with standardof care pembrolizumab (Keytruda). The primary endpoint for the EFS, which will enroll 10 to 12 subjects at a single center, will be safety,with secondary endpoints including measures of exosome clearance and characterization, as well as response and survival rates. This study,which is being conducted at the UPMC Hillman Cancer Center in Pittsburgh, PA, has been approved by the IRB and is in the process of recruitingand treating patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Exosome Sciences, Inc. – Majority Owned Biomarker DiscoveryCompany        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are the majority ownerof Exosome Sciences, Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threateningdisease conditions that may be current or future therapeutic targets for Aethlon Medical. At present, the priority of ESI is directedtoward exosomal biomarkers to diagnose and monitor cancer and neurological disorders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Since it began operationsin 2013, ESI researchers disclosed the discovery of an exosomal biomarker that may be associated with neurodegenerative diseases thatinvolve the abnormal accumulation of tau protein in the brain. These diseases, known as tauopathies, are a family of 21 different neurologicaldisorders that include Alzheimer’s disease and Chronic Traumatic Encephalopathy, or CTE. Related to CTE, the ESI team was invitedto participate in a National Institutes of Health, or NIH, funded research study with The Boston University CTE Center. In the study,ESI researchers investigated an exosomal tau biomarker, or TauSome, as a candidate to diagnose and monitor CTE in living individuals.At the present time, CTE can only be diagnosed through post-mortem brain autopsy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The results of the study indicatedthat TauSome levels in the blood of former professional American football players, a high CTE risk group, were significantly higher ascompared to same-age group control subjects who did not participate in activities that involved repetitive head trauma. Additionally,high TauSome levels also correlated with poor performance in cognitive decline testing. These results were published in an article entitled“Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy” in the        <i>         Journalof Alzheimer’s Disease        </i>        on April 12, 2016.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To further validate theseobservations, ESI has initiated a follow-on study to evaluate TauSome levels in up to 200 former professional football players and controlsubjects. If fully enrolled, the study would be the largest study to date related to the advancement of a candidate biomarker to diagnoseand monitor CTE in the living. Enrollment of study participants began in March 2018 at the Translational Genomics Research Institute,or TGEN, in Phoenix, AZ. Kendall Van Keuren-Jensen, Ph.D., Co-Director of TGEN’s Center for Noninvasive Diagnostics is the principalinvestigator at this site location. Dr. Van Keuren-Jensen is neurodegenerative disease thought leader whose research includes discoveryand detection of biomarkers for central nervous system disorders. Additional site locations are anticipated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 7 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In September 2019, we announcedthat ESI had entered into a collaboration with the Hoag Hospital Presbyterian in Newport Beach, California to identify and characterizepotential early disease markers for cancer diagnostics, cancer progression and treatment resistance. The Principal Investigator on thisstudy is Michael Demeure, M.D., program director of Precision Medicine at Hoag. Samples from patients at Hoag will be analyzed by ESIscientists to identify and characterize exosomal “liquid biopsy” markers of cancer incidence and progression. We believe thatour recently announced NCI-SBIR Phase II contract to develop a benchtop instrument to isolate and characterize exosomes could substantiallyexpand the capabilities of the ESI programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        U.S. GOVERNMENT CONTRACTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have recognized revenueunder the following three government contracts/grants over the past two years:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Phase 2 Melanoma Cancer Contract        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On September 12, 2019, theNational Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, awarded to us an SBIR Phase II Award Contract, forNIH/NCI Topic 359, entitled “A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring”,or the Award Contract. The Award Contract amount is $1,860,561 and runs for the period from September 16, 2019 through September 15, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The work to be performed pursuantto this Award Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitationthat ran from September 2017 through June 2018. Following on the phase I work, the deliverables in the phase II program involve the designand testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2021, we completed the milestones relevant to the first nine months of the fiscal year. As a result, we recorded $436,427 ofgovernment contract revenue on the Phase 2 Melanoma Cancer Contract in the fiscal year ended March 31, 2021.   During the threemonth period ended March 31, 2021, we did not complete all of the milestones relevant to that time period, as a result, we recorded $114,849as deferred revenue related to the Phase 2 Melanoma Cancer Contract.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Breast Cancer Grant        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the fiscal year ended March31, 2021, we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this SmallBusiness Innovation Research, or SBIR, Phase I grant is “The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomesfrom the Blood Circulation,” or the Breast Cancer Grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This NCI Phase I grant periodoriginally ran from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extensionon this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors to workwith us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2021, we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestonesrelated to the Breast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that our workunder the grant provided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount previouslywas recorded as deferred revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of March 31, 2021, we receivedall of the funds allocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 8 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Subaward with University of Pittsburgh        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In 2020, we entered into a cost reimbursable subawardarrangement with the University of Pittsburgh in connection with an NIH contract entitled “Depleting Exosomes to Improve Responsesto Immune Therapy in HNNCC.” Our share of the award is $256,750. We recorded $34,233 of revenue related to this subaward in thefiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Research and Development Costs        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        A substantial portion of ouroperating budget is used for research and development activities. The cost of research and development, all of which has been chargedto operations, amounted to approximately $2,072,000 and $927,000 in the fiscal years ended March 31, 2021 and 2020, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently own or have licenserights to a number of U.S. and foreign patents and patent applications and endeavor to continually improve our intellectual property position.We consider the protection of our technology, whether owned or licensed, to the exclusion of use by others, to be vital to our business.While we intend to focus primarily on patented or patentable technology, we also rely on trade secrets, unpatented property, know-how,regulatory exclusivity, patent extensions and continuing technological innovation to develop our competitive position. We also own certaintrademarks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our success depends in largepart on our ability to protect our proprietary technology, including the Hemopurifier® product platform, and to operate without infringingthe proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentialityagreements, licensing agreements and other agreements, to establish and protect our proprietary rights. Our success also depends, in part,on our ability to avoid infringing patents issued to others. If we were judicially determined to be infringing on any third-party patent,we could be required to pay damages, alter our products or processes, obtain licenses or cease sales of products or certain activities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To protect our proprietarymedical technologies, including the Hemopurifier® product platform and other scientific discoveries, we have a portfolio of over 50issued patents and pending applications worldwide. We currently have five issued U.S. patents and 35 issued patents in countries outsideof the United States. In addition, we have 11 patent applications pending worldwide related to our Hemopurifier® product platformand other technologies. We are seeking additional patents on our scientific discoveries.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        It is possible that our pendingpatent applications may not result in issued patents, that we will not develop additional proprietary products that are patentable, thatany patents issued to us may not provide us with competitive advantages or will be challenged by third parties and that the patents ofothers may prevent the commercialization of products incorporating our technology. Furthermore, others may independently develop similarproducts, duplicate our products or design around our patents. U.S. patent applications are not immediately made public, so it is possiblethat a third party may obtain a patent on a technology we are actively using.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There is a risk that any patentapplications that we file and any patents that we hold or later obtain could be challenged by third parties and declared invalid or unenforceable.For many of our pending applications, patent interference proceedings may be instituted with the U.S. Patent and Trademark Office, orthe USPTO, when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validityof an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitledto the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings,and the USPTO’s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patentapplications, we may experience significant expenses and delays in obtaining a patent, and if the outcome of the proceeding is unfavorableto us, the patent could be issued to a competitor rather than to us.  Third parties can file post-grant proceedings in the USPTO,seeking to have issued patent invalidated, within nine months of issuance. This means that patents undergoing post-grant proceedings maybe lost, or some or all claims may require amendment or cancellation, if the outcome of the proceedings is unfavorable to us. Post-grantproceedings are complex and could result in a reduction or loss of patent rights. The institution of post-grant proceedings against ourpatents could also result in significant expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 9 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Patent law outside the UnitedStates is uncertain and in many countries, is currently undergoing review and revisions. The laws of some countries may not protect ourproprietary rights to the same extent as the laws of the United States. Third parties may attempt to oppose the issuance of patents tous in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign countrycould have an adverse effect on our corresponding patents that are issued or pending in the United States. It may be necessary or usefulfor us to participate in proceedings to determine the validity of our patents or our competitors’ patents that have been issuedin countries other than the United States. This could result in substantial costs, divert our efforts and attention from other aspectsof our business, and could have a material adverse effect on our results of operations and financial condition. Outside of the UnitedStates, we currently have pending patent applications or issued patents in Europe, India, Russia, Canada and Hong Kong.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition to patent protection,we rely on unpatented trade secrets and proprietary technological expertise. It is possible that others could independently develop orotherwise acquire substantially equivalent technology, somehow gain access to our trade secrets and proprietary technological expertiseor disclose such trade secrets, or that we may not successfully ultimately protect our rights to such unpatented trade secrets and proprietarytechnological expertise. We rely, in part, on confidentiality agreements with our marketing partners, employees, advisors, vendors andconsultants to protect our trade secrets and proprietary technological expertise. We cannot assure you that these agreements will notbe breached, that we will have adequate remedies for any breach or that our unpatented trade secrets and proprietary technological expertisewill not otherwise become known or be independently discovered by competitors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Patents         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The following table lists our issued patents andpatent applications, including their ownership status:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Patents Issued in the United States        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; border-left: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PATENT #            </b>           </font>          </td>          <td style="width: 57%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PATENT NAME            </b>           </font>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             ISSUANCE            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             OWNED OR            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             LICENSED            </b>           </p>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-right: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             EXPIRATION            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             9,707,333            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/18/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/6/29           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             9,364,601            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/14/16           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10/2/29           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             8,288,172            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10/16/12           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/30/29           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             7,226,429            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/5/07           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             10,022,483            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Patent Applications Pending in the United States        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 17%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; border-left: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATION #            </b>           </font>          </td>          <td style="width: 61%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATION NAME            </b>           </font>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             FILING            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-right: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             OWNED OR            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             LICENSED            </b>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             16/415,713            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Affinity capture of circulating biomarkers           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/17/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             16/506,864            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/09/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             17/301,666            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/09/21           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             16/459,220            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods and compositions for quantifying exosomes           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/01/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             16/883,624            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Plasma exosomal tau as a biomarker for chronic traumatic encephalopathy           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/26/20           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 10 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Foreign Patents        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; border-left: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PATENT #            </b>           </font>          </td>          <td style="width: 60%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PATENT NAME            </b>           </font>          </td>          <td style="width: 10%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             ISSUANCE            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>          <td style="width: 10%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             OWNED OR            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             LICENSED            </b>           </p>          </td>          <td style="width: 10%; border-top: #A5A5A5 1pt solid; border-right: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             EXPIRATION            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Denmark)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (France)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Germany)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Ireland)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Great Britain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Sweden)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Netherlands)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3110977            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Switzerland)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/16/18           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2353399            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Russia)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/27/09           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Belgium)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Ireland)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Italy)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Great Britain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (France)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1624785            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Germany)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/17/13           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2516403            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Method for removal of viruses from blood by lectin affinity hemodialysis (Canada)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/12/14           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2591359            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods for quantifying exosomes (Germany)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/01/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/07/31           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2591359            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods for quantifying exosomes (France)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/01/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/07/31           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2591359            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods for quantifying exosomes (Great Britain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/01/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/07/31           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2591359            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods for quantifying exosomes (Spain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/01/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/07/31           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2644855            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Canada)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/19/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Germany)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Switzerland)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Spain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (France)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Great Britain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Italy)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Netherlands)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1993600            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Sweden)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/24/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1126138            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Hong Kong)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/19/20           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3517151            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Europe – not yet validated)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/21/21           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/20/24           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3366784            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Great Britain)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/13/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3366784            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (France)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/13/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3366784            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Germany)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/13/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3366784            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Netherlands)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/13/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/12/36           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 11 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Foreign Patent Applications        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 17%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; border-left: #A5A5A5 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATION #            </b>           </font>          </td>          <td style="text-align: center; width: 61%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATIONNAME            </b>           </font>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             FILING DATE            </b>           </font>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-right: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             OWNED OR LICENSED            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             DE 112016001400.7            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Methods of delivering regional citrate anticoagulation (RCA) during extracorporeal blood treatments           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10/23/17           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             8139/DELNP/2008            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (exosomes) (India)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/9/07           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             3061952            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Extracorporeal removal of microvesicular particles (Canada)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/18/19           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2939652            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Brain specific exosome based diagnostics and extracorporeal therapies (Canada)           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/12/06           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             16867003.2            </b>           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Plasma exosomal tau as a biomarker for chronic traumatic encephalopathy           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/16/16           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         International Patent Applications        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 17%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; border-left: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATION #            </b>           </font>          </td>          <td style="width: 61%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             APPLICATION NAME            </b>           </font>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             FILING            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             DATE            </b>           </p>          </td>          <td style="width: 11%; border-top: #A5A5A5 1pt solid; border-right: #A5A5A5 1pt solid; border-bottom: #A5A5A5 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             OWNED OR            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             LICENSED            </b>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-right: #C9C9C9 1pt solid; border-bottom: #C9C9C9 1pt solid; border-left: #C9C9C9 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             PCT/US2021/            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             026377            </b>           </p>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Devices and methods for treating a coronavirus infection and symptoms thereof           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/08/21           </font>          </td>          <td style="border-bottom: #C9C9C9 1pt solid; border-right: #C9C9C9 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Owned           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Licensing and Assignment Agreements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On November 7, 2006, we executedan assignment agreement with the London Health Science Center Research, Inc. under which an invention and related patent rights for amethod to treat cancer were assigned to us. The invention provides for the "Extracorporeal removal of microvesicular particles"for which the U.S. Patent and Trademark Office granted a patent (Patent No.8,288,172) in the U.S. as of October 2012. The agreement providedfor an upfront payment of 53 shares of unregistered common stock and a 2% royalty on any future net sales of all products or services,the sale of which would infringe in the absence of the assignment granted under this agreement. We are also responsible for paying certainpatent application and filing costs. Under the assignment agreement, we own the patents until their respective expirations. Under certaincircumstances, ownership of the patents may revert to the London Health Science Center Research, Inc. if there is an uncured substantialbreach of the assignment agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Industry &amp; Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The industry for treatinginfectious disease and cancer is extremely competitive, and companies developing new treatment procedures face significant capital andregulatory challenges. As our Hemopurifier is a clinical-stage device, we have the additional challenge of establishing medical industrysupport, which will be driven by treatment data resulting from human clinical studies. Should our device become market cleared by FDAor the regulatory body of another country, we may face significant competition from well-funded pharmaceutical organizations. Additionally,we would likely need to establish large-scale production of our device in order to be competitive. We believe that our Hemopurifier isa first-in-class therapeutic candidate and we are not aware of any affinity hemofiltration device being market cleared in any countryfor the single-use removal of circulating viruses or tumor-derived exosomes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Hemopurifier is subjectto regulation by numerous regulatory bodies, primarily the FDA, and comparable international regulatory agencies. These agencies requiremanufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling,marketing, storage, distribution, advertising and promotion, and post-marketing surveillance reporting of medical devices. As the primarymode of action of the Hemopurifier is attributable to the device component of this combination product, the FDA’s Center for Devicesand Radiological Health, or the CDRH, has primary jurisdiction over its premarket development, review and approval. Failure to complywith applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as issuance ofwarning letters, import detentions, civil monetary penalties and/or judicial sanctions, such as product seizures, injunctions and criminalprosecution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 12 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          FDA’s Pre-market Clearance and ApprovalRequirements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Each medical device we seekto commercially distribute in the United States will require either a prior 510(k) clearance, unless it is exempt, or a pre-market approvalfrom the FDA. Generally, if a new device has a predicate that is already on the market under a 510(k) clearance, the FDA will allow thatnew device to be marketed under a 510(k) clearance; otherwise, a premarket approval, or PMA, is required. Medical devices are classifiedinto one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with eachmedical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Class I devices aredeemed to be low risk and are subject to the general controls of the Federal Food, Drug and Cosmetic Act, such as provisions that relateto: adulteration; misbranding; registration and listing; notification, including repair, replacement, or refund; records and reports;and good manufacturing practices. Most Class I devices are classified as exempt from pre-market notification under section 510(k)of the FD&amp;C Act, and therefore may be commercially distributed without obtaining 510(k) clearance from the FDA. Class II devicesare subject to both general controls and special controls to provide reasonable assurance of safety and effectiveness. Special controlsinclude performance standards, post market surveillance, patient registries and guidance documents. A manufacturer may be required tosubmit to the FDA a pre-market notification requesting permission to commercially distribute some Class II devices. Devices deemedby the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantiallyequivalent to a previously cleared 510(k) device, are placed in Class III. A Class III device cannot be marketed in the UnitedStates unless the FDA approves the device after submission of a PMA. However, there are some Class III devices for which FDA hasnot yet called for a PMA. For these devices, the manufacturer must submit a pre-market notification and obtain 510(k) clearance in ordersto commercially distribute these devices. The FDA can also impose sales, marketing or other restrictions on devices in order to assurethat they are used in a safe and effective manner. We believe that the Hemopurifier will be classified as a Class III device and as suchwill be subject to PMA submission and approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Pre-market Approval Pathway         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        A pre-market approval applicationmust be submitted to the FDA for Class III devices for which the FDA has required a PMA. The pre-market approval application processis much more demanding than the 510(k) pre-market notification process. A pre-market approval application must be supported by extensivedata, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA’ssatisfaction reasonable evidence of safety and effectiveness of the device.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        After a pre-market approvalapplication is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive reviewand thus whether the FDA will file the application for review. The FDA has 180 days to review a filed pre-market approval application,although the review of an application generally occurs over a significantly longer period of time and can take up to several years. Duringthis review period, the FDA may request additional information or clarification of the information already provided. Also, an advisorypanel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA asto the approvability of the device.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Although the FDA is not boundby the advisory panel decision, the panel’s recommendations are important to the FDA’s overall decision making process. Inaddition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation,or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA’s regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Upon completion of the PMAreview, the FDA may: (i) approve the PMA which authorizes commercial marketing with specific prescribing information for one or moreindications, which can be more limited than those originally sought; (ii) issue an approvable letter which indicates the FDA’sbelief that the PMA is approvable and states what additional information the FDA requires, or the post-approval commitments that mustbe agreed to prior to approval; (iii) issue a not approvable letter which outlines steps required for approval, but which are typicallymore onerous than those in an approvable letter, and may require additional clinical trials that are often expensive and time consumingand can delay approval for months or even years; or (iv) deny the application. If the FDA issues an approvable or not approvableletter, the applicant has 180 days to respond, after which the FDA’s review clock is reset.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 13 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Emergency Use Authorizations,or EUAs, are granted by FDA in public health emergencies but allow use of the authorized device only during the period of the respectivepublic health emergency, and do not change the requirement to ultimately seek PMA approval after the authorization period has ended.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Clinical Trials         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Clinical trials are almostalways required to support pre-market approval and are sometimes required for 510(k) clearance. In the United States, for significantrisk devices, these trials require submission of an application for an IDE to the FDA. The IDE application must be supported by appropriatedata, such as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol isscientifically sound. The IDE must be approved in advance by the FDA for a specific number of patients at specified study sites. Duringthe trial, the sponsor must comply with the FDA’s IDE requirements for investigator selection, trial monitoring, reporting and recordkeeping.The investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the dispositionof investigational devices and comply with all reporting and recordkeeping requirements. Clinical trials for significant risk devicesmay not begin until the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinicaltrial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involvingsubjects and which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety and welfareof human research subjects. The FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinicaltrial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to complywith FDA or IRB requirements. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and effectivenessof the device, may be equivocal or may otherwise not be sufficient to obtain approval or clearance of the product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Ongoing Regulation by the FDA         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Even after a device receives clearance or approvaland is placed on the market, numerous regulatory requirements apply. These include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            establishment registration and device listing;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            labeling regulations and the FDA prohibitions against the promotion of products for uncleared, unapproved or “off-label” uses and other requirements related to promotional activities;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            medical device reporting regulations, which require that manufactures report to the FDA if their device may have caused or contributed to a death or serious injury, or if their device malfunctioned and the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            corrections and removal reporting regulations, which require that manufactures report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            post market surveillance regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Some changes to an approvedPMA device, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA approval ofa new PMA or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA often require the submission ofthe same type of information required for an original PMA, except that the supplement is generally limited to that information neededto support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewingPMA supplements as it does in reviewing original PMAs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 14 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Failure by us or by our suppliersto comply with applicable regulatory requirements can result in enforcement action by the FDA or state authorities, which may includeany of the following sanctions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            warning or untitled letters, fines, injunctions, consent decrees and civil penalties;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            customer notifications, voluntary or mandatory recall or seizure of our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            operating restrictions, partial suspension or total shutdown of production;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delay in processing submissions or applications for new products or modifications to existing products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            withdrawing approvals that have already been granted; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            criminal prosecution.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Medical Device Reportinglaws and regulations require us to provide information to the FDA when we receive or otherwise become aware of information that reasonablysuggests our device may have caused or contributed to a death or serious injury as well as a device malfunction that likely would causeor contribute to death or serious injury if the malfunction were to recur. In addition, the FDA prohibits an approved device from beingmarketed for off-label use. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-labeluses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantialmonetary penalties and criminal prosecution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Newly discovered or developedsafety or effectiveness data may require changes to a product’s labeling, including the addition of new warnings and contraindications,and also may require the implementation of other risk management measures. Also, new government requirements, including those resultingfrom new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory clearance orapproval of our products under development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Healthcare Regulation         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition to the FDA’srestrictions on marketing of pharmaceutical products, the U.S. healthcare laws and regulations that may affect our ability to operateinclude: the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy and securitylaws; and federal transparency laws related to payments and/or other transfers of value made to physicians (defined to include doctors,dentists, optometrists, podiatrists and chiropractors) and other healthcare professionals (beginning January 1, 2022) and teaching hospitals.Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating complianceefforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and mayapply regardless of payor. In addition, state data privacy laws that protect the security of health information may differ from each otherand may not be preempted by federal law. Moreover, several states have enacted legislation requiring pharmaceutical manufacturers to,among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures onsales and marketing activities, report information related to drug pricing, require the registration of sales representatives, and prohibitcertain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities with respect toany product candidate for which we receive approval to market in the United States by imposing administrative and compliance burdens onus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 15 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because of the breadth ofthese laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our businessactivities, particularly any sales and marketing activities after a product candidate has been approved for marketing in the United States,could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal andstate laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, andadministrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcareprograms, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement toresolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adverselyaffect our ability to operate our business and our results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        From time to time, legislationis drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufactureand marketing of regulated products or the reimbursement thereof. For example, in the U.S., the Patient Protection and Affordable CareAct, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, PPACA, among other things, reduced and/orlimited Medicare reimbursement to certain providers and imposed an annual excise tax of 2.3% on any entity that manufactures or importsmedical devices offered for sale in the United States, with limited exceptions. However, the 2020 federal spending package permanentlyeliminated, effective January 1, 2020, this PPACA-mandated medical device tax. On December 14, 2018, a Texas U.S. District Court Judgeruled that the PPACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as partof the legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S.Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded thecase back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Courtis currently reviewing the case, although it is unclear when a decision will be made or how the Supreme Court will rule. In addition,the Budget Control Act of 2011, as amended by subsequent legislation, further reduces Medicare’s payments to providers by two percentthrough fiscal year 2030. However, COVID-19 relief legislation suspended the two percent Medicare sequester from May 1, 2020 through December31, 2021. These reductions may reduce providers’ revenues or profits, which could affect their ability to purchase new technologies.Furthermore, the healthcare industry in the U.S. has experienced a trend toward cost containment as government and private insurers seekto control healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Legislationcould be adopted in the future that limits payments for our products from governmental payors. It is possible that additional governmentalaction will be taken to address the COVID-19 pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Coverage and Reimbursement         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In both the U.S. and internationalmarkets, the use of medical devices is dependent in part on the availability of reimbursement from third-party payors, such as governmentand private insurance plans. Healthcare providers that use medical devices generally rely on third-party payors to pay for all or partof the costs and fees associated with the medical procedures being performed or to compensate them for their patient care services. Shouldour Hemopurifier or any other products under development be approved for commercialization by the FDA, any such products may not be consideredcost-effective, reimbursement may not be available in the U.S. or other countries, if approved, and reimbursement may not be sufficientto allow sales of our future products on a profitable basis. The coverage decisions of third-party payors will be significantly influencedby the assessment of our future products by health technology assessment bodies. If approved for use in the U.S., we expect that any productsthat we develop, including the Hemopurifier, will be purchased primarily by medical institutions, which will in turn bill various third-partypayors for the health care services provided to patients at their facility. Payors may include the Centers for Medicare &amp; MedicaidServices, or CMS, which administers the Medicare program and works in partnership with state governments to administer Medicaid, othergovernment programs and private insurance plans. The process involved in applying for coverage and reimbursement from CMS is lengthy andexpensive. Further, Medicare coverage is based on our ability to demonstrate that the treatment is “reasonable and necessary”for Medicare beneficiaries. Even if products utilizing our Aethlon Hemopurifier technology receive FDA and other regulatory clearanceor approval, they may not be granted coverage and reimbursement by any payor, including by CMS. Many private payors use coverage decisionsand payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies and amounts. However, no uniformpolicy for coverage and reimbursement for medical devices exists among third-party payors in the United States. Therefore, coverage andreimbursement can differ significantly from payor to payor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 16 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Manufacturing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Manufacturing of our Hemopurifieroccurs in collaboration with two contract manufacturers based in California under Good Manufacturing Practice, or GMP, regulations promulgatedby the FDA.  Our contract manufacturers are registered with the FDA. To date, our manufacture of the Hemopurifier has been limitedto quantities necessary to support our clinical studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our costs of compliance with federal, state andlocal environmental laws have been immaterial to date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sources and Availability of Raw Materials and the Namesof Principal Suppliers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Hemopurifiers are currentlyassembled by Aethlon personnel in a GMP manufacturing facility provided by Life Science Outsourcing, Inc, or LSO. In the future, we planto bring our manufacturing operations in-house. Aethlon personnel assemble the various components of the Hemopurifier with materials fromour various suppliers, which are purchased and released by Aethlon and stored at LSO prior to use in manufacturing. Specifically, theHemopurifier contains three critical components with limited available suppliers. The base cartridge on which the Hemopurifier is constructedis sourced from Medica S.p.A and we are dependent on the continued availability of these cartridges. Although there are other suppliers,the process of qualifying a new supplier takes time and regulatory approvals must be obtained. We currently purchase the diatomaceousearth from Janus Scientific, Inc., as the distributor; however, the product is manufactured by Imerys Minerals Ltd. There potentiallyare other suppliers of this product, but as with the cartridges, qualifying and obtaining required regulatory approvals takes time andresources. The GNA lectin is sourced from Vector Laboratories Inc. and also is available from other suppliers; however, Sigma Aldrichis the only approved back up supplier at this time. A business interruption at any of these sources could have a material impact on ourability to manufacture the Hemopurifier.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sales and Marketing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We do not currently have anysales and marketing capability. With respect to commercialization efforts in the future, we intend to build or contract for distribution,sales and marketing capabilities for any product candidate that is approved. From time to time, we have had and are having strategic discussionswith potential collaboration partners for our product candidates, although no assurance can be given that we will be able to enter intoone or more collaboration agreements for our product candidates on acceptable terms, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Product Liability        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The risk of product liabilityclaims, product recalls and associated adverse publicity is inherent in the testing, manufacturing, marketing and sale of medical products.We have limited clinical trial liability insurance coverage. It is possible that future insurance coverage may not be adequate or available.We may not be able to secure product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liabilityfor mandatory damages could exceed the amount of our coverage. A successful product liability claim against us could require us to paya substantial monetary award. Moreover, a product recall could generate substantial negative publicity about our products and businessand inhibit or prevent commercialization of other future product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have ten full-time employees.All of our employees are located in the United States. We do intend to hire additional employees. We utilize, whenever appropriate, consultantsin order to conserve cash and resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We believe our employee relationsare good. None of our employees are represented by a labor union or are subject to collective-bargaining agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 17 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="k3">        </a>        <b>         ITEM 1A. RISK FACTORS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         An investment in our securitiesinvolves a high degree of risk. You should carefully consider the risks described below as well as the other information in this AnnualReport before deciding to invest in or maintain your investment in our company. The risks described below are not intended to be an all-inclusivelist of all of the potential risks relating to an investment in our securities. Any of the risk factors described below could significantlyand adversely affect our business, prospects, financial condition and results of operations. Additional risks and uncertainties not currentlyknown or that are currently considered to be immaterial may also materially and adversely affect our business. As a result, the tradingprice or value of our securities could be materially adversely affected and you may lose all or part of your investment.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Financial Position and Need for AdditionalCapital        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We have incurred significant losses and expect to continue toincur losses for the foreseeable future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have never been profitable.We have generated revenues during the fiscal years ended March 31, 2021 and March 31, 2020, in the amounts of $659,104, and $650,187,respectively, primarily from our contracts with the NIH. Our revenues, from research grants, continue to be insufficient to cover ourcost of operations. It is possible that we may not be able to enter into future government contracts beyond our current contract withthe NIH. Future profitability, if any, will require the successful commercialization of our Hemopurifier technology, other products thatmay emerge from our potential diagnostic products or from additional government contract or grant income. We may not be able to successfullycommercialize the Hemopurifier or any other products, and even if commercialization is successful, we may never be profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We will require additional financing to sustain our operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We will require significantadditional financing for our operations and for expected additional future clinical trials in the U.S., as well as to fund all of ourcontinued research and development activities for the Hemopurifier and other future products. In addition, as we expand our activities,our overhead costs to support personnel, laboratory materials and infrastructure will increase. If the financing we may require to sustainour working capital needs is unavailable to us on reasonable terms, or at all, we may be unable to support our research and FDA developmentactivities, including our planned clinical trials. The failure to implement our research and clearance activities would have a materialadverse effect on our ability to commercialize our products or continue our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We also will need to raise additional fundsthrough debt or equity financings to achieve our business objectives and to satisfy our cash obligations, which may dilute the ownershipof our existing stockholders.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We will need to raise additionalfunds through debt and/or equity financings in order to complete our ultimate business objectives, including funding working capital tosupport development and regulatory clearance of our potential products. We also may choose to raise additional funds in debt or equityfinancings if they are available to us on reasonable terms to increase our working capital and to strengthen our financial position. Anysales of additional equity or convertible debt securities could result in dilution of the equity interests of our existing stockholders,which could be substantial. Also, new investors may require that we and certain of our stockholders enter into voting arrangements thatgive them additional voting control or representation on our Board of Directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 18 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to Our Business Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We face intense competition in the medical device industry         </i>        </b>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We compete with numerous U.S.and foreign companies in the medical device industry, and many of our competitors have greater financial, personnel, operational and researchand development resources than we do. We believe that because the field of exosome research is burgeoning, multiple competitors are orwill be developing competing technologies to address exosomes in cancer. Progress is constant in the treatment and prevention of viraldiseases, so the opportunities for the Hemopurifier may be reduced there as well. Diagnostic technology may be developed that can supplantdiagnostics we are developing for neurodegenerative diseases and cancer. Our commercial opportunities will be reduced or eliminated ifour competitors develop and market products for any of the diseases we target that:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are more effective;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            have fewer or less severe adverse side effects;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are better tolerated;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are more adaptable to various modes of dosing;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are easier to administer; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are less expensive than the products or product candidates we are developing.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Even if we are successfulin developing the Hemopurifier and potential diagnostic products, and obtain FDA and other regulatory approvals necessary for commercializingthem, our products may not compete effectively with other successful products. Researchers are continually learning more about diseases,which may lead to new technologies for treatment. Our competitors may succeed in developing and marketing products that are either moreeffective than those that we may develop, alone or with our collaborators, or that are marketed before any products we develop are marketed.Our competitors include fully integrated pharmaceutical companies and biotechnology companies as well as universities and public and privateresearch institutions. Many of the organizations competing with us have substantially greater capital resources, larger research and developmentstaffs and facilities, greater experience in product development and in obtaining regulatory approvals, and greater marketing capabilitiesthan we do. If our competitors develop more effective pharmaceutical treatments for infectious disease or cancer, or bring those treatmentsto market before we can commercialize the Hemopurifier for such uses, we may be unable to obtain any market traction for our products,or the diseases we seek to treat may be substantially addressed by competing treatments. If we are unable to successfully compete againstlarger companies in the pharmaceutical industry, we may never generate significant revenue or be profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have limited experience in identifyingand working with large-scale contracts with medical device manufacturers; manufacture of our devices must comply with good manufacturingpractices in the U.S.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To achieve the levels of productionnecessary to commercialize our Hemopurifier and any other future products, we will need to secure large-scale manufacturing agreementswith contract manufacturers which comply with good manufacturing practice standards and other standards prescribed by various federal,state and local regulatory agencies in the U.S. and any other country of use. We have limited experience coordinating and overseeing themanufacture of medical device products on a large-scale. It is possible that manufacturing and control problems will arise as we attemptto commercialize our products and that manufacturing may not be completed in a timely manner or at a commercially reasonable cost. Inaddition, we may not be able to adequately finance the manufacture and distribution of our products on terms acceptable to us, if at all.If we cannot successfully oversee and finance the manufacture of our products if they obtain regulatory clearances, we may never generaterevenue from product sales and we may never be profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 19 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our Hemopurifier technology may become obsolete.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Hemopurifier product maybe made unmarketable prior to commercialization by us by new scientific or technological developments by others with new treatment modalitiesthat are more efficacious and/or more economical than our products. The homeland security industry is growing rapidly with many competitorsthat are trying to develop products or vaccines to protect against infectious disease. Any one of our competitors could develop a moreeffective product which would render our technology obsolete. Further, our ability to achieve significant and sustained penetration ofour key target markets will depend upon our success in developing or acquiring technologies developed by other companies, either independently,through joint ventures or through acquisitions. If we fail to develop or acquire, and manufacture and sell, products that satisfy ourcustomers’ demands, or we fail to respond effectively to new product announcements by our competitors by quickly introducing competitiveproducts, then market acceptance of our products could be reduced and our business could be adversely affected. Our products may not remaincompetitive with products based on new technologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our success is dependent in part on ourexecutive officers.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our success depends to a criticalextent on the continued services of our Chief Executive Officer, Charles J. Fisher, Jr., M.D., our Chief Financial Officer, James B. Frakes,our Chief Medical Officer, Steven LaRosa, M.D., and our Chief Business Officer, Guy Cipriani. If any of these key executive officers wereto leave us, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in both a delayin the implementation of our business plan and the diversion of limited working capital. The unique knowledge and expertise of these individualswould be difficult to replace within the biotechnology field. We do not currently carry key man life insurance policies on any of ourkey executive officers which would assist us in recouping our costs in the event of the loss of those officers. If either of our key officerswere to leave us, it could make it impossible, if not cause substantial delays and costs, to implement our long-term business objectivesand growth.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our inability to attract and retain qualifiedpersonnel could impede our ability to achieve our business objectives.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have ten full-time employees,consisting of our Chief Executive Officer, our Chief Financial Officer, a Chief Medical Officer, a Chief Business Officer, a Vice President,Manufacturing and Product Development, a Vice President, Clinical Operations, a Project Manager, and three research scientists. We utilize,whenever appropriate, consultants in order to conserve cash and resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Although we believe that theseemployees and consultants will be able to handle most of our additional administrative, research and development and business developmentin the near term, we will nevertheless be required over the longer-term to hire highly skilled managerial, scientific and administrativepersonnel to fully implement our business plan and growth strategies, including to mitigate the material weakness in our internal controlover financial reporting described above. Due to the specialized scientific nature of our business, we are highly dependent upon our abilityto attract and retain qualified scientific, technical and managerial personnel. Competition for these individuals, especially in San Diego,California, where many biotechnology companies are located, is intense and we may not be able to attract, assimilate or retain additionalhighly qualified personnel in the future. We may not be able to engage the services of qualified personnel at competitive prices or atall, particularly given the risks of employment attributable to our limited financial resources and lack of an established track record.Also, if we are required to attract personnel from other parts of the U.S. or abroad, we may have significant difficulty doing so dueto the high cost of living in the Southern California area and due to the costs incurred with transferring personnel to the area. If wecannot attract and retain qualified staff and executives, we will be unable to develop our products and achieve regulatory clearance,and our business could fail.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We plan to expand our operations, whichmay strain our resources; our inability to manage our growth could delay or derail implementation of our business objectives.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We will need to significantlyexpand our operations to implement our longer-term business plan and growth strategies. We will also be required to manage multiple relationshipswith various strategic partners, technology licensors, customers, manufacturers and suppliers, consultants and other third parties. Thisexpansion and these expanded relationships will require us to significantly improve or replace our existing managerial, operational andfinancial systems, procedures and controls; to improve the coordination between our various corporate functions; and to manage, train,motivate and maintain a growing employee base. The time and costs to effectuate these steps may place a significant strain on our managementpersonnel, systems and resources, particularly given the limited amount of financial resources and skilled employees that may be availableat the time. We cannot assure you that we will institute, in a timely manner or at all, the improvements to our managerial, operationaland financial systems, procedures and controls necessary to support our anticipated increased levels of operations and to coordinate ourvarious corporate functions, or that we will be able to properly manage, train, motivate and retain our anticipated increased employeebase. If we cannot manage our growth initiatives, we will be unable to commercialize our products on a large-scale in a timely manner,if at all, and our business could fail.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          As a public company with limited financial resources undertakingthe launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The directors and managementof publicly traded corporations are increasingly concerned with the extent of their personal exposure to lawsuits and stockholder claims,as well as governmental and creditor claims which may be made against them, particularly in view of recent changes in securities lawsimposing additional duties, obligations and liabilities on management and directors. Due to these perceived risks, directors and managementare also becoming increasingly concerned with the availability of directors’ and officers’ liability insurance to pay on atimely basis the costs incurred in defending such claims. While we currently carry directors’ and officers’ liability insurance,such insurance is expensive and difficult to obtain. If we are unable to continue or provide directors’ and officers’ liabilityinsurance at affordable rates or at all, it may become increasingly more difficult to attract and retain qualified outside directors toserve on our Board of Directors. We may lose potential independent board members and management candidates to other companies in the biotechnologyfield that have greater directors’ and officers’ liability insurance to insure them from liability or to biotechnology companiesthat have revenues or have received greater funding to date which can offer greater compensation packages. The fees of directors are alsorising in response to their increased duties, obligations and liabilities. In addition, our products could potentially be harmful to users,and we are exposed to claims of product liability including for injury or death. We have limited insurance and may not be able to affordrobust coverage even as our products are introduced into the market. As a company with limited resources and potential exposures to management,we will have a more difficult time attracting and retaining management and outside independent directors than a more established publicor private company due to these enhanced duties, obligations and potential liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we fail to comply with extensive regulationsof U.S. and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Hemopurifier product issubject to extensive government regulations related to development, testing, manufacturing and commercialization in the U.S. and othercountries. The determination of when and whether a product is ready for large-scale purchase and potential use will be made by the U.S.Government through consultation with a number of governmental agencies, including the FDA, the National Institutes of Health, the Centersfor Disease Control and Prevention and the Department of Homeland Security. Our Hemopurifier has not received required regulatory approvalfrom the FDA, or any foreign regulatory agencies, to be commercially marketed and sold. The process of obtaining and complying with FDAand other governmental regulatory approvals and regulations in the U.S. and in foreign countries is costly, time consuming, uncertainand subject to unanticipated delays. Obtaining such regulatory approvals, if any, can take several years. Despite the time and expenseexerted, regulatory approval is never guaranteed. We also are subject to the following risks and obligations, among others:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FDA may refuse to approve an application if it believes that applicable regulatory criteria are not satisfied;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FDA may require additional testing for safety and effectiveness;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FDA may interpret data from pre-clinical testing and clinical trials in different ways than we interpret them;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            if regulatory approval of a product is granted, the approval may be limited to specific indications or limited with respect to its distribution; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FDA may change its approval policies and/or adopt new regulations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 21 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Failure to comply with theseor other regulatory requirements of the FDA may subject us to administrative or judicially imposed sanctions, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            warning letters;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            civil penalties;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            criminal penalties;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            injunctions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            product seizure or detention;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            product recalls; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            total or partial suspension of productions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Delays in successfully completing our plannedclinical trials could jeopardize our ability to obtain regulatory approval.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our business prospects willdepend on our ability to complete studies, clinical trials, including our ongoing Early Feasibility trial in 10 to 12 patients in headand neck cancer and our study in Covid-19 patients, obtain satisfactory results, obtain required regulatory approvals and successfullycommercialize our Hemopurifier product candidate. Completion of our clinical trials, announcement of results of the trials and our abilityto obtain regulatory approvals could be delayed for a variety of reasons, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            slow patient enrollment;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            serious adverse events related to our medical device candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            unsatisfactory results of any clinical trial;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the failure of our principal third-party investigators to perform our clinical trials on our anticipated schedules;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            different interpretations of our pre-clinical and clinical data, which could initially lead to inconclusive results; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays resulting from the coronavirus pandemic.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our development costs willincrease if we have material delays in any clinical trial or if we need to perform more or larger clinical trials than planned. If thedelays are significant, or if any of our product candidates do not prove to be safe or effective or do not receive required regulatoryapprovals, our financial results and the commercial prospects for our product candidates will be harmed. Furthermore, our inability tocomplete our clinical trials in a timely manner could jeopardize our ability to obtain regulatory approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we or our suppliers fail to comply withongoing FDA or foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these productscould be subject to restrictions or withdrawal from the market.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Any product for which we obtainclearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activitiesfor such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic andforeign regulatory bodies. In particular, we and our third-party suppliers may be required to comply with the FDA’s Quality SystemRegulation, or QSR. These FDA regulations cover the methods and documentation of the design, testing, production, control, quality assurance,labeling, packaging, sterilization, storage and shipping of our products. Compliance with applicable regulatory requirements is subjectto continual review and is monitored rigorously through periodic inspections by the FDA. If we, or our manufacturers, fail to adhere toQSR requirements in the U.S., this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances,recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a materialadverse effect on our financial condition or results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, the FDA assessescompliance with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. The failure by usor one of our suppliers to comply with applicable statutes and regulations administered by the FDA, or the failure to timely and adequatelyrespond to any adverse inspectional observations or product safety issues, could result in any of the following enforcement actions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            unanticipated expenditures to address or defend such actions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            operating restrictions or partial suspension or total shutdown of production;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            withdrawing 510(k) clearances or premarket approvals that have already been granted;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            refusal to grant export approval for our products; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            criminal prosecution.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Moreover, the FDA strictlyregulates the promotional claims that may be made about approved products. In particular, a product may not be promoted for uses thatare not approved by the FDA as reflected in the product’s approved labeling. However, companies may share truthful and not misleadinginformation that is otherwise consistent with a product’s FDA approved labeling. The FDA and other agencies actively enforce thelaws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label usesmay be subject to significant civil, criminal and administrative penalties. The COVID-19 pandemic could also potentially affect the businessof the FDA and comparable authorities in other countries, which could result in delays in meetings related to planned clinical trialsand ultimately of reviews and approvals of our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Any of these sanctions couldhave a material adverse effect on our reputation, business, results of operations and financial condition. Furthermore, our key componentsuppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could resultin our failure to produce our products on a timely basis and in the required quantities, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Delays, interruptions or the cessation ofproduction by our third-party suppliers of important materials or delays in qualifying new materials, may prevent or delay our abilityto manufacture or process our Hemopurifier.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">        Mostof the raw materials used in the process for manufacturing our Hemopurifier are available from more than one supplier. However, thereare materials within the manufacturing and production process that come from single suppliers. We do not have written contracts with allof our single source suppliers, and at any time they could stop supplying our orders. FDA review of a new supplier may be required ifthese materials become unavailable from our current suppliers. Although there may be other suppliers that have equivalent materials thatwould be available to us, FDA review of any alternate suppliers, if required, could take several months or more to obtain, if able tobe obtained at all. Any delay, interruption or cessation of production by our third-party suppliers of important materials, or any delayin qualifying new materials, if necessary, would prevent or delay our ability to manufacture our Hemopurifiers. In addition, an uncorrectedimpurity, a supplier’s variation in a raw material or testing, either unknown to us or incompatible with its manufacturing process,or any other problem with our materials, testing or components, would prevent or delay the release of our Hemopurifiers for use in ourclinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <!-- Field: Page; Sequence: 23 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        For example, in late 2020,we identified during our device quality review procedures prior to product release that one of our critical suppliers had produced a Hemopurifiercomponent that was not produced to our specifications. Although no affected Hemopurifiers were released to us or to any trial sites, weare working to resolve the issue, and concurrently are working to identify alternative suppliers for this component. We believe that ourcurrent Hemopurifier inventory is sufficient for the conduct of our current ongoing clinical trials, but it is possible that the needfor our Hemopurifiers could increase or the resolution of the issue with one of our current suppliers and identification of an alternativesupplier could take longer than expected. Although we intend to procure alternative supply sources for our component and our current supplierintends to correct their issue, we can provide no assurance that we will do so in a timely manner. Any such delays could limit our abilityto meet demand for the Hemopurifier and delay our ongoing clinical trials, which would have a material adverse impact on our business,results of operations and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Difficulties in manufacturing our Hemopurifiercould have an adverse effect upon our expenses and our product revenues.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently outsource mostof the manufacturing of our Hemopurifier. The manufacturing of our Hemopurifier is difficult and complex. To support our current clinicaltrial needs, we comply with and intend to continue to comply with cGMP in the manufacture of our product. Our ability to adequately manufactureand supply our Hemopurifier in a timely matter is dependent on the uninterrupted and efficient operation of our facilities and those ofthird-parties producing raw materials and supplies upon which we rely in our manufacturing. The manufacture of our products may be impactedby:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            availability or contamination of raw materialsand components used in the manufacturing process, particularly those for which we have no other source or supplier;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            our ability to comply with new regulatory requirements,including our ability to comply with cGMP;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            inclement weather and natural disasters;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            changes in forecasts of future demand for productcomponents;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            potential facility contamination by microorganismsor viruses;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            updating of manufacturing specifications;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            product quality success rates and yields; and           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            global viruses and pandemics, including the currentCOVID-19 pandemic.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If efficient manufacture andsupply of our Hemopurifier is interrupted, we may experience delayed shipments or supply constraints. If we are at any time unable toprovide an uninterrupted supply of our products for our clinical trials, our ongoing clinical trials may be delayed, which could materiallyand adversely affect our business, results of operations and financial conditions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If our products, or malfunction of our products,cause or contribute to a death or a serious injury, we will be subject to medical device reporting regulations, which can result in voluntarycorrective actions or agency enforcement actions.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Under the FDA medical devicereporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have causedor contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injuryif the malfunction of the device or one of our similar devices were to recur. If we fail to report these events to the FDA within therequired timeframes, or at all, FDA could take enforcement action against us. Any such adverse event involving our products also couldresult in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcementaction. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedicationof our time and capital, distract management from operating our business, and may harm our reputation and financial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 24 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We outsource many of our operational anddevelopment activities, and if any party to which we have outsourced certain essential functions fails to perform its obligations underagreements with us, the development and commercialization of our lead product candidate and any future product candidates that we maydevelop could be delayed or terminated.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We rely on third-party consultantsor other vendors to manage and implement the much of the day-to-day conduct of conducting clinical trials and manufacturing our currentproduct candidates. Accordingly, we are and will continue to be dependent on the timeliness and effectiveness of the efforts of thesethird parties. Our dependence on third parties includes key suppliers and third-party service providers supporting the development, manufactureand regulatory approval of our Hemopurifier, as well as support for our information technology systems and other infrastructure. Whileour management team oversees these vendors, failure of any of these third parties to meet their contractual, regulatory and other obligationsor the development of factors that materially disrupt the performance of these third parties could have a material adverse effect on ourbusiness. For example, all of the key oversight responsibilities for the development and manufacture of our Hemopurifier are conductedby our management team, but all other activities are the responsibility of third-party vendors. It is possible that the current COVID-19epidemic might constrain the ability of needed third-party vendors to provide services that we require.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If a clinical research organizationthat we utilize is unable to allocate sufficient qualified personnel to our studies in a timely manner or if the work performed by itdoes not fully satisfy the requirements of the FDA or other regulatory agencies, we may encounter substantial delays and increased costsin completing our development efforts. Any manufacturer that we select may encounter difficulties in the manufacture of new products incommercial quantities, including problems involving product yields, product stability or shelf life, quality control, adequacy of controlprocedures and policies, compliance with FDA regulations and the need for further FDA approval of any new manufacturing processes andfacilities. If any of these occur, the development and commercialization of our product candidates could be delayed, curtailed or terminatedbecause we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we or our contractors or service providersfail to comply with regulatory laws and regulations, we or they could be subject to regulatory actions, which could affect our abilityto develop, market and sell our product candidates and any other or future product candidates that we may develop and may harm our reputation.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we or our manufacturersor other third-party contractors fail to comply with applicable federal, state or foreign laws or regulations, we could be subject toregulatory actions, which could affect our ability to successfully develop, market and sell our Hemopurifier product candidate or anyfuture product candidates under development and could harm our reputation and lead to reduced or non-acceptance of our proposed productcandidates by the market. Even technical recommendations or evidence by the FDA through letters, site visits, and overall recommendationsto academia or biotechnology companies may make the manufacturing of a clinical product extremely labor intensive or expensive, makingthe product candidate no longer viable to manufacture in a cost-efficient manner. The mode of administration may make the product candidatenot commercially viable. The required testing of the product candidate may make that candidate no longer commercially viable. The conductof clinical trials may be critiqued by the FDA, or a clinical trial site’s Institutional Review Board or Institutional BiosafetyCommittee, which may delay or make impossible clinical testing of a product candidate. The Institutional Review Board for a clinical trialmay stop a trial or deem a product candidate unsafe to continue testing. This would have a material adverse effect on the value of theproduct candidate and our business prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We will need to outsource and rely on thirdparties for the clinical development and manufacture, sales and marketing of Hemopurifier or any future product candidates that we maydevelop, and our future success will be dependent on the timeliness and effectiveness of the efforts of these third parties.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We do not have the requiredfinancial and human resources to carry out on our own all the pre-clinical and clinical development for our Hemopurifier product candidateor any other or future product candidates that we may develop, and do not have the capability and resources to manufacture, market orsell our Hemopurifier product candidate or any future product candidates that we may develop. Our business model calls for the partialor full outsourcing of the clinical and other development and manufacturing, sales and marketing of our product candidates in order toreduce our capital and infrastructure costs as a means of potentially improving our financial position. Our success will depend on theperformance of these outsourced providers. If these providers fail to perform adequately, our development of product candidates may bedelayed and any delay in the development of our product candidates would have a material and adverse effect on our business prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We are and will be exposed to product liability risks, and clinicaland preclinical liability risks, which could place a substantial financial burden upon us should we be sued.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our business exposes us topotential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of medical devices.Claims may be asserted against us. A successful liability claim or series of claims brought against us could have a material adverse effecton our business, financial condition and results of operations. We may not be able to continue to obtain or maintain adequate productliability insurance on acceptable terms, if at all, and such insurance may not provide adequate coverage against potential liabilities.Claims or losses in excess of any product liability insurance coverage that we may obtain could have a material adverse effect on ourbusiness, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Hemopurifier product candidatemay be used in connection with medical procedures in which it is important that those products function with precision and accuracy. Ifour product candidates, including our Hemopurifier, do not function as designed, or are designed improperly, we may be forced by regulatoryagencies to withdraw such products from the market. In addition, if medical personnel or their patients suffer injury as a result of anyfailure of our products to function as designed, or our products are designed inappropriately, we may be subject to lawsuits seeking significantcompensatory and punitive damages. The risk of product liability claims, product recalls and associated adverse publicity is inherentin the testing, manufacturing, marketing and sale of medical products. We have recently obtained general clinical trial liability insurancecoverage. However, our insurance coverage may not be adequate or available. We may not be able to secure product liability insurance coverageon acceptable terms or at reasonable costs when needed. Any product recall or lawsuit seeking significant monetary damages may have amaterial effect on our business and financial condition. Any liability for mandatory damages could exceed the amount of our coverage.Moreover, a product recall could generate substantial negative publicity about our products and business and inhibit or prevent commercializationof other future product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have not received, and may never receive,approval from the FDA to market a medical device in the United States.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Before a new medical devicecan be marketed in the U.S., it must first receive a PMA or 510(k) clearance from the FDA, unless an exemption applies. A PMA submission,which is a higher standard than a 510(k) clearance, is used to demonstrate to the FDA that a new or modified device is safe and effective.The 510(k) is used to demonstrate that a device is “substantially equivalent” to a predicate device (one that has been clearedby the FDA). We expect that any product we seek regulatory approval for, including the Hemopurifier, will require a PMA. The FDA approvalprocess involves, among other things, successfully completing clinical trials and filing for and obtaining a PMA. The PMA process requiresus to prove the safety and effectiveness of our products to the FDA’s satisfaction. This process, which includes preclinical studiesand clinical trials, can take many years and requires the expenditure of substantial resources and may include post-marketing surveillanceto establish the safety and efficacy of the product. Notwithstanding the effort and expense incurred, the process may never result inthe FDA granting a PMA. Data obtained from preclinical studies and clinical trials are subject to varying interpretations that could delay,limit or prevent regulatory approval. Delays or rejections may also be encountered based upon changes in governmental policies for medicaldevices during the period of product development. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our inability to demonstrate safety or effectiveness of the Hemopurifier or any other product we develop to the FDA’s satisfaction;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            insufficient data from our preclinical studies and clinical trials, including for our Hemopurifier, to support approval;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure of the facilities of our third-party manufacturer or suppliers to meet applicable requirements;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            inadequate compliance with preclinical, clinical or other regulations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our failure to meet the FDA’s statistical requirements for approval; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in the FDA’s approval policies, or the adoption of new regulations that require additional data or additional clinical studies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 26 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Modifications to productsthat are approved through a PMA application generally need FDA approval. Similarly, some modifications made to products cleared througha 510(k) may require a new 510(k). The FDA’s 510(k) clearance process usually takes from three to 12 months, but may last longer.The process of obtaining a PMA is much costlier and more uncertain than the 510(k) clearance process and generally takes from one to threeyears, or even longer, from the time the application is submitted to the FDA until an approval is obtained. Any of our products consideredto be a class III device, which are considered to pose the greatest risk and the approval of which is governed by the strictest guidelines,will require the submission and approval of a PMA in order for us to market it in the U.S. We also may design new products in the futurethat could require the clearance of a 510(k).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Although we have receivedapproval to proceed with clinical trials of the Hemopurifier in the U.S. under the investigational device exemption, the current approvalfrom the FDA to proceed could be revoked, the study could be unsuccessful, or the FDA PMA approval may not be obtained or could be revoked.Even if we obtain approval, the FDA or other regulatory authorities may require expensive or burdensome post-market testing or controls.Any delay in, or failure to receive or maintain, clearance or approval for our future products could prevent us from generating revenuefrom these products or achieving profitability. Additionally, the FDA and other regulatory authorities have broad enforcement powers.Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some physicians from using our products and adverselyaffect our reputation and the perceived safety and efficacy of our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The approval requirements for medical products used to fightbioterrorism and pandemics are still evolving, and any products we develop for such uses may not meet these requirements.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are advancing product candidatesunder governmental policies that regulate the development and commercialization of medical treatment countermeasures against bioterrorand pandemic threats.  While we intend to pursue FDA market clearance to treat infectious bioterror and pandemic threats, it is oftennot feasible to conduct human studies against these deadly high threat pathogens. For example, the Hemopurifier is an investigationaldevice that has not yet received FDA approval for any indication. We continue to investigate the potential for the use of the Hemopurifierin viral diseases under an open IDE and our FDA Breakthrough Designation for “…the treatment of life-threatening glycosylatedviruses that are not addressed with an approved therapy.” We currently have an open FDA approved Expanded Access Protocol for thetreatment of Ebola infected patients in the U.S. and a corresponding HealthCanada approval in Canada. Based on our studies to date, theHemopurifier can potentially clear many viruses that are pathogenic in humans, including HCV, HIV and Ebola. We do have preclinical datasuggesting that it could clear a closely related coronavirus (MERS).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 17, 2020, the FDAapproved a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients withSARS-CoV-2/COVID-19 in a New Feasibility Study.        <font style="background-color: white">         That study’s plan is to enroll up to 40 subjectsat up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit,or ICU, and will have acute lung injury and/or severe or life threatening disease, among other criteria. Endpoints for this study, inaddition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT # 04595903). The initial sites for thistrial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital – Irvine in Irvine, CA and Loma Linda Hospitalin Loma Linda, CA, have completed clinical trial agreements, and have received IRB approval in the case of the Hoag hospitals, and arepreparing to open for patient enrollment. Under Single Patient Emergency Use regulations, the Company has also treated two patients withCOVID-19 with the Hemopurifier.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Additionally, we have a verylimited supply of Hemopurifiers and therefore any use in this pandemic will be only investigational in a very small number of patients,even if it appears that the device can help those patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Thus, we may not be able todemonstrate the effectiveness of our treatment countermeasures through controlled human efficacy studies. Additionally, a change in governmentpolicies could impair our ability to obtain regulatory approval and the FDA may not approve any of our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 27 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The results of our clinical trials may notsupport our product candidate claims or may result in the discovery of adverse side effects.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Any research and development,pre-clinical testing and clinical trial activities involving our Hemopurifier and any additional products that we may develop are subjectto extensive regulation and review by numerous governmental authorities both in the U.S. and abroad. Clinical studies must be conductedin compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimatelybe used to support market clearance for these products. Even if our clinical trials are completed as planned, the results of these trialsmay not support our product candidate claims and the FDA may not agree with our conclusions regarding the trial results. Success in pre-clinicalstudies and early clinical trials does not ensure that later clinical trials will be successful, and the later trials may not replicatethe results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates aresafe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others.Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercializeour product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse sideeffects that are not currently part of the product candidate’s profile.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          U.S. legislative or FDA regulatory reformsmay make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distributeour products after approval is obtained.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        From time to time, legislationis drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufactureand marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpretedby the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretationsof existing regulations may impose additional costs or lengthen review times of future products. It is impossible to predict whether legislativechanges will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be ornew product development efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our current and future business activitiesare subject to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy andsecurity and other healthcare laws and regulations, which could expose us to significant penalties.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are currently and willin the future be subject to healthcare regulation and enforcement by the U.S. federal government and the states in which we will conductour business once our product candidates are approved by the FDA and commercialized in the United States. In addition to the FDA’srestrictions on marketing of approved products, the U.S. healthcare laws and regulations that may affect our ability to operate include:the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy and security laws; andfederal transparency laws related to payments and/or other transfers of value made to physicians (defined to include doctors, dentists,optometrists, podiatrists and chiropractors) and other healthcare professionals (beginning January 1, 2022) and teaching hospitals. Manystates have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating complianceefforts. These laws may adversely affect our sales, marketing and other activities with respect to any product candidate for which wereceive approval to market in the United States by imposing administrative and compliance burdens on us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because of the breadth ofthese laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our businessactivities, particularly any sales and marketing activities after a product candidate has been approved for marketing in the United States,could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal andstate laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, andadministrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcareprograms, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement toresolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adverselyaffect our ability to operate our business and our results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 28 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We are subject to stringent and changingprivacy laws, regulations and standards as well as policies, contracts and other obligations related to data privacy and security. Ouractual or perceived failure to comply with such obligations could lead to government enforcement actions (that could include fines andpenalties), a disruption of our clinical trials or commercialization of our products, private litigation, harm to our reputation, or otheradverse effects on our business or prospects.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We collect, receive, store,process, use, generate, transfer, disclose, make accessible, protect and share personal information and other information, including informationwe collect in connection with clinical trials, or “Process” or “Processing”, as necessary to operate our business,for legal and marketing purposes, and for other business-related purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There are numerous federal,state, local and international laws, regulations and guidance regarding privacy, information security and Processing, the number and scopeof which is changing, subject to differing applications and interpretations, and which may be inconsistent. We are, or may become, subjectto these laws, regulations, and guidance, and we are also subject to the terms of our external and internal privacy and security policies,representations, certifications, standards, publications, frameworks, and contractual obligations to third parties related to privacy,information security and Processing, or Data Protection Obligations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we fail, or are perceivedto have failed, to address or comply with Data Protection Obligations, it could: increase our compliance and operational costs; exposeus to regulatory scrutiny, actions, fines and penalties; result in reputational harm; interrupt or stop our clinical trials; result inlitigation and liability; result in an inability to process personal data or to operate in certain jurisdictions; harm our business operationsor financial results or otherwise result in a material harm to our business, or each, a Material Adverse Impact. Additionally, given thatData Protection Obligations impose complex and burdensome obligations and that there is substantial uncertainty over the interpretationand application of these obligations, we may be required to incur material costs, divert management attention, and change our businessoperations, including our clinical trials, in an effort to comply, which could materially adversely affect our business operations andfinancial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The California Consumer PrivacyAct of 2018, CCPA, is an example of the increasingly stringent data protection legislation in the United States. The CCPA gives Californiaresidents expanded rights to access and require deletion of their personal information, opt-out of certain personal information sharing,and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, aswell as a private right of action for data breaches and statutory damages ranging from $100 to $750 per violation, which is expected toincrease data breach class action litigation and result in significant exposure to costly legal judgements and settlements. Although thereare limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities dependingon how they are interpreted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The European Union’sGeneral Data Protection Regulation, or GDPR, is an example of the type of data protection legislation being passed in international jurisdictions.The GDPR requires covered businesses to, among other requirements, provide detailed disclosures, contractually commit to data protectionmeasures in our contracts, maintain adequate data security measures, notify regulators and affected individuals of certain data breachesand meet extensive privacy governance and documentation requirements. Companies that violate the GDPR can face private litigation, restrictionson data processing, and fines of up to the greater of 20 million Euros or 4% of their worldwide annual revenue. In addition, the GDPRincludes restrictions on cross-border data transfers. A Recent decision by the Court of Justice of the European Union, or the “SchremsII” ruling, however, has created substantial uncertainty regarding how to legally transfer personal data from Europe to the UnitedStates. There are few, if any, viable options for us or our vendors to legally transfer personal data from Europe to the United States,which could materially impact our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If our security measures, or those maintainedon our behalf, are compromised, or the security, confidentiality, integrity or availability of our information technology, software, services,networks, communications or data is compromised, limited or fails, this could result in a Material Adverse Impact         </i>        </b>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the ordinary course ofour business, we Process proprietary, confidential and sensitive information, including personal data, intellectual property, trade secrets,and proprietary business information owned or controlled by ourselves or other third parties, or collectively, Sensitive Information.We may use and share Sensitive Information with service providers and subprocessors and other third parties upon whom we rely to helpus operate our business. If we, our service providers, partners, or other relevant third parties have experienced, or in the future experience,any security incident(s) that result in any data loss; deletion or destruction; unauthorized access to; loss, unauthorized acquisition,disclosure, or exposure of, Sensitive Information, or compromise related to the security, confidentiality, integrity of our (or their)information technology, software, services, communications or data (any, a “Security Breach”), it may result in a MaterialAdverse Impact (as defined above), including the diversion of funds to address the breach, and interruptions, delays, or outages in ouroperations and development programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 29 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Cyberattacks, malicious internet-basedactivity and online and offline fraud are prevalent and continue to increase. In addition to threats from traditional computer “hackers,”threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, denial-of-service attacks (such ascredential stuffing) and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (includingadvanced persistent threat intrusions). We may also be the subject of phishing attacks, viruses, malware installation, server malfunction,software or hardware failures, loss of data or other computer assets, or other similar issues.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may be required to expendsignificant resources, fundamentally change our business activities and practices, or modify our operations, including clinical trialactivities, or information technology in an effort to protect against Security Breaches and to mitigate, detect and remediate actual andpotential vulnerabilities. Applicable Data Protection Obligations (as defined above) may require us to implement specific security measuresor use industry-standard or reasonable measures to protect against Security Breaches. There can be no assurances that our security measuresor those of third parties upon whom we rely will be effective in protecting against Security Incidents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Applicable Data ProtectionObligations (as defined above) may require us to notify relevant stakeholders of Security Breaches, including affected individuals, partners,collaborators, regulators, law enforcement agencies and others. Such disclosures are costly, and the disclosures or the failure to complywith such requirements could lead to Material Adverse Impacts. There can be no assurances that any limitations or exclusions of liabilityin our contracts would be adequate or would otherwise protect us from liabilities or damages if we fail to comply with Data ProtectionObligations related to information security or Security Breaches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We cannot be sure that ourinsurance coverage, if any, will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect toclaims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or Material Adverse Impacts arisingout of our Processing operations, privacy and security practices, or Security Breaches that we may experience. The successful assertionof one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies(including premium increases or the imposition of large excess or deductible or co-insurance requirements), could have a Material AdverseImpact.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Should our products be approved for commercialization,lack of third-party coverage and reimbursement for our devices could delay or limit their adoption.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In both the U.S. and internationalmarkets, the use of medical devices is dependent in part on the availability of reimbursement from third-party payors, such as governmentand private insurance plans. Healthcare providers that use medical devices generally rely on third-party payors to pay for all or partof the costs and fees associated with the medical procedures being performed or to compensate them for their patient care services. Shouldour products under development be approved for commercialization by the FDA, any such products may not be considered cost-effective, reimbursementmay not be available in the U.S. or other countries, if approved, and reimbursement may not be sufficient to allow sales of our futureproducts, including the Hemopurifier, on a profitable basis. The coverage decisions of third-party payors will be significantly influencedby the assessment of our future products by health technology assessment bodies. These assessments are outside our control and any suchevaluations may not be conducted or have a favorable outcome.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If approved for use in theU.S., we expect that any products that we develop, including the Hemopurifier, will be purchased primarily by medical institutions, whichwill in turn bill various third-party payors for the health care services provided to patients at their facility. Payors may include theCenters for Medicare &amp; Medicaid Services, or CMS, which administers the Medicare program and works in partnership with state governmentsto administer Medicaid, other government programs and private insurance plans. The process involved in applying for coverage and incrementalreimbursement from CMS is lengthy and expensive. Further, Medicare coverage is based on our ability to demonstrate that the treatmentis “reasonable and necessary” for Medicare beneficiaries. Even if products utilizing our Aethlon Hemopurifier technology receiveFDA and other regulatory clearance or approval, they may not be granted coverage and reimbursement by any payor, including by CMS. Forsome governmental programs, such as Medicaid, coverage and adequate reimbursement differ from state to state and some state Medicaid programsmay not pay adequate amounts for the procedure necessary to utilize products utilizing our technology system, or any payment at all. Moreover,many private payors use coverage decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursementpolicies and amounts. However, no uniform policy requirement for coverage and reimbursement for medical devices exists among third-partypayors in the United States. Therefore, coverage and reimbursement can differ significantly from payor to payor. If CMS or other agencieslimit coverage or decrease or limit reimbursement payments for doctors and hospitals, this may affect coverage and reimbursement determinationsby many private payors for any products that we develop.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Should any of our potential products, includingthe Hemopurifier, be approved for commercialization, adverse changes in reimbursement policies and procedures by payors may impact ourability to market and sell our products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Healthcare costs have risensignificantly over the past decade, and there have been and continue to be proposals by legislators, regulators and third-party payorsto decrease costs. Third-party payors are increasingly challenging the prices charged for medical products and services and institutingcost containment measures to control or significantly influence the purchase of medical products and services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        For example, in the U.S.,the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively,PPACA, among other things, reduced and/or limited Medicare reimbursement to certain providers. However, on December 14, 2018, a TexasU.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the “individual mandate”was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals forthe 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the DistrictCourt to determine whether the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court is currently reviewing thecase, although it is unclear when a decision will be made or how the Supreme Court will rule. The Budget Control Act of 2011, as amendedby subsequent legislation, further reduces Medicare’s payments to providers by two percent through fiscal year 2030. However, COVID-19relief legislation suspended the two percent Medicare sequester from May 1, 2020 through December 31, 2021. These reductions may reduceproviders’ revenues or profits, which could affect their ability to purchase new technologies. Furthermore, the healthcare industryin the U.S. has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs by imposinglower payment rates and negotiating reduced contract rates with service providers. Legislation could be adopted in the future that limitspayments for our products from governmental payors. It is possible that additional governmental action is taken to address the COVID-19pandemic. In addition, commercial payors such as insurance companies, could adopt similar policies that limit reimbursement for medicaldevice manufacturers’ products. Therefore, it is possible that our product or the procedures or patient care performed using ourproduct will not be reimbursed at a cost-effective level. We face similar risks relating to adverse changes in reimbursement proceduresand policies in other countries where we may market our products. Reimbursement and healthcare payment systems vary significantly amonginternational markets. Our inability to obtain international reimbursement approval, or any adverse changes in the reimbursement policiesof foreign payors, could negatively affect our ability to sell our products and have a material adverse effect on our business and financialcondition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our ability to use net operating loss carryforwardsand certain other tax attributes to offset future taxable income or taxes may be limited.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Under the Tax Cuts and JobsAct of 2017, as modified by the CARES Act, federal net operating losses incurred in tax years beginning after December 31, 2017, may becarried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020,is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act of2017 or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisionsof state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change inits equity ownership value over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwardsand other pre-change tax attributes to offset its post-change income or taxes may be limited. We believe we have not experienced an ownershipchange in the past three years, however, we could experience ownership changes in the future as a result of subsequent shifts in our stockownership, some of which may be outside of our control. If we achieve profitability and an ownership change occurs and our ability touse our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing ourfuture tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwardsis suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limitson the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our use of hazardous materials, chemicalsand viruses exposes us to potential liabilities for which we may not have adequate insurance.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our research and developmentinvolves the controlled use of hazardous materials, chemicals and viruses. The primary hazardous materials include chemicals needed toconstruct the Hemopurifier cartridges and the infected plasma samples used in preclinical testing of the Hemopurifier. All other chemicalsare fully inventoried and reported to the appropriate authorities, such as the fire department, which inspects the facility on a regularbasis. We are subject to federal, state, local and foreign laws governing the use, manufacture, storage, handling and disposal of suchmaterials. Although we believe that our safety procedures for the use, manufacture, storage, handling and disposal of such materials complywith the standards prescribed by federal, state, local and foreign regulations, we cannot completely eliminate the risk of accidentalcontamination or injury from these materials. We have had no incidents or problems involving hazardous chemicals or biological samples.In the event of such an accident, we could be held liable for significant damages or fines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 31 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently carry a limitedamount of insurance to protect us from damages arising from hazardous materials. Our product liability policy has a $5,000,000 limit ofliability that would cover certain releases of hazardous substances away from our facilities. For our facilities, our property policyprovides $25,000 in coverage for contaminant clean-up or removal and $50,000 in coverage for damages to the premises resulting from contamination.Should we violate any regulations concerning the handling or use of hazardous materials, or should any injuries or death result from ouruse or handling of hazardous materials, we could be the subject of substantial lawsuits by governmental agencies or individuals. We maynot have adequate insurance to cover all or any of such claims, if any. If we were responsible to pay significant damages for violationsor injuries, if any, we might be forced to cease operations since such payments could deplete our available resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our products may in the future be subjectto product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, includinga third-country authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The FDA and similar foreigngovernmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies ordefects in design or manufacture. For the FDA, the authority to require a recall must be based on a finding that there is reasonable probabilitythat the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recallof our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative,recall a product if any material deficiency in a device is found. The FDA requires that certain classifications of recalls be reportedto the FDA within 10 working days after the recall is initiated. A government-mandated or voluntary recall by us or one of our internationaldistributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, designor labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources andhave an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce ourproducts in a cost-effective and timely manner in order to meet our customers’ demands. We may also be subject to liability claims,be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generateprofits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA or another third-countrycompetent authority. We may initiate voluntary recalls involving our products in the future that we determine do not require notificationof the FDA or another third-country competent authority. If the FDA disagrees with our determinations, they could require us to reportthose actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition,the FDA could take enforcement action for failing to report recalls. We are also required to follow detailed recordkeeping requirementsfor all firm-initiated medical device corrections and removals.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our business is subject to risks arisingfrom the recent COVID-19 pandemic.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The current COVID-19 worldwidepandemic has presented substantial public health and economic challenges and is affecting our employees, patients, communities and businessoperations, as well as the U.S. and global economy and financial markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        International and U.S. governmentalauthorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of “stay-at-home”orders, and restricting business functions outside of one’s home. In response, we have implemented a work from home policy for allnon-laboratory employees, following the guidelines or directives issued by federal, state and local government agencies in the U.S.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To date, we do not currentlyanticipate any interruptions in supply. In addition, while we are continuing the process of getting our clinical trial underway, we expectthat COVID-19 precautions may directly or indirectly impact the timeline for the trial. As the COVID-19 pandemic continues to spread aroundthe globe, we may experience disruptions that could severely impact our business, clinical trials and manufacturing and supply chains,including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            further delays or difficulties in enrolling patients in our clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 32 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            30            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="text-align: justify; width: 48px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and interruption in global shipping that may affect the transport of clinical trial materials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays in receiving feedback or approvals from the FDA or other regulatory authorities with respect to future clinical trials or regulatory submissions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            refusal of the FDA to accept data from clinical trials in affected geographies; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, the spread ofCOVID-19 has had and may continue to impact the trading price of shares of our common stock and could further negatively impact our abilityto raise additional capital on a timely basis or at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The COVID-19 pandemic continuesto rapidly evolve. The extent to which COVID-19 may impact our business, including our clinical trials, manufacturing and supply chainsand financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such asthe continued geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the UnitedStates and other countries, continued business closures or business disruptions and the effectiveness of actions taken in the United Statesand other countries to contain and treat the disease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our products are manufactured with raw materialsthat are sourced from specialty suppliers with limited competitors and we may therefore be unable to access the materials we need to manufactureour products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Specifically, the Hemopurifiercontains three critical components with limited supplier numbers. The base cartridge on which the Hemopurifier is constructed is sourcedfrom Medica S.p.A and we are dependent on the continued availability of these cartridges. We currently purchase the diatomaceous earthfrom Janus Scientific Inc., our distributor; however, the product is manufactured by Imerys Minerals Ltd., which is the only supplierof this product. The Galanthus nivalis agglutinin, or GNA, is sourced from Vector Laboratories, Inc. and also is available from othersuppliers; however, Sigma Aldrich is the only approved back up supplier at this time. A business interruption at any of these sources,including interruption resulting from the coronavirus pandemic, could have a material impact on our ability to manufacture the Hemopurifier.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 33 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            31            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Even though we have received breakthroughdevice designation for the Hemopurifier for two independent indications, this designation may not expedite the development or review ofthe Hemopurifier and does not provide assurance ultimately of PMA submission or approval by the FDA.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Breakthrough Devices Programis a voluntary program intended to expedite the review, development, assessment and review of certain medical devices that provide formore effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions for which no approvedor cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives. All submissions for devicesdesignated as Breakthrough Devices will receive priority review, meaning that the review of the submission is placed at the top of theappropriate review queue and receives additional review resources, as needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Although breakthrough designationor access to any other expedited program may expedite the development or approval process, it does not change the standards for approval.Although we obtained breakthrough device designation for the Hemopurifier for two indications, we may not experience faster developmenttimelines or achieve faster review or approval compared to conventional FDA procedures. For example, the time required to identify andresolve issues relating to manufacturing and controls, the acquisition of a sufficient supply of our product for clinical trial purposesor the need to conduct additional nonclinical or clinical studies may delay approval by the FDA, even if the product qualifies for breakthroughdesignation or access to any other expedited program. Access to an expedited program may also be withdrawn by the FDA if it believes thatthe designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited reviewprocedure does not ensure that we will ultimately obtain regulatory approval for the product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Compliance with laws, regulations, and relatedinterpretations and related legal claims or other regulatory enforcement actions could impact our business, and we face additional risksand uncertainties related to any potential actions resulting from the Securities and Exchange Commission’s, or the SEC, ongoinginvestigation, or any other investigation or action.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On February 7, 2020, the SECissued an Order of Suspension of Trading, or SEC Order, temporarily suspending trading in our stock for a period of ten days. The SECOrder stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appearedto be disseminated by third party promotors and recent and unusual market activity since at least January 22, 2020. Although our stockresumed trading upon expiration of the SEC Order, we are unable to predict the outcome of the SEC investigation or any other actions theSEC may take in connection therewith. Furthermore, the Company’s reputation may be negatively impacted. As a result, the potentialimpact to the Company’s business, if any, cannot be determined.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our bylaws designate the Eighth JudicialDistrict Court of Clark County, Nevada, as the sole and exclusive forum for certain types of actions and proceedings that may be initiatedby our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or ourdirectors, officers, employees or agents.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our bylaws require that, tothe fullest extent permitted by law, and unless the Company consents in writing to the selection of an alternative forum, the Eighth JudicialDistrict Court of Clark County, Nevada, will, to the fullest extent permitted by law, be the sole and exclusive forum for each of thefollowing:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any derivative action or proceeding brought in the name or right of the Company or on its behalf,           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Company to the Company or the Company’s stockholders,           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any action arising or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of our articles of incorporation or bylaws, or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any action asserting a claim governed by the internal affairs doctrine, including, without limitation, any action to interpret, apply, enforce or determine the validity of our articles of incorporation or bylaws.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 34 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            32            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        However, our bylaws providethat the exclusive forum provisions do not apply to suits brought to enforce any liability or duty created by the Exchange Act or anyother claim for which the federal courts have exclusive jurisdiction. We note that there is uncertainty as to whether a court would enforcethe provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Althoughwe believe this provision benefits us by providing increased consistency in the application of Nevada law in the types of lawsuits towhich it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to Our Intellectual Property and Related Litigation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We rely upon licenses and patent rights from third parties whichare subject to termination or expiration.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We rely in part upon third-partylicenses and ownership rights assigned from third parties for the development of specific uses for our Hemopurifier devices. For example,we are researching, developing and testing cancer-related applications for our devices under patents assigned from the London Health ScienceCenter Research, Inc. Should any of our licenses be prematurely terminated for any reason, or if the patents and intellectual propertyassigned to us or owned by such entities that we have licensed are challenged or defeated by third parties, our research efforts couldbe materially and adversely affected. Our licenses and patents assigned to us may not continue in force for as long as we require forour research, development and testing of cancer treatments. It is possible that, if our licenses terminate or the underlying patents andintellectual property is challenged or defeated or the patents and intellectual property assigned to us is challenged or defeated, suitablereplacements may not be obtained or developed on terms acceptable to us, if at all. There is also the related risk that we may not beable to make the required payments under any patent license or assignment agreement, in which case we may lose to ability to use one ormore of the licensed or assigned patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We could become subject to intellectualproperty litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, preventus from selling our commercially available products and/or reduce the margins we may realize from our products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The medical devices industryis characterized by extensive litigation and administrative proceedings over patent and other intellectual property rights. Whether aproduct infringes a patent involves complex legal and factual issues, and the determination is often uncertain. There may be existingpatents of which we are unaware that our products under development may inadvertently infringe. The likelihood that patent infringementclaims may be brought against us increases as the number of participants in the infectious market increases and as we achieve more visibilityin the market place and introduce products to market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Any infringement claim againstus, even if without merit, may cause us to incur substantial costs, and would place a significant strain on our financial resources, divertthe attention of management from our core business, and harm our reputation. In some cases, litigation may be threatened or brought bya patent holding company or other adverse patent owner who has no relevant product revenues and against whom our patents may provide littleor no deterrence. If we are found to infringe any patents, we could be required to pay substantial damages, including triple damages ifan infringement is found to be willful. We also could be required to pay royalties and could be prevented from selling our products unlesswe obtain a license or are able to redesign our products to avoid infringement. We may not be able to obtain a license enabling us tosell our products on reasonable terms, or at all. If we fail to obtain any required licenses or make any necessary changes to our technologiesor the products, we may be unable to commercialize one or more of our products or may have to withdraw products from the market, all ofwhich would have a material adverse effect on our business, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If the combination of patents, trade secretsand contractual provisions upon which we rely to protect our intellectual property is inadequate, our ability to commercialize our productssuccessfully will be harmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our success depends significantlyon our ability to protect our proprietary rights to the technologies incorporated in our products. We currently have five issued U.S.patents and five pending U.S. patent applications. We also have 33 issued foreign patents and have applied for six additional internationalpatents. Our issued patents begin to expire in 2024, with the last of these patents expiring in 2036, although terminal disclaimers, patentterm extension or patent term adjustment can shorten or lengthen the patent term. We rely on a combination of patent protection, tradesecret laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, thesemay not adequately protect our rights or permit us to gain or keep any competitive advantage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 35 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            33            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The issuance of a patent isnot conclusive as to its scope, validity or enforceability. The scope, validity or enforceability of our issued patents can be challengedin litigation or proceedings before the U.S. Patent and Trademark Office or foreign patent offices where our applications are pending.The U.S. Patent and Trademark Office or foreign offices may deny or require significant narrowing of claims in our pending patent applications.Patents issued as a result of the pending patent applications, if any, may not provide us with significant commercial protection or beissued in a form that is advantageous to us. Proceedings before the U.S. Patent and Trademark Office or foreign offices could result inadverse decisions as to the priority of our inventions and the narrowing or invalidation of claims in issued patents. The laws of someforeign countries may not protect our intellectual property rights to the same extent as the laws of the U.S., if at all. Some of ourpatents may expire before we receive FDA approval to market our products in the U.S. or we receive approval to market our products ina foreign country. Although we believe that certain patent applications and/or other patents issued more recently will help protect theproprietary nature of the Hemopurifier treatment technology, this protection may not be sufficient to protect us during the developmentof that technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our competitors may successfullychallenge and invalidate or render unenforceable our issued patents, including any patents that may issue in the future, which could preventor limit our ability to market our products and could limit our ability to stop competitors from marketing products that are substantiallyequivalent to ours. In addition, competitors may be able to design around our patents or develop products that provide outcomes that arecomparable to our products but that are not covered by our patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have also entered intoconfidentiality and assignment of intellectual property agreements with all of our employees, consultants and advisors directly involvedin the development of our technology as one of the ways we seek to protect our intellectual property and other proprietary technology.However, these agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary informationin the event of unauthorized use or disclosure or other breaches of the agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the event a competitorinfringes upon any of our patents or other intellectual property rights, enforcing our rights may be difficult, time consuming and expensive,and would divert management’s attention from managing our business. We may not be successful on the merits in any enforcement effort.In addition, we may not have sufficient resources to litigate, enforce or defend our intellectual property rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may rely on licenses for new technology,which may affect our continued operations with respect thereto.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As we develop our technology,we may need to license additional technologies to optimize the performance of our products. We may not be able to license these technologieson commercially reasonable terms or at all. In addition, we may fail to successfully integrate any licensed technology into our proposedproducts. Our inability to obtain any necessary licenses could delay our product development and testing until alternative technologiescan be identified, licensed and integrated. The inability to obtain any necessary third-party licenses could cause us to abandon a particulardevelopment path, which could seriously harm our business, financial position and results of our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          New technology may lead to our competitorsdeveloping superior products which would reduce demand for our products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Research into technologiessimilar to ours is proceeding at a rapid pace, and many private and public companies and research institutions are actively engaged inthe development of products similar to ours. These new technologies may, if successfully developed, offer significant performance or priceadvantages when compared with our technologies. Our existing patents or our pending and proposed patent applications may not offer meaningfulprotection if a competitor develops a novel product based on a new technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we are unable to protect our proprietarytechnology and preserve our trade secrets, we will increase our vulnerability to competitors which could materially adversely impact ourability to remain in business.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our ability to successfullycommercialize our products will depend on our ability to protect those products and our technology with domestic and foreign patents.We will also need to continue to preserve our trade secrets. The issuance of a patent is not conclusive as to its validity or as to theenforceable scope of the claims of the patent. The patent positions of technology companies, including us, are uncertain and involve complexlegal and factual issues. Our patents may not prevent other companies from developing similar products or products which produce benefitssubstantially the same as our products, and other companies may be issued patents that may prevent the sale of our products or requireus to pay significant licensing fees in order to market our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 36 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            34            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        From time to time, we mayneed to obtain licenses to patents and other proprietary rights held by third parties in order to develop, manufacture and market ourproducts. If we are unable to timely obtain these licenses on commercially reasonable terms, our ability to commercially exploit suchproducts may be inhibited or prevented. Our pending patent applications may not result in issued patents, patent protection may not besecured for any particular technology, and our issued patents may not be valid or enforceable or provide us with meaningful protection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we are required to engage in expensiveand lengthy litigation to enforce our intellectual property rights, such litigation could be very costly and the results of such litigationmay not be satisfactory.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Although we have entered intoinvention assignment agreements with our employees and with certain advisors, and we routinely enter into confidentiality agreements withour contract partners, if those employees, advisors or contract partners develop inventions or processes independently that may relateto products or technology under development by us, disputes may arise about the ownership of those inventions or processes. Time-consumingand costly litigation could be necessary to enforce and determine the scope of our rights under these agreements. In addition, we maybe required to commence litigation to enforce such agreements if they are violated, and it is certainly possible that we will not haveadequate remedies for breaches of our confidentiality agreements as monetary damages may not be sufficient to compensate us. We may beunable to fund the costs of any such litigation to a satisfactory conclusion, which could leave us without recourse to enforce contractsthat protect our intellectual property rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Other companies may claim that our technologyinfringes on their intellectual property or proprietary rights and commence legal proceedings against us which could be time-consumingand expensive and could result in our being prohibited from developing, marketing, selling or distributing our products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because of the complex anddifficult legal and factual questions that relate to patent positions in our industry, it is possible that our products or technologycould be found to infringe upon the intellectual property or proprietary rights of others. Third parties may claim that our products ortechnology infringe on their patents, copyrights, trademarks or other proprietary rights and demand that we cease development or marketingof those products or technology or pay license fees. We may not be able to avoid costly patent infringement litigation, which will divertthe attention of management away from the development of new products and the operation of our business. We may not prevail in any suchlitigation. If we are found to have infringed on a third-party’s intellectual property rights, we may be liable for money damages,encounter significant delays in bringing products to market or be precluded from manufacturing particular products or using particulartechnology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Other parties may challengecertain of our foreign patent applications. If any such parties are successful in opposing our foreign patent applications, we may notgain the protection afforded by those patent applications in particular jurisdictions and may face additional proceedings with respectto similar patents in other jurisdictions, as well as related patents. The loss of patent protection in one jurisdiction may influenceour ability to maintain patent protection for the same technology in other jurisdictions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to U.S. Government Contracts        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may not obtain additional U.S. Governmentcontracts to further develop our technology.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may not be successful inobtaining additional government grants or contracts. The process of obtaining government contracts is lengthy with the uncertainty thatwe will be successful in obtaining announced grants or contracts for therapeutics as a medical device technology. Accordingly, althoughwe have obtained government contracts in the past, we may not be awarded any additional U.S. Government grants or contracts utilizingour Hemopurifier platform technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 37 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            35            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          U.S. Government agencies have special contractingrequirements, including a right to audit us which create additional risks         </i>        </b>        ;        <b>         <i>          a negative audit would be detrimental tous.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our business plan to utilizethe Aethlon Hemopurifier technology is likely to continue to involve contracts with the U.S. Government. Many government contracts, typicallycontain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which subjectsus to additional risks. These risks include the ability of the U.S. Government to unilaterally:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            suspend or prevent us for a period of time from receiving new contracts or extending existing contracts based on violations or suspected violations of laws or regulations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            audit and object to our contract-related costs and fees, including allocated indirect costs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            control and potentially prohibit the export of our products; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            change certain terms and conditions in our contracts.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a U.S. Government contractor,we are required to comply with applicable laws, regulations and standards relating to our accounting practices and would be subject toperiodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with,our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and managementinformation systems. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, includingallocated indirect costs. In addition, if an audit or review uncovers any improper or illegal activity, we would possibly be subject tocivil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension ofpayments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputationif allegations of impropriety were made against us. Although we have not had any government audits and reviews to date, future auditsand reviews could cause adverse effects. In addition, under U.S. Government purchasing regulations, some of our costs, including mostfinancing costs, amortization of intangible assets, portions of our research and development costs, and some marketing expenses, wouldpossibly not be reimbursable or allowed under such contracts. Further, as a U.S. Government contractor, we would be subject to an increasedrisk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          As a U.S. Government contractor, we are subject to a number ofprocurement rules and regulations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Government contractors mustcomply with specific procurement regulations and other requirements. These requirements, although customary in government contracts, impactour performance and compliance costs. In addition, current U.S. Government budgetary constraints could lead to changes in the procurementenvironment, including the Department of Defense’s recent initiative focused on efficiencies, affordability and cost growth andother changes to its procurement practices. If and to the extent such changes occur, they could impact our results of operations and liquidity,and could affect whether and, if so, how we pursue certain opportunities and the terms under which we are able to do so.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, failure to complywith these regulations and requirements could result in reductions of the value of contracts, contract modifications or termination, andthe assessment of penalties and fines, which could negatively impact our results of operations and financial condition. Our failure tocomply with these regulations and requirements could also lead to suspension or debarment, for cause, from government contracting or subcontractingfor a period of time. Among the causes for debarment are violations of various statutes, including those related to procurement integrity,export control, government security regulations, employment practices, protection of the environment, accuracy of records and the recordingof costs, and foreign corruption. The termination of our government contract as a result of any of these acts could have a negative impacton our results of operations and financial condition and could have a negative impact on our reputation and ability to procure other governmentcontracts in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 38 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            36            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Common Stock and Our Corporate Governance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our failure to meet the continued listingrequirements of The Nasdaq Capital Market could result in a de-listing of our common stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we fail to satisfy thecontinued listing requirements of The Nasdaq Capital Market, or Nasdaq, such as the minimum stockholders’ equity requirement orthe minimum closing bid price requirement, Nasdaq may take steps to de-list our common stock. For example, in May 2019 we received a letterfrom Nasdaq indicating that Nasdaq had determined that we had failed to comply with the minimum bid price requirement of Nasdaq ListingRule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum closingbid price of at least $1.00 per share. In July 2019, we received another letter from Nasdaq indicating that Nasdaq has determinedthat we have failed to comply with the minimum stockholder’s equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq ListingRule 5550(b)(1) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2,500,000 in stockholder’s equity.If we fail to maintain compliance with these, or any other of the continued listing requirements of The Nasdaq Capital Market, Nasdaqmay take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock andwould impair your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would take actionsto restore our compliance with Nasdaq’s listing requirements, but any such action taken by us may not be successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Historically we have not paid dividendson our common stock, and we do not anticipate paying any cash dividends in the foreseeable future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have never paid cash dividendson our common stock. We intend to retain our future earnings, if any, to fund operational and capital expenditure needs of our business,and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stockwill be the sole source of gain for our common stockholders in the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our stock price is speculative, and thereis a risk of litigation.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The trading price of our commonstock has in the past and may in the future be subject to wide fluctuations in response to factors such as the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to raise additional funds when needed;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements regarding our ongoing development of the Hemopurifier;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            results from our clinical trials with the Hemopurifier;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to meet the continued listing requirements of and maintain our listing on Nasdaq;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            results of operations or revenue in any quarter failing to meet the expectations, published or otherwise, of the investment community;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reduced investor confidence in equity markets;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            speculation in the press or analyst community;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            wide fluctuations in stock prices, particularly with respect to the stock prices for other medical device companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements of technological innovations by us or our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 39 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            37            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            new products or the acquisition of significant customers by us or our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in interest rates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in investors’ beliefs as to the appropriate price-earnings ratios for us and our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in recommendations or financial estimates by securities analysts who track our common stock or the stock of other medical device companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in management;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sales of common stock by directors and executive officers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            rumors or dissemination of false or misleading information, particularly through Internet chat rooms, instant messaging, and other rapid-dissemination methods;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            conditions and trends in the medical device industry generally;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the announcement of acquisitions or other significant transactions by us or our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            adoption of new accounting standards affecting our industry;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in the structure of healthcare payment systems;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general market conditions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            domestic or international terrorism and other factors, including the effects of the ongoing pandemic; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the other factors described in this section.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Fluctuations in the priceof our common stock may expose us to the risk of securities class action lawsuits. Although no such lawsuits are currently pending againstus and we are not aware that any such lawsuit is threatened to be filed in the future, future lawsuits are possible as a result of fluctuationsin the price of our common stock. Defending against any such suits could result in substantial cost and divert management’s attentionand resources. In addition, any settlement or adverse determination of such lawsuits could subject us to significant liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If at any time our common stock is subjectto the SEC’s penny stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activityin our securities may be adversely affected.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 40 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            38            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If at any time our commonstock is not listed on a national securities exchange or we have net tangible assets of $2,000,000 or less, or we have an average revenueof less than $6,000,000 for the last three years, and our common stock has a market price per share of less than $5.00, transactions inour common stock will be subject to the SEC’s “penny stock” rules. If our common stock is subject to the “pennystock” rules promulgated under the Exchange Act, broker-dealers may find it difficult to effectuate customer transactions and tradingactivity in our securities may be adversely affected. For any transaction involving a penny stock, unless exempt, the rules require:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            that a broker or dealer approve a person’s account for transactions in penny stocks;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            furnish the investor a disclosure document describing the risks of investing in penny stocks;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disclose to the investor the current market quotation, if any, for the penny stock;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            disclose to the investor the amount of compensation the firm and its broker will receive for the trade; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In order to approve a person’saccount for transactions in penny stocks, the broker or dealer must:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtain financial information and investment experience objectives of the person; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The broker or dealer mustalso deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market,which, in highlight form:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sets forth the basis on which the broker or dealer made the suitability determination; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            that the broker or dealer received a signed, written agreement from the investor prior to the transaction.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Generally, brokers may beless willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult forinvestors to dispose of our common stock and cause a decline in the market value of our stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Disclosure also has to bemade about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payableto both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies availableto an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price informationfor the penny stock held in the account and information on the limited market in penny stocks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 41 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            39            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our common stock has had an unpredictabletrading volume which means you may not be able to sell our shares at or near trading prices or at all.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Trading in our common shareshistorically has been volatile and often has been thin, meaning that the number of persons interested in purchasing our common sharesat or near trading prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors,including the fact that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors andothers in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase ofour shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more whentrading activity in our shares is minimal, as compared to a seasoned issuer which has a large and steady volume of trading activity thatwill generally support continuous sales without an adverse effect on share price. A broader or more active public trading market for ourcommon shares may not develop or be sustained, and current trading levels may decrease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The market price for our common stock isvolatile; you may not be able to sell our common stock at or above the price you have paid for it, which may result in losses to you.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The market for our commonstock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continueto be more volatile than a seasoned issuer for the indefinite future. During the 52-week period ended June 10, 2021, the high and lowclosing sale prices for a share of our common stock were $10.79 and $1.29, respectively. The volatility in our share price is attributableto a number of factors. First, as noted above, trading in our common stock often has been thin. As a consequence of this lack of liquidity,the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares ineither direction. The price for our shares could, for example, decline precipitously in the event that a large number of our common sharesare sold on the market without commensurate demand, as compared to a seasoned issuer which could better absorb those sales without adverseimpact on its share price. Secondly, we are a speculative investment due to our limited operating history, limited amount of cash andrevenue, lack of profit to date, and the uncertainty of future market acceptance for our potential products. As a consequence of thisenhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment in the event of negative newsor lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the casewith the stock of a seasoned issuer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following factors alsomay add to the volatility in the price of our common stock: actual or anticipated variations in our quarterly or annual operating results;announcements regarding our clinical trials and the development of the Hemopurifier; acceptance of our proprietary technology as a viablemethod of augmenting the immune response of clearing viruses and toxins from human blood; government regulations, announcements of significantacquisitions, strategic partnerships or joint ventures; our capital commitments and additions or departures of our key personnel. Manyof these factors are beyond our control and may decrease the market price of our common shares regardless of our operating performance.We cannot make any predictions or projections as to what the prevailing market price for our common shares will be at any time, includingas to whether our common shares will sustain their current market prices, or as to what effect the sale of shares or the availabilityof common shares for sale at any time will have on the prevailing market price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our issuance of additional shares of commonstock or convertible securities, could be dilutive.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are entitled under ourarticles of incorporation to issue up to 30,000,000 shares of common stock. We have reserved for issuance 2,836,062 of those shares ofcommon stock for outstanding restricted stock units, stock options and warrants. As of March 31, 2021, we had issued and outstanding 12,150,597shares of common stock. As a result, as of March 31, 2021 we had 15,013,341 shares of common stock available for issuance to new investorsor for use to satisfy indebtedness or pay service providers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 42 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            40            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Board of Directors maygenerally issue shares of common stock, restricted stock units or stock options or warrants to purchase those shares, without furtherapproval by our stockholders, based upon such factors as our Board of Directors may deem relevant at that time. It is likely that we willbe required to issue a large amount of additional securities to raise capital to further our development. It is also likely that we willbe required to issue a large amount of additional securities to directors, officers, employees and consultants as compensatory grantsin connection with their services, both in the form of stand-alone grants or under our stock plans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Our officers and directors are entitled to indemnification fromus for liabilities under our articles of incorporation, which could be costly to us and may discourage the exercise of stockholder rights.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our articles of incorporationprovide that we possess and may exercise all powers of indemnification of our officers, directors, employees, agents and other personsand our bylaws also require us to indemnify our officers and directors as permitted under the provisions of the Nevada Revised Statutes,or NRS. We may also have contractual indemnification obligations under our agreements with our directors, officers and employees. Theforegoing indemnification obligations could result in our company incurring substantial expenditures to cover the cost of settlement ordamage awards against directors and officers. These provisions and resultant costs may also discourage our company from bringing a lawsuitagainst directors, officers and employees for breaches of their fiduciary duties, and may similarly discourage the filing of derivativelitigation by our stockholders against our directors, officers and employees even though such actions, if successful, might otherwisebenefit our company and stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our bylaws and Nevada law may discourage,delay or prevent a change of control of our company or changes in our management, would have the result of depressing the trading priceof our common stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Certain anti-takeover provisionsof Nevada law could have the effect of delaying or preventing a third-party from acquiring us, even if the acquisition arguably couldbenefit our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Nevada’s “combinationswith interested stockholders” statutes (NRS 78.411 through 78.444, inclusive) prohibit specified types of business “combinations”between certain Nevada corporations and any person deemed to be an “interested stockholder” for two years after such personfirst becomes an “interested stockholder” unless the corporation’s board of directors approves the combination (or thetransaction by which such person becomes an “interested stockholder”) in advance, or unless the combination is approved bythe board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder,its affiliates and associates. Further, in the absence of prior approval certain restrictions may apply even after such two year period.However, these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four yearsafter the person first became an interested stockholder. For purposes of these statutes, an “interested stockholder” is anyperson who is (1) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting sharesof the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficialowner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The definitionof the term “combination” is sufficiently broad to cover most significant transactions between a corporation and an “interestedstockholder.” A Nevada corporation may elect in its articles of incorporation not to be governed by these particular laws, but ifsuch election is not made in the corporation’s original articles of incorporation, the amendment (1) must be approved by the affirmativevote of the holders of stock representing a majority of the outstanding voting power of the corporation not beneficially owned by interestedstockholders or their affiliates and associates, and (2) is not effective until 18 months after the vote approving the amendment and doesnot apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment.We did not make such an election in our original articles of incorporation and have not amended our articles of incorporation to so elect.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 43 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            41            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Nevada’s “acquisitionof controlling interest” statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controllinginterest in certain Nevada corporations. These “control share” laws provide generally that any person that acquires a “controllinginterest” in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of thecorporation elects to restore such voting rights. These laws would apply to us if we were to have 200 or more stockholders of record (atleast 100 of whom have addresses in Nevada appearing on our stock ledger) and do business in the State of Nevada directly or through anaffiliated corporation, unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controllinginterest provide otherwise. These laws provide that a person acquires a “controlling interest” whenever a person acquiresshares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1)one fifth or more, but less than one third, (2) one third or more, but less than a majority or (3) a majority or more, of all of the votingpower of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in thetransaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offeredto acquire a controlling interest become “control shares” to which the voting restrictions described above apply. These lawsmay have a chilling effect on certain transactions if our articles of incorporation or bylaws are not amended to provide that these provisionsdo not apply to us or to an acquisition of a controlling interest, or if our disinterested stockholders do not confer voting rights inthe control shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Various provisions of ourbylaws may delay, defer or prevent a tender offer or takeover attempt of us that a stockholder might consider in his or her best interest.Our bylaws may be adopted, amended or repealed by the affirmative vote of the holders of at least a majority of our outstanding sharesof capital stock entitled to vote for the election of directors, and except as provided by Nevada law, our Board of Directors shall havethe power to adopt, amend or repeal the bylaws by a vote of not less than a majority of our directors. The interests of these stockholdersand directors may not be consistent with your interests, and they may make changes to the bylaws that are not in line with your concerns.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Nevada law also provides thatdirectors may resist a change or potential change in control if the directors determine that the change is opposed to, or not in the bestinterests of, the corporation. The existence of the foregoing provisions and other potential anti-takeover measures could limit the pricethat investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of ourcompany, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We incur substantial costs as a result ofbeing a public company and our management expects to devote substantial time to public company compliance programs.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a public company, we incursignificant legal, insurance, accounting and other expenses, including costs associated with public company reporting. We intend to investresources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrativeexpenses and may divert management’s time and attention from product development and commercialization activities. If our effortsto comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguitiesrelated to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. These laws andregulations could make it more difficult and costly for us to obtain director and officer liability insurance for our directors and officers,and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also makeit more difficult for us to attract and retain qualified executive officers and qualified members of our Board of Directors, particularlyto serve on our audit and compensation committees. In addition, if we are unable to continue to meet the legal, regulatory and other requirementsrelated to being a public company, we may not be able to maintain the quotation of our common stock on the Nasdaq Capital Market or onany other senior market to which we may apply for listing, which would likely have a material adverse effect on the trading price of ourcommon stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 44 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            42            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If securities or industry analysts do notpublish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock priceand trading volume could decline.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The trading market for ourcommon stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. Ourresearch coverage by industry and financial analysts is currently limited. Even if our analyst coverage increases, if one or more of theanalysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of ourcompany or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stockprice or trading volume to decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k4">        </a>        <b>         ITEM 1B. UNRESOLVED STAFF COMMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k5">        </a>        <b>         ITEM 2. PROPERTIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently lease approximately2,600 square feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego        <i>         ,        </i>        California 92123 under a 39-monthgross plus utilities lease that commenced on December 1, 2014 and expires on August 31, 2021. The current rental rate under the leaseextension is $8,265 per month.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We also rent approximately1,700 square feet of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $6,148 permonth on a one-year lease that originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extensionrunning from December 1, 2020 through the completion date of our construction of our planned new laboratory space which is adjacent toour current laboratory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In December 2020, we entered into an agreementto lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space. The agreement carries a term of 63months and we will commence paying rent when we take occupancy of those spaces, which is expected to occur in the third calendar quarterof 2021. For the initial year of the lease, the rental rate will be $13,385.55 per month. Thereafter, the base rent will increase eachyear.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k6">        </a>        <b>         ITEM 3. LEGAL PROCEEDINGS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may be involved from timeto time in various claims, lawsuits, and/or disputes with third parties or breach of contract actions incidental to the normal courseof our business operations. We are currently not involved in any litigation or any pending legal proceedings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k7">        </a>        <b>         ITEM 4. MINE SAFETY DISCLOSURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have no disclosure applicable to this item.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 45 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            43            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k8">        </a>        <b>         PART II        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <a name="k9">         </a>         ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDERMATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Market Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our common stock is tradedon the Nasdaq Capital Market under the trading symbol “AEMD.” On July 7, 2015, The Nasdaq Stock Market LLC approved our applicationfor listing our common stock on the Nasdaq Capital Market under the symbol “AEMD,” and we commenced trading on the NasdaqCapital Market on July 13, 2015. Previously, our common stock was quoted on the OTCQB Marketplace under the trading symbol “AEMD.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Holders of Record        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There were approximately 67record holders of our common stock at June 21, 2021. The number of registered stockholders includes any beneficial owners of common sharesheld in street name.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Dividend Policy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have not paid any dividendson our common stock to date and do not anticipate that we will pay dividends in the foreseeable future. Any payment of cash dividendson our common stock in the future will be dependent upon the amount of funds legally available, our earnings, if any, our financial condition,our anticipated capital requirements and other factors that the board of directors may think are relevant. However, we currently intendfor the foreseeable future to follow a policy of retaining all of our earnings, if any, to finance the development and expansion of ourbusiness and, therefore, do not expect to pay any dividends on our common stock in the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Recent Sales of Unregistered Securities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company did not have anysales of unregistered securities for the period covered by this Annual Report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Securities Authorized for Issuance Under EquityCompensation Plans        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Information about our equitycompensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <a name="k10">         </a>         ITEM 6. SELECTED FINANCIAL DATA        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a Smaller Reporting Company,we are not required to furnish information under this Item 6.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="k11">        </a>        <b>         ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSISOF FINANCIAL CONDITION AND RESULTS OF OPERATIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following discussion andanalysis should be read in conjunction with the consolidated Financial Statements and Notes thereto appearing elsewhere in this AnnualReport.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 46 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            44            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are a medical technologycompany focused on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier is a clinical-stageimmunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to depletethe presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefitof leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a “Breakthrough Device”for two independent indications:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">          </td>          <td style="width: 48px; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">          </td>          <td style="width: 48px; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of life-threatening viruses that are not addressed with approved therapies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We believe the Hemopurifiercan be a substantial advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promotethe growth and spread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patientswith advanced and metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinalcancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites to navigate and assess theimpact of the COVID-19 global pandemic on our clinical trials and current timelines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On October 4, 2019, the FDAapproved our Investigational Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifierin patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda). The primary endpoint for the EFS,which will enroll 10-12 subjects at a single center, will be safety, with secondary endpoints including measures of exosome clearanceand characterization, as well as response and survival rates. This study is being conducted at the UPMC Hillman Cancer Center in Pittsburgh,PA, is in the process of recruiting and treating patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We also believe the Hemopurifiercan be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressedwith an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat individualsinfected with human immunodeficiency virus, or HIV, hepatitis-C, and Ebola.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Additionally,        <i>         in-vitro        </i>        ,the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplexvirus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and thereconstructed Spanish flu virus of 1918. In several cases, these validations were conducted in collaboration with leading government ornon-government research institutes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 17, 2020, the FDAapproved a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients withSARS-CoV-2/COVID-19 in a New Feasibility Study.        <font style="background-color: white">         That study’s plan is to enroll up to 40 subjectsat up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit,or ICU, and will have acute lung injury and/or severe or life threatening disease, among other criteria. Endpoints for this study, inaddition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT # 04595903). The initial sites for thistrial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital – Irvine in Irvine, CA and Loma Linda Hospitalin Loma Linda, CA, have completed clinical trial agreements, and have received IRB approval in the case of the Hoag hospitals, and arepreparing to open for patient enrollment. Under Single Patient Emergency Use regulations, the Company has also treated two patients withCOVID-19 with the Hemopurifier.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are also the majority ownerof Exosome Sciences, Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threateningdiseases. Included among ESI’s activities is the advancement of a TauSome™ biomarker candidate to diagnose chronic traumaticencephalopathy, or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than sameage-group control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for, a number ofcancers. We consolidate ESI’s activities in our consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 47 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            45            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Successful outcomes of humantrials will also be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of ourpatents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patentapplications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We were formed on March 10,1999. Our executive offices are located at 9635 Granite Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858)459-7800. Our website address is www.aethlonmedical.com.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Our common stock is listed on the Nasdaq CapitalMarket under the symbol “AEMD.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         COVID-19 Update        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In March 2020, the World HealthOrganization declared COVID-19 a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supplychains and created significant volatility and disruption of financial markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are monitoring closelythe impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety of our employeeswhile continuing our operations, including clinical trials. Given the level of uncertainty regarding the duration and impact of the COVID-19pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and the resultingCOVID-19 pandemic on our future access to capital. Further, while we have not experienced significant disruptions to our manufacturingsupply chain, business, results of operations, financial condition, clinical trials, or preclinical research to date, we are unable toassess the potential impact this pandemic could have on our manufacturing supply chain, business, results of operations, financial condition,clinical trials, or preclinical research in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As we continue to activelyadvance our clinical trials, we remain in close contact with our clinical sites and are assessing the impact of COVID-19 on our trials,expected timelines and costs on an ongoing basis. We will assess any potential delays in our ability to timely ship clinical trial materials,including internationally, due to transportation interruptions. The extent of the impact of COVID-19 on our operational and financialperformance will depend on certain developments, including the duration and spread of the outbreak, impact on our clinical trials, employeesand vendors, all of which are uncertain and cannot be predicted. Given these uncertainties, we cannot reasonably estimate the relatedimpact to our business, operating results and financial condition, if any.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Fiscal Years Ended March 31, 2021 and 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Results of Operations         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Government Contract Revenues       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We recorded government contractrevenue in the fiscal years ended March 31, 2021 and 2020. This revenue resulted from work performed under our government contracts withthe NIH and our subaward with the University of Pittsburgh as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Year           <br/>           Ended 3/31/21          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Year           <br/>           Ended 3/31/20          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Change in           <br/>           Dollars          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 55%; text-align: left">           Phase 2 Melanoma Cancer Contract          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           436,427          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           620,187          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           (183,760          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Breast Cancer Grant          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           188,444          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           158,444          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Subaward with University of Pittsburgh          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           34,233          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           34,233          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Government Contract and Grant Revenue          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           659,104          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           650,187          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           8,917          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 48 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            46            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have recognized revenueunder the following three government contracts/grants over the past two years:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Phase 2 Melanoma Cancer Contract        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On September 12, 2019, theNational Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, awarded to us an SBIR Phase II Award Contract, forNIH/NCI Topic 359, entitled “A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring”,or the Award Contract. The Award Contract amount is $1,860,561 and runs for the period from September 16, 2019 through September 15, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The work to be performed pursuantto this Award Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitationthat ran from September 2017 through June 2018. Following on the phase I work, the deliverables in the phase II program involve the designand testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2021, we completed the milestones relevant to the first nine months of the fiscal year. As a result, we recorded $436,427 ofgovernment contract revenue on the Phase 2 Melanoma Cancer Contract in the fiscal year ended March 31, 2021.   Of the totalrevenue recognized during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three monthsended December 31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the three month periodended March 31, 2021, we did not complete all of the milestones relevant to that time period, as a result, we recorded $114,849 as deferredrevenue related to the Phase 2 Melanoma Cancer Contract.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Breast Cancer Grant        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the fiscal year ended March31, 2021, we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this SmallBusiness Innovation Research, or SBIR, Phase I grant is “The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomesfrom the Blood Circulation,” or the Breast Cancer Grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This NCI Phase I grant periodoriginally ran from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extensionon this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors to workwith us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2021, we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestonesrelated to the Breast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that our workunder the grant provided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount previouslywas recorded as deferred revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of March 31, 2021, we receivedall of the funds allocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Subaward with University of Pittsburgh        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In 2020, we entered into acost reimbursable subaward arrangement with the University of Pittsburgh in connection with an NIH contract entitled “DepletingExosomes to Improve Responses to Immune Therapy in HNNCC.” Our share of the award is $256,750. We recorded $34,233 of revenue relatedto this subaward in the fiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 49 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            47            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Operating Costs and Expenses        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Consolidated operating expenseswere $8,549,023 for the fiscal year ended March 31, 2021, compared to $6,580,175 for the fiscal year ended March 31, 2020, an increaseof $1,968,848. The $1,968,848 increase was due to increases in payroll and related expenses of $1,152,342 and in general and administrativeexpense of $907,867, which were partially offset by a decrease of $91,361 in professional fees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The $1,152,342 increase infiscal year ended March 31, 2021 in our payroll and related expenses was due to an increase in cash-based compensation of $1,216,919,which was partially offset by a decrease in our stock-based compensation of $64,577. Approximately $444,729 of the increase in cash-basedcompensation related to an accrual for severance payments to our former Chief Executive Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The $907,867 increase in fiscalyear ended March 31, 2021 in our general and administrative expenses primarily arose from increases of $460,817 in our clinical trialexpenses and $469,304 in laboratory supplies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The $91,361 decrease in fiscalyear ended March 31, 2021 in our professional fees primarily arose from decreases of $295,022 in legal fees and $116,536 in accountingfees, which were partially offset by increases of $179,457 in scientific consulting fees, $94,548 in recruiting fees and $58,966 in contractlabor costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Other Expense        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the fiscal year ended March31, 2021, we recognized other expenses of $1,580, compared to $450,053 of other expense in the fiscal year ended March 31, 2020. The followingtable breaks out the various components of our other expense over the fiscal years ended March 31, 2021 and 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid">           Components of Other Expense           <br/>           in Fiscal Year Ended          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2020          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Change          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 55%; text-align: left">           Loss on debt extinguishment          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           –          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           447,011          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           (447,011          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           (Gain) on share for warrant exchanges          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (51,190          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           51,190          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Interest and other debt expenses          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,580          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           54,232          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (52,652          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total other expense          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,580          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           450,053          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (448,473          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Loss on Debt Extinguishment        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2020, we reduced the conversion price on our outstanding convertible notes from $45.00 per share to $10.20 per share. The modificationof the convertible notes was evaluated under ASC 470-50-40 and the instruments were determined to be substantially different, and thetransaction qualified for extinguishment accounting. Under the extinguishment accounting we recorded a loss on debt extinguishment of$447,011. There was no comparable loss on debt extinguishment in the fiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 50 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            48            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Gain on Common Stock for Warrant Cancellation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal year endedMarch 31, 2020, we agreed with seven accredited investors to issue an aggregate of 3,992 shares of our common stock to these investorsin exchange for the cancellation of outstanding warrants then held by the investors to purchase an aggregate of 39,900 shares of our commonstock. We measured the fair value of the shares issued and the fair value of the warrants exchanged for those shares and recorded a gainof $51,190 on those exchanges based on the changes in fair value between the instruments exchanged. There was no comparable gain on commonstock for warrant cancellation in the fiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Interest and Other Debt Expenses        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our interest and other debtexpense decreased by $52,652 in the fiscal year ended March 31, 2021, from the fiscal year ended March 31, 2020. The following table breaksout the various components of our interest expense over the fiscal years ended March 31, 2021 and 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid">           Components of Interest Expense and Other Debt           <br/>           Expenses in Fiscal Year Ended          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2020          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Change          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 55%; text-align: left">           Interest expense and financing charges          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           1,580          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           23,945          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           (22,365          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Amortization of note discounts          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           30,287          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (30,287          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total interest and other debt expenses          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,580          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           54,232          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (52,652          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As noted in the above table,the factors in the $52,652 overall decrease in fiscal year ended March 21, 2021 in interest and other debt expenses were a $30,287 decreasein the amortization of note discounts and a $22,365 decrease in interest expense in fiscal year ended March 31, 2021 as the result ofpaying off our convertible notes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a result of the above factors,our net loss before noncontrolling interests increased to $7,891,499 for the fiscal year ended March 31, 2021, from $6,380,041 for thefiscal year ended March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Liquidity and Capital Resources         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        At March 31, 2021, we hada cash balance of $9,861,575 and working capital of $8,976,512. This compares to a cash balance of $9,604,780 and working capital of $8,973,393at March 31, 2020. We expect our existing cash as of March 31, 2021 to be sufficient to fund the Company’s operations for at leasttwelve months from the issuance date of this Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The primary source of ourincrease in cash during the fiscal year ended March 31, 2021 resulted from our Common Stock Sales Agreement with H.C. Wainwright &amp;Co., LLC, or Wainwright, entered into originally in 2016. The cash raised from that activity is described below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Common Stock Sales Agreement with Wainwright        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 28, 2016, we enteredinto a Common Stock Sales Agreement, or the 2016 Agreement, with Wainwright, which established an at-the-market equity program pursuantto which we may offer and sell shares of our common stock from time to time as set forth in the 2016 Agreement. The 2016 Agreement providedfor the sale of shares of our common stock having an aggregate offering price of up to $12,500,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 51 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            49            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On March 30, 2020, we executedAmendment No. 2 to the 2016 Agreement with Wainwright, effective as of the same date. The amendment provides that references in the 2016Agreement to the registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filedwith the SEC on March 19, 2020, declared effective by the SEC on March 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Subject to the terms and conditionsset forth in the 2016 Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and salespractices to sell the shares under the 2016 Agreement from time to time, based upon our instructions. We provided Wainwright with customaryindemnification rights under the 2016 Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent ofthe gross proceeds per share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the 2016 Agreement,including up to $50,000 of the fees and disbursements of their counsel. The 2016 Agreement will terminate upon the sale of all of theshares under the 2016 Agreement, unless terminated earlier by either party as permitted under the 2016 Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of March 31, 2021, no furthersales will be made under the 2016 Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On March 22, 2021, we enteredinto an At the Market Offering Agreement, or the Offering Agreement, with Wainwright as sales agent, pursuant to which we may offer andsell shares of our common stock, from time to time as set forth in the Offering Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="background-color: white">         Theoffering was registered under the        </font>        Securities Act of 1933, as amended, or Securities Act        <font style="background-color: white">         ,pursuant to our shelf registration statement on Form        </font>        S-3 (Registration Statement No. 333-237269), as previously filed withthe SEC and declared effective on March 30, 2020. We filed a prospectus supplement, dated March 22, 2021, with the SEC in connection withthe offer and sale of the shares of common stock,        <font style="background-color: white">         pursuant to which we may offer and sell sharesof common stock having an aggregate offering price of up to $5,080,000 from time to time.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Subject to the terms and conditionsset forth in the Offering Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading andsales practices to sell the shares under the Offering Agreement from time to time, based upon our instructions. We provided Wainwrightwith customary indemnification rights under the Offering Agreement, and Wainwright is entitled to a commission at a fixed rate equal tothree percent of the gross proceeds per share sold. In addition, we agreed to reimburse Wainwright for certain specified expenses in connectionwith entering into the Offering Agreement. The Offering Agreement will terminate upon the written termination by either party as permittedthereunder.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Sales of the shares, if any,under the 2016 Agreement and the Offering Agreement will be made in transactions that are deemed to be “at the market offerings”as defined in Rule 415 under the Securities Act, including sales made by means of ordinary brokers’ transactions, including on theNasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. We have no obligation to sell any of the shares, and,at any time, we may suspend offers under the 2016 Agreement and the Offering Agreement or terminate the Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the fiscal year ended March31, 2021, we raised aggregate net proceeds of $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses,under the 2016 Agreement through the sale of 2,685,600 shares at an average price of $2.70 per share of net proceeds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Future capital requirementswill depend upon many factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinicalprograms, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietaryrights, the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as ourability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements. We expect tocontinue to incur increasing negative cash flows and net losses for the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            50            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a result of the COVID-19pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, includingdiminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemploymentrates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets andconfidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financingmore difficult to obtain, more costly and/or more dilutive. Any of these actions could materially harm our business, results of operationsand future prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Cash Flows         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Cash flows from operating,investing and financing activities, as reflected in the accompanying Consolidated Statements of Cash Flows, are summarized as follows(in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           (In thousands)           <br/>           For the year ended          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31,           <br/>           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Cash (used in) provided by:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 70%; text-align: left">           Operating activities          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           (6,765          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           (5,198          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Investing activities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (60          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (152          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Financing activities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           7,128          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           11,126          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Net increase in cash          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           303          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           5,776          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Net Cash Used in Operating Activities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We used cash in our operatingactivities due to our losses from operations. Net cash used in operating activities was approximately $6,765,000 in fiscal 2021, comparedto net cash used in operating activities of approximately $5,198,000 in fiscal 2020, an increase of approximately $1,567,000. The primaryfactors in this $1,567,000 increase in cash used in operations was a $1,511,000 increase in our net loss.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Net Cash Used in Investing Activities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the fiscal years endedMarch 31, 2121 and 2020, we purchased approximately $60,000 and $152,000 of equipment, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Net Cash from Financing Activities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Net cash generated from financingactivities decreased from approximately $11,126,000 in the fiscal year ended March 31, 2020 to approximately $7,128,000 in the fiscalyear ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the fiscal year ended March31, 2021, we raised approximately $7,261,000 from the issuance of common stock, which was partially offset by the use of approximately$133,000 to pay for the tax withholding on the issuance of restricted stock units. In the fiscal year ended March 31, 2020, we raisedapproximately $12,160,000 from the issuance of common stock. We used approximately $993,000 to pay off our convertible notes in the fiscalyear ended March 31, 2020 and we also used approximately $41,000 to pay for the tax withholding on restricted stock units issued in thefiscal year ended March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 53 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            51            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Recent Events         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         RSU Grants        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On April 1, 2021, pursuantto the terms of the Company’s 2012 Non-Employee Directors Compensation Program, as amended, or the Directors Plan, the CompensationCommittee of the Board granted RSUs under the Company’s 2020 Equity Incentive Plan, or the 2020 Plan, to each non-employee directorof the Company. The Director’s Plan provides for a grant of $50,000 worth of RSUs at the beginning of each fiscal year, priced atthe average for the closing prices for the five days preceding and including the date of grant, or $2.06 per share as of April 1, 2021.Each eligible director was granted an RSU in the amount of 24,295 shares under the 2020 Plan. The RSU’s are subject to vesting infour equal quarterly installments on June 30, September 30, December 31, 2021, and March 31, 2022, subject to the recipient's continuedservice with the Company on each such vesting date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sales Under ATM Facility        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In June 2021, we raised aggregatenet proceeds of $4,947,785, net of $126,922 in commissions to Wainwright and $2,154 in other offering expenses, under the Offering Agreementdescribed above through the sale of 626,000 shares of our common stock at an average purchase price of $8.11 per share of gross proceeds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Registered Direct Financing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In June 2021, we sold an aggregateof 1,380,555 shares of our common stock at a purchase price per share of $9.00, for aggregate gross proceeds to us of approximately $12.425million, before deducting fees payable to Maxim Group LLC, the placement agent and other offering expenses. These shares were sold pursuantto a securities purchase agreement entered into by the Company with certain institutional investors, The shares of common stock were issuedin this offering pursuant to an effective shelf registration statement on Form S-3, which was originally filed with the SEC on March 19,2020, and was declared effective on March 30, 2020 (File No. 333-237269) (the “Registration Statement”) and a prospectus supplementthereunder.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Warrant Exercises        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In June 2021, pursuant tothe exercise of outstanding warrants held by institutional investors, we issued 531,167 shares of our common stock and received proceedsin the amount of $820,938.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Also in June 2021, pursuantto the exercise on a cashless, net exercise basis, of 874,664 outstanding warrants, we issued 675,554 shares of our common stock. Thedifference of 199,110 outstanding warrants were cancelled in connection with the exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Critical Accounting Policies         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Use of Estimates        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The preparation of consolidatedfinancial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires usto make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingentassets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expensesduring the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various otherfactors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differfrom these estimates under different future conditions. We believe that the estimates and assumptions that are most important to the portrayalof our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form thebasis for the accounting policies deemed to be most critical to us. These critical accounting estimates relate to revenue recognition,stock purchase warrants issued with notes payable, beneficial conversion feature of convertible notes payable, impairment of intangibleassets and long lived assets, stock compensation, deferred tax asset valuation allowance, and contingencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 54 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            52            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Revenue Recognition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our revenues consist entirelyof amounts earned under contracts and grants with the National Institutes of Health, or NIH. During the fiscal years ended March 31, 2021and 2020, we recognized revenues totaling $659,104 and $650,187, respectively, under such contracts. We have concluded that these agreementsare not within the scope of ASC Topic, 606, Revenue from Contracts with Customers, or Topic 606, as the NIH grants and contracts do notmeet the definition of a “customer” as defined by Topic 606. Prior to the effective date of ASC Topic 606, which for the Companywas April 1, 2018, we accounted for our grant/contract revenues under the Milestone Method as prescribed by the legacy guidance of ASC605-28, Revenue Recognition – Milestone Method, or the Milestone Method. In the absence of other applicable guidance under US GAAP,effective April 1, 2018, we elected to continue to use the Milestone Method by analogy to recognize revenue under these grants/contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Common Stock Warrants        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We often grant warrants topurchase our common stock in connection with financing transactions. When such warrants are classified as equity, we measure the relativeestimated fair value of such warrants which represents a discount from the face amount of the notes payable. Such discounts are amortizedto interest expense over the term of the notes. We analyze such warrants for classification as either equity or derivative liabilitiesand value them based on binomial lattice models.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Share-based Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We account for share-basedcompensation awards using the fair-value method and record such expense based on the grant date fair value in the consolidated financialstatements over the requisite service period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Derivative Instruments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We evaluate free-standingderivative instruments (or embedded derivatives) to properly classify such instruments within equity or as liabilities in our financialstatements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The classification of a derivativeinstrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrumentis reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract maybe reclassified.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Instruments classified asderivative liabilities are remeasured each reporting period (or upon reclassification) and the change in fair value is recorded on ourconsolidated statement of operations in other expense (income). We had no derivative instruments at March 31, 2021 or March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Income Taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Deferred tax assets are recognizedfor the future tax consequences attributable to the difference between the consolidated financial statements and their respective taxbasis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilitiesfor financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards. We record a valuationallowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable future, it is more likelythan not that some portion of the deferred tax assets may not be realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 55 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            53            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Off-Balance Sheet Arrangements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have not entered into anyoff-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changesin financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is materialto investors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Convertible Notes Payable and Warrants         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        In July 2019, we paid off our then outstandingconvertible notes in the amount of $992,591. There were no convertible notes outstanding as of March 31, 2021 or 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Restricted Stock Unit Grants to Non-EmployeeDirectors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In 2012, as amended throughOctober 30, 2020, our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensationfor persons serving as non-employee directors of the Company. Under this program, each new director receives either stock options or agrant of restricted stock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs are subjectto vesting and represent the right to be issued on a future date shares of our common stock upon vesting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On April 3, 2020, pursuantto the terms of the Company’s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directorsgranted RSUs to each non-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUswith a grant date fair value of $35,000, priced at the average of the closing prices for the five trading days ending on the date of grant,which was $1.41 per share, so that the total number of RSUs to be granted to each non-employee director for fiscal year 2020 would be24,822 shares of our common stock.  On April 3, 2020, each eligible director was granted an RSU for 23,893 shares under theCompany’s 2010 Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under the 2010 Plan was notsufficient for each director’s full RSU grant. The Compensation Committee also granted to each eligible director a contingent grantunder our 2020 Equity Incentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU grants, or 929 RSU’s to eacheligible director, contingent upon stockholder approval of the 2020 Plan at the Company’s 2020 Annual Meeting of Stockholders, orthe Annual Meeting. These grants are subject to vesting as follows: 50% of the RSUs subject to the grants will vest on December 31, 2020and 50% of the RSUs will vest on March 31, 2021, subject in each case to the continuous service of each director, through such vestingdates, as well as approval of the 2020 Plan by the stockholders at the Annual Meeting, which was obtained at the Annual Meeting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In June 2020, 29,866 vestedRSUs held by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directorselected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resultingin 11,947 of the vested RSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In September 2020, 29,866vested RSUs held by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employeedirectors elected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances,resulting in 11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Also in September 2020, ourstockholders approved the 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directorsfor a total of 4,645 RSUs were considered effective and no longer contingent as of that date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December 2020, 32,189 vestedRSUs held by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directorselected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resultingin 12,876 of the vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 56 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            54            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In March 2021, 32,189 vestedRSUs held by our non-employee directors were exchanged into the same number of shares of our common stock. All five directors electedto return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in12,875 of the vested RSUs being cancelled in exchange for $26,136 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        There were no vested RSUs outstanding as of March31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k12">        </a>        <b>         ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a Smaller Reporting Company,we are not required to furnish information under this Item 7A.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k13">        </a>        <b>         ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The consolidated financialstatements listed in the accompanying Index to Financial Statements are attached hereto and filed as a part of this Report under Item15.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k14">        </a>        <b>         ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTINGAND FINANCIAL DISCLOSURE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k15">        </a>        <b>         ITEM 9A. CONTROLS AND PROCEDURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Disclosure Controls and Procedures        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We maintain “disclosurecontrols and procedures,” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, orthe Exchange Act) that are designed to ensure that information required to be disclosed, in our Exchange Act reports is recorded, processed,summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulatedand communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, toallow timely decisions regarding required disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In designing and evaluatingthe disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, canprovide only reasonable assurance of achieving the desired control objectives, and we were required to apply our judgment in evaluatingthe cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of the end of the period coveredby this report under the supervision and with the participation of our management, including our Chief Executive Officer and Chief FinancialOfficer, of the effectiveness of the design and operation of our disclosure controls and procedures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Based on such evaluation,our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosurecontrols and procedures were effective.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Internal Control over Financial Reporting       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 60px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <i>              (a)             </i>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <i>              Management’s Report on Internal Control Over Financial Reporting             </i>            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our management is responsiblefor establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) underthe Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliabilityof financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accountingprinciples.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 57 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            55            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Under the supervision andwith the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluationof the effectiveness of our internal control over financial reporting as of March 31, 2021. According to the guidelines established byInternal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, one or morematerial weaknesses renders a company’s internal control over financial reporting ineffective. Based on this evaluation, we haveconcluded that our internal control over financial reporting was effective as of March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 60px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (b)           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <i>              Changes in Internal Control Over Financial Reporting             </i>            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There was no change in ourinternal control over financial reporting during the last fiscal quarter ended March 31, 2021 that has materially affected, or is reasonablylikely to materially affect, our internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <a name="k16">         </a>         ITEM 9B. OTHER INFORMATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        We have no disclosure applicable to this item.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 58 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            56            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k17">        </a>        <b>         PART III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <a name="k18">         </a>         ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Except as set forth below,the information required by this item will be contained in our Definitive Proxy Statement to be filed with the SEC in connection withour 2021 Annual Meeting of Stockholders, the Proxy Statement, within 120 days after the end of the fiscal year ended March 31, 2021, andis incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On February 23, 2005, theBoard of Directors approved a “Code of Business Conduct and Ethics,” or the Code, which applies to our principal executiveofficer, our principal financial officer, our principal accounting officer and persons performing similar tasks. On February 6, 2020,the Board of Directors adopted an amended Code, which supersedes the Company’s existing Code previously adopted by the Board ofDirectors. Our Code is available on our company website at www.aethlonmedical.com. If we make any substantive amendments to, or grantany waivers from, the Code of Business Conduct and Ethics for any officer or director, we will disclose the nature of such amendment orwaiver on our website or in a Current Report on Form 8-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k19">        </a>        <b>         ITEM 11. EXECUTIVE COMPENSATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The information required by this item will be containedin our Proxy Statement and is incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k20">        </a>        <b>         ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENTAND RELATED STOCKHOLDER MATTERS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The information required by this item will be containedin our Proxy Statement and is incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k21">        </a>        <b>         ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTORINDEPENDENCE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The information required by this item will be containedin our Proxy Statement and is incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k22">        </a>        <b>         ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The information required by this item will be containedin our Proxy Statement and is incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 59 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            57            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k23">        </a>        <b>         PART IV        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k24">        </a>        <b>         ITEM 15. EXHIBITS ANDFINANCIAL STATEMENT SCHEDULES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following documents are filed as part of this report on Form 10-K:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        1. Consolidated Financial Statements for the years ended March 31,2021 and 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Report of Independent Registered Public AccountingFirm       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Consolidated Balance Sheets       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Consolidated Statements of Operations       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Consolidated Statements of Equity       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Consolidated Statements of Cash Flows       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Notes to Consolidated Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        2. Exhibits       </p>       <p style="font: bold 7pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="2" style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td colspan="7" style="border-bottom: black 1pt solid; vertical-align: top; text-align: left">           <font style="font-size: 10pt">            Incorporated by Reference           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top; text-align: left">           <font style="font-size: 10pt">            Exhibit            <br/>            Number           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            Exhibit Description           </font>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            Form           </font>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            SEC File No.           </font>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            Exhibit            <br/>            Number           </font>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            Date           </font>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            Filed            <br/>            Herewith           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="2" style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; width: 3%; text-align: left">          </td>          <td style="vertical-align: top; width: 8%; text-align: left">           <font style="font-size: 10pt">            3.1           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 32%; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968716006120/aethlon_s1-ex0301.htm">            <font style="font-size: 10pt">             Articles of Incorporation.            </font>           </a>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 4%; text-align: center">           <font style="font-size: 10pt">            S-3           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 11%; text-align: left">           <font style="font-size: 10pt">            333-211151           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 11%; text-align: center">           <font style="font-size: 10pt">            3.1           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 17%; text-align: left">           <font style="font-size: 10pt">            May 5, 2016           </font>          </td>          <td style="vertical-align: top; width: 1%; text-align: left">          </td>          <td style="vertical-align: top; width: 8%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            3.2           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819002910/aethlon_8k-ex0301.htm">            <font style="font-size: 10pt">             Amended and Restated Bylaws of the Company.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            September 12, 2019           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex0401.htm">            <font style="font-size: 10pt">             Form of Common Stock Certificate.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-201334           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            December 31, 2014           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.2           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            <br/>           </font>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968712003217/aethlon_8k-ex0401.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated August 29, 2012.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            September 6, 2012           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.3           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968713000435/aemd_10q-ex401.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated October, November and December 2012.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            February 13, 2013           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.4           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968713003054/aethlon_10q-ex401.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated June 14, 2013.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            August 13, 2013           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.5           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714002585/aethlon_8k-ex0401.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated June 24, 2014.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            June 30, 2014           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.6           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714002828/aethlon_8k-ex401.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated July 24, 2014.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            July 28, 2014           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.7           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004132/aemd_10q-ex0403.htm">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant dated August and September 2014.            </font>           </a>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.3           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            November 10, 2014           </font>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: top; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 60 -->       <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            58            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 3%">          </td>          <td style="vertical-align: top; text-align: left; width: 8%">           <font style="font-size: 10pt">            4.10           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817000627/aethlon_ex0401.htm">            <font style="font-size: 10pt">             Form of Warrant Agreement dated March 27, 2017.            </font>           </a>          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; text-align: center; width: 4%">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; text-align: left; width: 11%">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; text-align: center; width: 11%">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td style="width: 1%">          </td>          <td style="vertical-align: top; text-align: left; width: 17%">           <font style="font-size: 10pt">            March 22, 2017           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 8%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.11           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817002401/aethlon_s1a-ex0429.htm">            <font style="font-size: 10pt">             Form of Warrant dated _______, 2017.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1/A           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-219589           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.29           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            September 18, 2017           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.12           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817002459/aethlon_s1a2-ex0430.htm">            <font style="font-size: 10pt">             Form of Placement Agent Warrant dated _______, 2017.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1/A           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-219589           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.30           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            September 22, 2017           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.13           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0414.htm" style="-sec-extract: exhibit">             Form of Warrant to Purchase Common Stock.            </a>           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1/A           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-234712           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.14           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            December 11, 2019           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.14           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0415.htm" style="-sec-extract: exhibit">             Form of Underwriter Warrant.            </a>           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1/A           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-234712           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.15           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            December 11, 2019           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.15           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex0401.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            January 17, 2020           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            4.16           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820002070/aethlon_ex4016.htm" style="-sec-extract: exhibit">            Description of Aethlon Medical, Inc.’s Securities.           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           10-K          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           001-37487          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           4.16          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           June 25, 2020          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968716005682/aethlon_8k-ex1001.htm">            <font style="font-size: 10pt">             Amended 2010 Stock Incentive Plan.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            March 30, 2016           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            10.2           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968709004139/aethlon_10qex10-7.txt">            <font style="font-size: 10pt">             Standard Industrial Net Lease, by and between Glenborough Aventine, LLC and Aethlon Medical, Inc., dated September 28, 2009.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.6           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            November 16, 2009           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            10.3           </font>          </td>          <td>          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex1052.htm">            <font style="font-size: 10pt">             Second Amendment to Standard Industrial Net Lease, by and between AGP Sorrento Business Complex and Aethlon Medical, Inc., dated October 10, 2014.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            333-201334           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.52           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            December 31, 2014           </font>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.4           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004404/aethlon_8k-ex1001.htm">            <font style="font-size: 10pt">             Office Lease, by and between T-C Stonecrest LLC and Aethlon Medical, Inc., dated November 13, 2014.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K/A           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            November 19, 2014           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968715001438/aethlon_ex1001.htm">            <font style="font-size: 10pt">             UCI Clinical Trial Agreement, by and between The Regents of the University of California, on behalf of its Irvine campus and Aethlon Medical, Inc., dated March 24, 2015.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            000-21846           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            April 15, 2015           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.8           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968715004160/aethlon_10q-ex1005.htm">            <font style="font-size: 10pt">             Third Amendment to Standard Industrial Net Lease, by and between AGP Sorrento Business Complex, L.P. and Aethlon Medical, Inc., dated October 21, 2015.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            November 16, 2015           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.9           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968716006780/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Common Stock Sales Agreement, by and between H.C. Wainwright &amp; Co., LLC and Aethlon Medical, Inc., dated June 28, 2016.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            June 28, 2016           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 61 -->       <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            59            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">        <tbody>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.10           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819002527/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Amendment No. 1 to Common Stock Sales Agreement, by and between H.C. Wainwright &amp; Co., LLC and Aethlon Medical, Inc., dated June 28, 2016.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            August 12, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.11           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820002625/aethlon_ex1001.htm" style="-sec-extract: exhibit">             Amendment No. 2 to Common Stock Sales Agreement, by and between H.C. Wainwright &amp; Co., LLC and Aethlon Medical, Inc., dated March 30, 2020.            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           10-Q          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           001-37487          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           10.1          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            August 11, 2020           </p>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.12           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <a href="aethlon_ex1012.htm">             Aethlon Medical, Inc. Amended and Restated Non-Employee Directors Compensation Policy, as Modified on October 30, 2020.            </a>           </p>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: bottom">           X          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.13           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817001671/aethlon_ex1080.htm">            <font style="font-size: 10pt">             Fourth Amendment to Standard Industrial Net Lease, by and between AGP Sorrento Business Complex, L.P. and Aethlon Medical, Inc., dated October 5, 2016.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.80           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            June 28, 2017           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.14           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817000627/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement, by and among each purchaser identified on the signature pages therein and Aethlon Medical, Inc., dated March 22, 2017.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            March 22, 2017           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-size: 10pt">            10.15           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817002395/aethlon_s1-ex1084.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement, by and among each purchaser identified on the signature pages therein and Aethlon Medical, Inc., dated September ______, 2017.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            S-1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            333-220490           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            10.84           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font-size: 10pt">            September 15, 2017           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom; width: 3%">          </td>          <td style="text-align: left; vertical-align: top; width: 8%; font-size: 10pt">           <font style="font-size: 10pt">            10.16           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; width: 32%; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316817002820/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Fifth Amendment to Standard Industrial Net Lease, by and between AGP Sorrento Business Complex, L.P. and Aethlon Medical, Inc., dated October 16, 2017.            </font>           </a>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; width: 4%; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 11%">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 11%">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left; width: 17%">           <font style="font-size: 10pt">            November 2, 2017           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; width: 8%">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.17           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316818003253/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Sixth Amendment to Standard Industrial Net Lease, by and between AGP Sorrento Business Complex, L.P. and Aethlon Medical, Inc., dated September 18, 2018.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            November 6, 2018           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.18           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1003.htm">            <font style="font-size: 10pt">             Employment Agreement, by and between Aethlon Medical, Inc. and James Frakes, dated December 12, 2018.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.3           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            February 11, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.19           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1004.htm">            <font style="font-size: 10pt">             Form of Indemnification Agreement for Officers and Directors.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.4           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            February 11, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.20           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1005.htm">            <font style="font-size: 10pt">             Form of Option Grant Agreement for Officers and Directors.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            February 11, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 62 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            60            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">        <tbody>         <tr style="background-color: White">          <td style="vertical-align: bottom; width: 3%">          </td>          <td style="text-align: left; vertical-align: top; width: 8%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; width: 32%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="text-align: center; vertical-align: top; width: 4%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="text-align: center; vertical-align: top; width: 11%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="text-align: center; vertical-align: top; width: 11%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="text-align: left; vertical-align: top; width: 17%">          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; width: 8%">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.21           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1006.htm">            <font style="font-size: 10pt">             Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Directors.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.6           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            February 11, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.22           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1007.htm">            <font style="font-size: 10pt">             Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Executives.            </font>           </a>           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.7           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            February 11, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            10.23           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003421/aethlon_ex1001.htm">            <font style="font-size: 10pt">             Seventh Amendment to Standard Industrial Net Lease, by and between Aethlon Medical, Inc. and San Diego Inspire 1, LLC., dated September 9, 2019.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            November 1, 2019           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="font-size: 10pt">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            10.24           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003421/aethlon_ex1002.htm">            <font style="font-size: 10pt">             SBIR Phase II Award Contract, by and among Aethlon Medical, Inc., the National Institutes of Health and the National Cancer Institute, dated September 12, 2019.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10-Q           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.2           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            November 1, 2019           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.25           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003664/aethlon_ex-1027.htm">            <font style="font-size: 10pt">             Assignment Agreement, by and between Aethlon Medical, Inc. and London Health Sciences Center Research Inc., dated November 7, 2006.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            S-1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.27           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            November 15, 2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            10.26           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex1001.htm" style="-sec-extract: exhibit">             Form of Securities Purchase Agreement, by and    between Aethlon Medical, Inc. and the Purchasers thereto, dated January 17, 2020.            </a>           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            8-K           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            001-37487           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            10.1           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            January 17, 2020           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.27           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font: 10pt Times New Roman, Times, Serif">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820003129/aethlon_ex1001.htm" style="-sec-extract: exhibit">             Aethlon Medical, Inc. 2020 Equity Incentive Plan, Form of Restricted Stock Grant, Form of Option Grant and Agreement.            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            September 15, 2020           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.28           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1001.htm" style="-sec-extract: exhibit">            <font style="font: 10pt Times New Roman, Times, Serif">             Separation Agreement between the Company and Dr. Rodell, dated October 30, 2020.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            November 3, 2020           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.29           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1002.htm" style="-sec-extract: exhibit">            Employment Agreement between the Company and Dr. Fisher, dated October 30, 2020.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.2           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            November 3, 2020           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.30           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1003.htm" style="-sec-extract: exhibit">            Lease, by and between the Company and San Diego Inspire 1, LLC. and San Diego Inspire 2, LLC, effective December 7, 2020.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.3           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            February 10, 2021           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.31           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font: 10pt Times New Roman, Times, Serif">            <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1004.htm" style="-sec-extract: exhibit">             Eighth Amendment to Standard Industrial Net Lease, by and between the Company and San Diego Inspire 1, LLC., effective December 7, 2020.            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.4           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            February 10, 2021           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 63 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            61            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">        <tbody>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.32           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1005.htm" style="-sec-extract: exhibit">            Executive Employment Agreement between the Company and Guy Cipriani, dated January 1, 2021.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            February 10, 2021           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.33           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1006.htm" style="-sec-extract: exhibit">            Executive Employment Agreement between the Company and Steven P. LaRosa, MD, dated January 4, 2021.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10-Q           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            10.6           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            February 10, 2021           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom">           <p style="margin-top: 0; margin-bottom: 0">           </p>           <p style="margin-top: 0; margin-bottom: 0">           </p>          </td>          <td style="vertical-align: top">           <font style="font: 10pt Times New Roman, Times, Serif">            10.34           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000168316821001017/aethlon_ex0101.htm" style="-sec-extract: exhibit">            At the Market Offering Agreement, March 22, 2021, by and between Aethlon Medical, Inc. and H.C. Wainwright &amp; CO., LLC.           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            8-K           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            001-37487           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            1.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: left">           <font style="font: 10pt Times New Roman, Times, Serif">            March 22, 2021           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; font-size: 10pt; width: 3%">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt; width: 8%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; width: 32%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 4%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 11%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 11%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left; width: 17%">          </td>          <td style="vertical-align: bottom; font-size: 10pt; width: 1%">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 8%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            21.1           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex2101.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             List of Subsidiaries.            </font>           </a>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            S-1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            333-201334           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            21.1           </font>          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            December 31, 2014           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            23.1           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            <a href="aethlon_ex2301.htm">             Consent of Independent Registered Public Accounting Firm            </a>           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            31.1           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            <a href="aethlon_ex3101.htm">             Certification of our Chief Executive Officer, pursuant to Securities Exchange Act rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.            </a>           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="font-size: 10pt">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            31.2           </font>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            <a href="aethlon_ex3102.htm">             Certification of our Chief Financial Officer, pursuant to Securities Exchange Act rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002            </a>            .           </font>          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            32.1           </font>          </td>          <td>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            <a href="aethlon_ex3201.htm">             Statement of our Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).            </a>           </font>          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="font-size: 10pt">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: top; text-align: left">          </td>          <td>          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">           <font style="font-size: 10pt">            32.2           </font>          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            <a href="aethlon_ex3202.htm">             Statement of our Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).            </a>           </font>          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.INS           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Instance Document           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.SCH           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Schema Document           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.CAL           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Calculation Linkbase Document           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.DEF           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Definition Linkbase Document           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: rgb(238,238,238)">          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.LAB           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Label Linkbase Document           </font>          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: left">          </td>          <td style="vertical-align: bottom; font-size: 10pt">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            101.PRE           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt">           <font style="font-size: 10pt">            XBRL Presentation Linkbase Document           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: center; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="text-align: left; vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; font-size: 10pt; text-align: center">           <font style="font-size: 10pt">            X           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        ___________________       </p>       <table cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 8px">          </td>          <td style="width: 16px; font-size: 10pt">           <font style="font-size: 10pt">            ++           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 10pt">            Indicates management contract or compensatory plan.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="k25">        </a>        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         ITEM 16. FORM 10-K SUMMARY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 64 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            62            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k26">        </a>        <b>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Pursuant to the requirementsof Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned, thereunto duly authorized, on the 24th day of June, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%">          </td>          <td style="width: 5%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            By:           </font>          </td>          <td style="width: 35%; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ CHARLES J. FISHER, JR., M.D.           </font>          </td>          <td style="width: 10%">          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Charles J. Fisher, Jr., M.D.           </font>          </td>          <td style="vertical-align: top">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Executive Officer           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         POWER OF ATTORNEY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        KNOW ALL PERSONS BY THESE PRESENTS, that eachperson whose signature appears below constitutes and appoints James B. Frakes and Timothy C. Rodell, his or her true and lawful attorney-in-factand agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to signany and all amendments to this Annual Report on form 10-K, and to file the same, with all exhibits thereto, and other documents in connectiontherewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full powerand authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to allintents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents,or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Pursuant to the requirementsof the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and inthe capacities and on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Signature           </font>          </td>          <td>          </td>          <td colspan="5" style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title           </font>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Date           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr>          <td style="vertical-align: bottom; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ CHARLES J. FISHER, JR., MD           </font>          </td>          <td style="vertical-align: top">          </td>          <td colspan="5" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Executive Officer, Principal Executive Officer and Director           </font>          </td>          <td style="vertical-align: top">          </td>          <td colspan="2" style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Charles J. Fisher, Jr., MD           </font>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ JAMES B. FRAKES           </font>          </td>          <td>          </td>          <td colspan="5">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer and Principal Accounting Officer           </font>          </td>          <td>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            James B. Frakes           </font>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ EDWARD G. BROENNIMAN           </font>          </td>          <td>          </td>          <td colspan="5">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman and Director           </font>          </td>          <td>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Edward G. Broenniman           </font>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ CHETAN S. SHAH           </font>          </td>          <td>          </td>          <td colspan="5">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chetan S. Shah           </font>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ SABRINA MARTUCCI JOHNSON           </font>          </td>          <td>          </td>          <td colspan="5">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Sabrina Martucci Johnson           </font>          </td>          <td>          </td>          <td colspan="5">          </td>          <td>          </td>          <td colspan="2">          </td>         </tr>         <tr>          <td style="width: 34%">          </td>          <td style="width: 1%">          </td>          <td style="width: 6%">          </td>          <td style="width: 37%">          </td>          <td style="width: 1%">          </td>          <td style="width: 4%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 14%">          </td>          <td style="width: 1%">          </td>         </tr>         <tr>          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            /s/ GUY CIPRIANI           </font>          </td>          <td>          </td>          <td colspan="2">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            SVP and Chief Business Officer and Director           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            June 24, 2021           </font>          </td>          <td>          </td>         </tr>         <tr>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Guy Cipriani           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            63            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        AETHLON MEDICAL, INC. AND SUBSIDIARY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        INDEX TO CONSOLIDATED FINANCIAL STATEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td>          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Consolidated Financial Statements            </b>           </font>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k27">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k28">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets as of March 31, 2021 and 2020            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k29">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations for the Years Ended March 31, 2021 and 2020            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k30">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Equity for the Years Ended March 31, 2021 and 2020            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k31">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows for the Years Ended March 31, 2021 and 2020            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <a href="#k32">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-7           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 66; Options: NewSection -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            1            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="k27">        </a>        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTINGFIRM       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To the Stockholders and the Board of Directorsof Aethlon Medical, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Opinion on the Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have audited the accompanying consolidatedbalance sheets of Aethlon Medical, Inc. and its subsidiary (the Company) as of March 31, 2021 and 2020, the related consolidated statementsof operations, equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively,the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position ofthe Company as of March 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformitywith accounting principles generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Basis for Opinion       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These financial statements are the responsibilityof the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on ouraudits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and arerequired to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulationsof the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We conducted our audits in accordance with thestandards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financialstatements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engagedto perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understandingof internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internalcontrol over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our audits included performing procedures to assessthe risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respondto those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluatingthe overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Critical Audit Matters       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Critical audit matters are matters arising fromthe current period audit of the financial statements that were communicated or required to be communicated to the audit committee andthat: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,subjective, or complex judgments. We determined that there are no critical audit matters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Baker Tilly US, LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have served as the Company's auditor since2001.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        San Diego, California       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        June 24, 2021       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 67 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            2            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        AETHLON MEDICAL, INC. AND SUBSIDIARY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k28">        </a>        CONSOLIDATED BALANCE SHEETS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: center">           ASSETS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           CURRENT ASSETS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-indent: -10pt; padding-left: 20pt">           Cash          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           9,861,575          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           9,604,780          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           149,082          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           206,729          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Prepaid expenses and other current assets          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           341,081          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           229,604          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">           TOTAL CURRENT ASSETS          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           10,351,738          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           10,041,113          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Property and equipment, net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           160,976          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           140,484          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Right-of-use lease asset          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           40,363          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           136,426          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Patents, net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           56,954          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           57,504          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Restricted cash          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           46,726          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           Deposits          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           12,159          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           12,159          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 40pt">           TOTAL ASSETS          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,668,916          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,387,686          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: 31.5pt; padding-left: 20pt">           LIABILITIES AND STOCKHOLDERS’ EQUITY          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           CURRENT LIABILITIES          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Accounts payable          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           337,678          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           285,036          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Due to related parties          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           118,520          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           111,707          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Deferred revenue          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           114,849          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Lease liability, current portion          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           42,543          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           98,557          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Other current liabilities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           761,636          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           472,420          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">           TOTAL CURRENT LIABILITIES          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,375,226          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,067,720          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Lease liability, less current portion          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           42,540          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">           TOTAL LIABILITIES          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,375,226          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,110,260          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           COMMITMENTS AND CONTINGENCIES (Note 11)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           STOCKHOLDERS’ EQUITY          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Common stock, $0.001 par value, 30,000,000 shares authorized at March 31, 2021 and 2020; 12,150,597 and 9,366,873 issued and outstanding at March 31, 2021 and 2020, respectively          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12,152          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,368          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Additional paid-in capital          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           129,331,542          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           121,426,563          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Accumulated deficit          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (119,913,090          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (112,026,381          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">           TOTAL AETHLON MEDICAL, INC. STOCKHOLDERS’ EQUITY BEFORE NONCONTROLLING INTERESTS          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,430,604          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,409,550          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           NONCONTROLLING INTERESTS          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (136,914          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (132,124          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           TOTAL STOCKHOLDERS’ EQUITY          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,293,690          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,277,426          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,668,916          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,387,686          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidated financialstatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 68 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            3            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        AETHLON MEDICAL, INC. AND SUBSIDIARY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k29">        </a>        CONSOLIDATED STATEMENTS OF OPERATIONS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           Years Ended March 31,          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           REVENUES:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 66%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Government contract and grant revenue          </td>          <td style="width: 2%; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">           659,104          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: left">          </td>          <td style="width: 2%; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">           650,187          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">           Total revenues          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           659,104          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           650,187          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           OPERATING COSTS AND EXPENSES          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Professional fees          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,637,664          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,729,025          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Payroll and related expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,454,941          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,302,599          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           General and administrative          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           2,456,418          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,548,551          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">           Total operating expenses          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           8,549,023          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           6,580,175          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           OPERATING LOSS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (7,889,919          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (5,929,988          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           OTHER EXPENSE          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Loss on debt extinguishment          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           447,011          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           (Gain) on share for warrant exchanges          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (51,190          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Interest and other expenses          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,580          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           54,232          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">           Total other expense          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,580          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           450,053          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           NET LOSS BEFORE NONCONTROLLING INTERESTS          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (7,891,499          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (6,380,041          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (4,790          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (6,093          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (7,886,709          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (6,373,948          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Basic and diluted net loss per share attributable to common stockholders          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (0.65          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (1.87          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Weighted average number of common shares outstanding - basic and diluted          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           12,090,884          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           3,414,840          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidated financialstatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 69 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            4            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        AETHLON MEDICAL, INC. AND SUBSIDIARY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k30">        </a>        CONSOLIDATED STATEMENTS OF EQUITY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        FOR THE YEARS ENDED MARCH 31, 2021 AND 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">           <font style="font-size: 9pt">            ATTRIBUTABLE TO AETHLON    MEDICAL, INC.           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           <font style="font-size: 9pt">            COMMON STOCK           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-size: 9pt">            ADDITIONAL            <br/>            PAID IN           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-size: 9pt">            ACCUMULATED           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-size: 9pt">            NON-            <br/>            CONTROLLING           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-size: 9pt">            TOTAL           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            SHARES           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            AMOUNT           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            CAPITAL           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            DEFICIT           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            INTERESTS           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-size: 9pt">            EQUITY           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 34%">           <font style="font-size: 9pt">            BALANCE - MARCH 31, 2019           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            1,266,979           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            1,267           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            108,076,275           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            (105,652,433           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            (126,031           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="width: 1%">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 9pt">            2,299,078           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuances of common stock for cash    under at the market program           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            161,149           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            162           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            895,869           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            896,031           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Loss on debt extinguishment           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            447,011           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            447,011           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuances of common stock for cash    under warrant exercises           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            2,700,000           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            2,700           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            3,804,462           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            3,807,162           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuance of common shares upon    vesting of restricted stock units.           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            12,393           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            12           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (40,950           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (40,938           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Proceeds from the issuance of common    stock in public offerings, net           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            5,218,712           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            5,219           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            7,451,096           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            7,456,315           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuances of common stock upon    warrant exchanges           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            3,992           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            4           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (51,194           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (51,190           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Par value of DTC roundup of shares    following reverse split           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            3,946           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            4           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (4           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           <font style="font-size: 9pt">            Adjustment           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (298           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           <font style="font-size: 9pt">            Stock-based compensation expense           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            843,998           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            843,998           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           <font style="font-size: 9pt">            Net loss           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (6,373,948           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (6,093           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (6,380,041           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">            BALANCE - MARCH 31, 2020           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            9,366,873           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            9,368           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            121,426,563           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            (112,026,381           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            (132,124           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            9,277,426           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuances of common stock for cash    under at the market program           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            2,685,600           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            2,686           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            7,258,183           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            7,260,869           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Issuance of common shares upon    vesting of restricted stock units and net stock option exercise           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            98,124           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            98           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (132,625           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            (132,527           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           <font style="font-size: 9pt">            Stock-based compensation expense           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            779,421           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">            779,421           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           <font style="font-size: 9pt">            Net loss           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            –           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (7,886,709           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (4,790           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           <font style="font-size: 9pt">            (7,891,499           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td>           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">            BALANCE - MARCH 31, 2021           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            12,150,597           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            12,152           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            129,331,542           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            (119,913,090           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            (136,914           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-size: 9pt">            9,293,690           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidated financialstatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 70 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            5            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        AETHLON MEDICAL, INC. AND SUBSIDIARY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k31">        </a>        CONSOLIDATED STATEMENTS OF CASH FLOWS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        FOR THE YEARS ENDED MARCH 31, 2021 AND 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Cash flows from operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">           Net loss          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           (7,891,499          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           (6,380,041          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Adjustments to reconcile net loss to net cash used in operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Depreciation and amortization          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           39,939          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           26,366          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Gain on share for warrant exchanges          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (51,190          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Loss on debt extinguishment          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           447,011          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Stock based compensation          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           779,421          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           843,998          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Amortization of debt discount and deferred financing costs          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,287          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Non-cash rent expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,491          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           964          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Changes in operating assets and liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Accounts receivable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           57,647          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (206,729          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Prepaid expenses and other current assets          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (111,477          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (19,562          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Accounts payable and other current liabilities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           341,858          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (16,765          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Deferred revenue          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,849          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Due to related parties          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           6,813          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           28,053          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Net cash used in operating activities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (6,764,940          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (5,197,608          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Cash flows from investing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Purchases of property and equipment          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (59,881          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (151,665          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Net cash used in investing activities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (59,881          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (151,665          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Cash flows from financing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (132,527          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (40,938          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Principal repayments of notes payable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (992,591          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">           Net proceeds from the issuance of common stock and exercise of warrants          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           7,260,869          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           12,159,508          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Net cash provided by financing activities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           7,128,342          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           11,125,979          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Net increase in cash and restricted cash          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           303,521          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,776,706          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Cash and restricted cash at beginning of year          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,604,780          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           3,828,074          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Cash and restricted cash at end of year          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,908,301          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,604,780          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Supplemental disclosures of cash flow information:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Cash paid during the period for:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">           Interest          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           83,332          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Supplemental information of non-cash investing and financing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">           Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           98          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           12          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">           Issuance of common stock upon warrant exchanges          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           51,190          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">           Initial recognition of right-of-use lease asset and lease liability          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           228,694          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">           Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">           Cash and cash equivalents          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           9,861,575          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           9,604,780          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">           Restricted cash          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           46,729          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">           Cash and restricted cash          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,908,301          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,604,780          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidated financialstatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 71 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            6            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Aethlon Medical, Inc. and Subsidiary       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="k32">        </a>        Notes to Consolidated Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        ORGANIZATION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Aethlon Medical, Inc. and its subsidiary (collectively,“Aethlon”, the “Company”, “we” or “us”), is a medical technology company focused on developingproducts to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic devicedesigned to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulatingtumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies.The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a “Breakthrough Device” for two independentindications:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the treatment of life-threatening viruses that are not addressed with approved therapies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe the Hemopurifier can be a substantialadvance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth andspread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patients with advancedand metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinal cancersand other cancers. As we advance our clinical trials, we are in close contact with our clinical sites to navigate and assess the impactof the COVID-19 global pandemic on our clinical trials and current timelines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 4, 2019, the FDA approved our InvestigationalDevice Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients with head and neckcancer in combination with standard of care pembrolizumab (Keytruda).  The primary endpoint for the EFS, which will enroll 10 to12subjects at a single center, will be safety, with secondary endpoints including measures of exosome clearance and characterization, aswell as response and survival rates. This study, which is being conducted at the UPMC Hillman Cancer Center in Pittsburgh, PA, is in theprocess of recruiting and treating patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also believe the Hemopurifier can be a partof the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with analready approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat individuals infectedwith human immunodeficiency virus, or HIV, hepatitis-C, and Ebola.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Additionally,        <i>         in vitro,        </i>        the Hemopurifierhas been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunyavirus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and the reconstructed Spanishflu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government researchinstitutes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 17, 2020, the FDA approved a supplementto our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19in a New Feasibility Study.        <font style="background-color: white">         That study’s plan is to enroll up to 40 subjects at up to 20 centersin the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted to an intensive care unit, or ICU, and will haveacute lung injury and/or severe or life threatening disease, among other criteria. Endpoints for this study, in addition to safety, willinclude reduction in circulating virus as well as clinical outcomes (NCT # 04595903). The initial sites for this trial, Hoag MemorialHospital Presbyterian in Newport Beach, CA and Hoag Hospital – Irvine in Irvine, CA and Loma Linda Hospital in Loma Linda, CA, havecompleted clinical trial agreements, and have received IRB approval in the case of the Hoag hospitals, and are preparing to open for patientenrollment. Under Single Patient Emergency Use regulations, the Company has also treated two patients with COVID-19 with the Hemopurifier.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 72 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            7            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are also the majority owner of Exosome Sciences,Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Included amongESI’s activities is the advancement of a TauSome™ biomarker candidate to diagnose chronic traumatic encephalopathy, or CTE,in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than same age-group control subjects.Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for, a number of cancers. We consolidate ESI’sactivities in our consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Successful outcomes of human trials will alsobe required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents may expirebefore FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications and/orother patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition to the foregoing, we are monitoringclosely the impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety of ouremployees while continuing our operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic oncapital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and the resulting COVID-19pandemic on our timelines and future access to capital. We are continuing to monitor the spread of COVID-19 and its potential impact onour operations. The full extent to which the COVID-19 pandemic will impact our business, results of operations, financial condition, clinicaltrials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treatCOVID-19 and their effectiveness, as well as the economic impact on national and international markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our executive offices are located at 9635 GraniteRidge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800. Our website address is www.aethlonmedical.com.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our common stock is listed on the Nasdaq Capital Market under the symbol“AEMD.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        REVERSE STOCK SPLIT       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Effective October 14, 2019, the Company completeda 1-for-15 reverse stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one shareof common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stockremained at 30,000,000 shares. The accompanying consolidated financial statements and accompanying notes have been retroactively revisedto reflect such reverse stock split as if it had occurred on April 1, 2018. All shares and per share amounts have been revised accordingly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        LIQUIDITY AND GOING CONCERN       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management expects existing cash as of March 31,2021 and additional cash raised in June 2021 to be sufficient to fund the Company’s operations for at least twelve months from theissuance date of these consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        PRINCIPLES OF CONSOLIDATION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The accompanying consolidated financial statementsinclude the accounts of Aethlon Medical, Inc. and its majority-owned (80% ownership) and controlled subsidiary, Exosome Sciences, Inc.,or ESI. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has classified the (20%ownership) noncontrolling interests in ESI as part of consolidated net loss in the fiscal years ended March 31, 2021 and 2020 and includesthe accumulated amount of noncontrolling interests as part of equity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The losses at ESI during the fiscal year endedMarch 31, 2021 reduced the noncontrolling interests on our consolidated balance sheet by $4,790 from $(132,124) at March 31, 2020 to $(136,914)at March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 73 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            8            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        RISKS AND UNCERTAINTIES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We operate in an industry that is subject to intensecompetition, government regulation and rapid technological change. Our operations are subject to significant risk and uncertainties includingfinancial, operational, technological, regulatory, and including the potential risk of business failure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        USE OF ESTIMATES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We prepare our consolidated financial statementsin conformity with accounting principles generally accepted in the United States of America, or GAAP, which requires us to make a numberof estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilitiesat the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period.On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances.We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimatesunder different future conditions. We believe that the estimates and assumptions that are most important to the portrayal of our financialcondition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for theaccounting policies deemed to be most critical to us. These critical accounting estimates relate to revenue recognition, stock purchasewarrants issued with notes payable, beneficial conversion feature of convertible notes payable, impairment of intangible assets and longlived assets, stock compensation, deferred tax asset valuation allowance, and contingencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        CASH AND CASH EQUIVALENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Accounting standards define “cash and cashequivalents” as any short-term, highly liquid investment that is both readily convertible to known amounts of cash and so near theirmaturity that they present insignificant risk of changes in value because of changes in interest rates. For the purpose of financial statementpresentation, we consider all highly liquid investment instruments with original maturities of three months or less when purchased, orany investment redeemable without penalty or loss of interest to be cash equivalents. As of March 31, 2021 and 2020, we had no assetsthat were classified as cash equivalents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        CONCENTRATIONS OF CREDIT RISKS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Cash is maintained at one financial institutionin checking accounts. Accounts at this institution are secured by the Federal Deposit Insurance Corporation up to $250,000. Our March31, 2021 cash balances were approximately $9,712,000 over such insured amount.        <font style="background-color: white">         We do not believethat the Company is exposed to any significant risk with respect to its cash.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All of our accounts receivable at March 31, 2021 and all of our revenuein the fiscal years ended March 31, 2021 and 2020 related to our government contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Restricted Cash       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To comply with the terms of our new laboratory and office lease, wecaused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in favor of the landlord. The L/C is in lieuof a security deposit. In order to support the L/C, we agreed to have our bank withdraw $46,726 from our operating accounts and to placethat amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a long-term asset, on our balancesheet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        PROPERTY AND EQUIPMENT       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Property and equipment are stated at cost. Depreciationis computed using the straight-line method over the estimated useful lives of the related assets, which range from two to five years.Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale or retirement of propertyand equipment, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss included in the consolidatedstatements of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 74 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            9            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        INCOME TAXES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Deferred tax assets and liabilities are recognizedfor the future tax consequences attributable to the difference between the consolidated financial statements and their respective taxbasis. Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilitiesfor financial reporting purposes and the amounts reported for income tax purposes, and (b) tax credit carryforwards. We record a valuationallowance for deferred tax assets when, based on our best estimate of taxable income (if any) in the foreseeable future, it is more likelythan not that some portion of the deferred tax assets may not be realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        LONG-LIVED ASSETS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Long-lived assets are reviewed for impairmentwhenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the cost basis of a long-livedasset is greater than the projected future undiscounted net cash flows from such asset, an impairment loss is recognized. We believe noimpairment charges were necessary during the fiscal years ended March 31, 2021 and 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        LOSS PER SHARE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Basic loss per share is computed by dividing netincome available to common stockholders by the weighted average number of common shares outstanding during the period of computation.Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additionalcommon shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive.Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shareshave been excluded as their effect would be antidilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of March 31, 2021 and 2020, a total of 2,836,062and 2,072,492 potential common shares, consisting of shares underlying outstanding stock options, restricted stock units, warrants andconvertible notes payable were excluded as their inclusion would be antidilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SEGMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Historically, we operated in one segment thatwas based on our development of therapeutic devices. However, in the December 2013 quarter, we initiated the operations of ESI to developdiagnostic tests. As a result, we now operate in two segments, Aethlon for therapeutic applications and ESI for diagnostic applications(See Note 9).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We record discrete financial information for ESIand our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocatedto the ESI segment and to assess its performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        DEFERRED FINANCING COSTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Costs related to the issuance of debt are capitalizedas a deduction to our convertible notes based on the new accounting standard on imputation of interest, and amortized to interest expenseover the life of the related debt using the effective interest method. There was no amortization related to our deferred financing costsin the fiscal years ended March 31, 2021 and 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        REVENUE RECOGNITION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our revenues consist entirely of amounts earnedunder contracts and grants with the National Institutes of Health, or NIH. During the fiscal years ended March 31, 2021 and 2020, we recognizedrevenues totaling $659,104 and $650,187, respectively, under such contracts. We have concluded that these agreements are not within thescope of ASC Topic, 606, Revenue from Contracts with Customers, or Topic 606, as the NIH grants and contracts do not meet the definitionof a “customer” as defined by Topic 606. Prior to the effective date of ASC Topic 606, which for the Company was April 1,2018, we accounted for our grant/contract revenues under the Milestone Method as prescribed by the legacy guidance of ASC 605-28, RevenueRecognition – Milestone Method, or Milestone Method. In the absence of other applicable guidance under US GAAP, effective April1, 2018, we elected to continue to use the Milestone Method by analogy to recognize revenue under these grants/contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 75 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            10            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We identify the deliverables included within theseagreements and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whetherthe delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting,and the applicable revenue recognition criteria are applied to each of the separate units.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A milestone is an event having all of the followingcharacteristics:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (1) There is substantive uncertainty at the datethe arrangement is entered into that the event will be achieved. A vendor’s assessment that it expects to achieve a milestone doesnot necessarily mean that there is not substantive uncertainty associated with achieving the milestone.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (2) The event can only be achieved based in wholeor in part on either: (a) the vendor’s performance; or (b) a specific outcome resulting from the vendor’s performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (3) If achieved, the event would result in additionalpayments being due to the vendor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A milestone does not include events for whichthe occurrence is either: (a) contingent solely upon the passage of time; or (b) the result of a counterparty’s performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The policy for recognizing deliverable considerationcontingent upon achievement of a milestone must be applied consistently to similar deliverables.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The assessment of whether a milestone is substantiveis performed at the inception of the arrangement. The consideration earned from the achievement of a milestone must meet all of the followingfor the milestone to be considered substantive:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (1) The consideration is commensurate with either:(a) the vendor’s performance to achieve the milestone; or (b) the enhancement of the value of the delivered item or items as a resultof a specific outcome resulting from the vendor’s performance to achieve the milestone;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (2) The consideration relates solely to past performance;and       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        (3) The consideration is reasonable relative toall of the deliverables and payment terms (including other potential milestone consideration) within the arrangement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A milestone is not considered substantive if anyportion of the associated milestone consideration relates to the remaining deliverables in the unit of accounting (i.e., it does not relatesolely to past performance). To recognize the milestone consideration in its entirety as revenue in the period in which the milestoneis achieved, the milestone must be substantive in its entirety. Milestone consideration cannot be bifurcated into substantive and nonsubstantivecomponents. In addition, if a portion of the consideration earned from achieving a milestone may be refunded or adjusted based on futureperformance, the related milestone is not considered substantive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have recognized revenue under the followingthree government contracts/grants over the past two years:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Phase 2 Melanoma Cancer Contract        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On September 12, 2019, the National Cancer Institute,or NCI, part of the National Institutes of Health, or NIH, awarded to us an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled“A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring”, or the Award Contract. TheAward Contract amount is $1,860,561 and runs for the period from September 16, 2019 through September 15, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 76 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            11            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The work to be performed pursuant to this AwardContract focuses on melanoma exosomes. This work follows from our completion of a Phase I contract for the Topic 359 solicitation thatran from September 2017 through June 2018. Following on the Phase I work, the deliverables in the Phase II program involve the designand testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2021, wecompleted the milestones relevant to the first nine months of the fiscal year. As a result, we recorded $436,427 of government contractrevenue on the Phase 2 Melanoma Cancer Contract in the fiscal year ended March 31, 2021.   Of the total revenue recognized duringthe current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December 31, 2020and we recorded $318,578 which had previously been recognized as deferred revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the three month period ended March 31,2021, we did not complete all of the milestones relevant to that time period, as a result, we recorded $114,849 as deferred revenue relatedto the Phase 2 Melanoma Cancer Contract.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Breast Cancer Grant        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the fiscal year ended March 31, 2021, we completedand submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small Business Innovation Research,or SBIR, Phase I grant is “The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation,”or the Breast Cancer Grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This NCI Phase I grant period originally ran fromSeptember 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extension on this grant;through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors to work with us. Thosesubcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020, we have received all of thefunds allocated to the Breast Cancer Grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2021, werecorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestones related to theBreast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that our work under the grantprovided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount previously was recordedas deferred revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of March 31, 2021, we received all of the fundsallocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Subaward with University of Pittsburgh        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In 2020, we entered into a cost reimbursable subawardarrangement with the University of Pittsburgh in connection with an NIH contract entitled “Depleting Exosomes to Improve Responsesto Immune Therapy in HNNCC.” Our share of the award is $256,750. We recorded $34,233 of revenue related to this subaward in thefiscal year ended March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        STOCK-BASED COMPENSATION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Employee stock options and rights to purchaseshares under stock participation plans are accounted for under the fair value method. Accordingly, share-based compensation is measuredwhen all granting activities have been completed, generally the grant date, based on the fair value of the award. The exercise price ofoptions is generally equal to the market price of the Company’s common stock (defined as the closing price as quoted on the NasdaqCapital Market or OTCBB on the date of grant). Compensation cost recognized by the Company includes (a) compensation cost for all equityincentive awards granted prior to April 1, 2006, but not yet vested, based on the grant-date fair value estimated in accordance with theoriginal provisions of the then current accounting standards, and (b) compensation cost for all equity incentive awards granted subsequentto March 31, 2006, based on the grant-date fair value estimated in accordance with the provisions of subsequent accounting standards.We use a Binomial Lattice option pricing model for estimating fair value of options granted (see Note 5).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 77 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            12            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table summarizes share-based compensationexpenses relating to shares and options granted and the effect on loss per common share during the years ended March 31, 2021 and 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Years Ended          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left; padding-bottom: 1pt">           Vesting of Stock Options and Restricted Stock Units          </td>          <td style="width: 2%; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">           779,421          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: left">          </td>          <td style="width: 2%; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">           843,998          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Stock-Based Compensation Expense          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           779,421          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           843,998          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Weighted average number of common shares outstanding – basic and diluted          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           12,090,884          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           3,414,840          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Basic and diluted loss per common share          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (0.06          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (0.25          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We record share-based compensation expenses forawards of stock options and restricted stock units, or RSUs, under ASC 718, Share-based compensation, or ASC 718. For awards to non-employeesfor periods prior to the adoption of ASU 2018-07, Compensation-Stock Compensation: Improvements to Non-employee Share-Based Payment Accounting,on April 1, 2019, the Company had applied ASC 505-50, Equity – Equity-based payments to non-employees, or ASC 505-50. ASC 718 establishesguidance for the recognition of expenses arising from the issuance of share-based compensation awards at their fair value at the grantdate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We recognize share-based compensation expenserelated to stock options and SARs granted to employees, directors and consultants based on the estimated fair value of the awards on thedate of grant. We estimate the grant date fair value, and the resulting share-based compensation expense, for stock options that onlyhave service vesting requirements or performance-based vesting requirements without market conditions using the binomial lattice option-pricingmodel. The grant date fair value of the share-based awards with service vesting requirements is generally recognized on a straight-linebasis over the requisite service period, which is generally the vesting period of the respective awards. Determining the appropriate amountto expense for performance-based awards based on the achievement of stated goals requires judgment. The estimate of expense is revisedperiodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulativeimpact of any revisions is reflected in the period of change. If any applicable financial performance goals are not met, no compensationcost is recognized and any previously recognized compensation cost is reversed. For performance-based awards with market conditions, wedetermine the fair value of awards as of the grant date using a Monte Carlo simulation model.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We review share-based compensation on a quarterlybasis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiturerate for all expense amortization after March 31, 2007 is recognized in the period the forfeiture estimate is changed. The effect of forfeitureadjustments for the fiscal year ended March 31, 2020 was insignificant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        PATENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Patents include both foreign and domestic patents.We capitalize the cost of patents, some of which were acquired, and amortize such costs over the shorter of the remaining legal life ortheir estimated economic life, upon issuance of the patent. The unamortized costs of patents are subject to our review for impairmentunder our long-lived asset policy above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        STOCK PURCHASE WARRANTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We grant warrants in connection with the issuanceof common stock for cash. Warrants issued in connection with common stock for cash, if classified as equity, are considered issued inconnection with equity transactions and the warrant fair value is recorded to additional paid-in-capital.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 78 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            13            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE NOTESPAYABLE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The convertible feature of certain notes payableprovides for a rate of conversion that is below market value. Such feature is normally characterized as a Beneficial Conversion Feature,or BCF. We measure the estimated fair value of the BCF in circumstances in which the conversion feature is not required to be separatedfrom the host instrument and accounted for separately, and record that value in the consolidated financial statements as a discount fromthe face amount of the notes. Such discounts are amortized to interest expense over the term of the notes. As of March 31, 2021, we didnot have any unamortized debt discount relating to BCF.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        RESEARCH AND DEVELOPMENT EXPENSES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our research and development costs are expensedas incurred. We incurred approximately $2,072,000 and $927,000 of research and development expenses for the years ended March 31, 2021and 2020, respectively, which are included in various operating expenses in the accompanying consolidated statements of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        OFF-BALANCE SHEET ARRANGEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have not entered into any off-balance sheetarrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SIGNIFICANT RECENT ACCOUNTING PRONOUNCEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2018, the FASB issued ASU No. 2018-07,Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, or ASU No. 2018-07. ASU No. 2018-07expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU No.2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption is permitted. Entitiesmust apply the guidance retrospectively with a cumulative effect adjustment to retained earnings as of the beginning of the period ofadoption. The adoption of ASU No. 2018-07 on April 1, 2019 did not have a material impact on the Company's consolidated financial position,results of operations and related disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 1, 2019, the Company adopted ASC Topic842, Leases,” utilizing the alternative transition method allowed for under this guidance. As a result, the Company recorded leaseliabilities and right-of-use lease assets of $228,694 on its balance sheet as of April 1, 2019. The lease liabilities represent the presentvalue of the remaining lease payments of the Company’s corporate headquarters lease (see Note 13), discounted using the Company’sincremental borrowing rate as of April 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease liabilitiesand the cumulative difference between rent expense and amounts paid under its corporate headquarters lease. The Company also elected theshort-term lease recognition exemption for its laboratory lease. For the laboratory lease that qualified as short-term, the Company didnot recognize ROU assets or lease liabilities at adoption.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Topic 842 also allows lessees and lessors to electcertain practical expedients. The Company elected the following practical expedients:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Transitional practical expedients, which must be elected as a package and applied consistently to all of the Company’s leases:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            °           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company need not reassess whether any expired or existing contracts are or contain leases.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            °           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company need not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with the previous guidance will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with the previous guidance will be classified as finance leases).           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            °           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company need not reassess initial direct costs for any existing leases.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <!-- Field: Page; Sequence: 79 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            14            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Hindsight practical expedient. The Company elected the hindsight practical expedient in determining the lease term (that is, when considering lessee options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of the Company’s right-of-use assets.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        2. PROPERTY AND EQUIPMENT, NET       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Property and equipment, net, consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Furniture and office equipment, at cost          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           585,910          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           526,029          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Accumulated depreciation          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (424,934          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (385,545          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           160,976          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           140,484          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Depreciation expense for the fiscal years ended March 31, 2021 and2020 was $39,389 and $17,202, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        3. PATENTS, NET       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Patents, net consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Issued patents          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           157,442          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           157,442          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Accumulated amortization          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (154,691          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (154,141          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Issued patents, net of accumulated amortization          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2,751          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,301          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Patents pending          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           54,203          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           54,203          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Patents, net          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           56,954          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           57,504          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Amortization expense for our capitalized issuedpatents for each of the fiscal years ended March 31, 2021 and 2020 was $550 and $9,164, respectively. As several patents expired duringthe fiscal year ended March 31, 2020 and only one capitalized patent remains to be amortized, future amortization expense on patents isestimated to be approximately $550 per year based on the estimated life of the patent. The weighted average remaining life of our remainingcapitalized patent is approximately 5 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        4. CONVERTIBLE NOTES PAYABLE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We paid off our convertible notes in full in July2019. We also paid $83,332 of accrued interest during the fiscal year ended March 31, 2020. The following table shows the activity relatedto our convertible notes during the fiscal year ended March 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 83%; text-align: justify">           Total Convertible Notes Payable at March 31, 2019          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           992,591          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1pt">           Less Principal Payments in Cash on Convertible Notes During the Fiscal Year Ended March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (992,591          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: justify; padding-bottom: 2.5pt">           Total Convertible Notes Payable at March 31, 2020          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2020, werecorded interest expense of $23,759 related to the contractual interest rates of our convertible notes and interest expense of $30,287related to the amortization of the note discount, for a total interest expense of $54,046 related to our convertible notes in the fiscalyear ended March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 80 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            15            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        5. EQUITY TRANSACTIONS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        ISSUANCES OF COMMON STOCK AND WARRANTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Equity Transactions in the Fiscal Year Ended March 31, 2021.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Common Stock Sales Agreement with H.C. Wainwright        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 28, 2016, we entered into a Common StockSales Agreement, or the 2016 Agreement, with Wainwright, which established an at-the-market equity program pursuant to which we may offerand sell shares of our common stock from time to time as set forth in the 2016 Agreement. The 2016 Agreement provided for the sale ofshares of our common stock having an aggregate offering price of up to $12,500,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 30, 2020, we executed Amendment No. 2to the 2016 Agreement with Wainwright, effective as of the same date. The amendment provides that references in the 2016 Agreement tothe registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filed with the SECon March 19, 2020, declared effective by the SEC on March 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subject to the terms and conditions set forthin the 2016 Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales practicesto sell the shares under the 2016 Agreement from time to time, based upon our instructions. We provided Wainwright with customary indemnificationrights under the 2016 Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent of the gross proceedsper share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the 2016 Agreement, includingup to $50,000 of the fees and disbursements of their counsel. The 2016 Agreement will terminate upon the sale of all of the shares underthe 2016 Agreement, unless terminated earlier by either party as permitted under the 2016 Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of March 31, 2021, no further sales will bemade under the 2016 Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 22, 2021, we entered into an At the MarketOffering Agreement, or the Offering Agreement, with Wainwright as sales agent, pursuant to which we may offer and sell shares of our commonstock, from time to time as set forth in the Offering Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="background-color: white">         The offeringhas been registered under the        </font>        Securities Act of 1933, as amended, or Securities Act        <font style="background-color: white">         , pursuantto our shelf registration statement on Form        </font>        S-3 (Registration Statement No. 333-237269), as previously filed with the SECand declared effective on March 30, 2020. We filed a prospectus supplement, dated March 22, 2021, with the SEC in connection with theoffer and sale of the shares of common stock,        <font style="background-color: white">         pursuant to which we may offer and sell sharesof common stock having an aggregate offering price of up to $5,080,000 from time to time.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subject to the terms and conditions set forthin the Offering Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales practicesto sell the shares under the Offering Agreement from time to time, based upon our instructions. We provided Wainwright with customaryindemnification rights under the Offering Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percentof the gross proceeds per share sold. In addition, we agreed to reimburse Wainwright for certain specified expenses in connection withentering into the Offering Agreement. The Offering Agreement will terminate upon the written termination by either party as permittedthereunder.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Sales of the shares, if any, under the 2016 Agreement and the OfferingAgreement will be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the SecuritiesAct, including sales made by means of ordinary brokers’ transactions, including on the Nasdaq Capital Market, at market prices oras otherwise agreed with Wainwright. We have no obligation to sell any of the shares, and, at any time, we may suspend offers under the2016 Agreement and the Offering Agreement or terminate the Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the fiscal year ended March 31, 2021, we raised aggregate net proceedsof $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses, under the Agreement, through the saleof 2,685,600 shares at an average price of $2.70 per share of net proceeds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 81 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            16            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Restricted Stock Unit Grants to Non-EmployeeDirectors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In 2012, as amended through October 30, 2020,our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation for personsserving as non-employee directors of the Company. Under this program, each new director receives either stock options or a grant of restrictedstock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs are subject to vesting and representthe right to be issued on a future date shares of our common stock upon vesting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 3, 2020, pursuant to the terms of theCompany’s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directors granted RSUs to eachnon-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUs with a grant date fairvalue of $35,000, priced at the average of the closing prices for the five trading days ending on the date of grant, which was $1.41 pershare, so that the total number of RSUs to be granted to each non-employee director for fiscal year 2020 would be 24,822 shares of ourcommon stock.  On April 3, 2020, each eligible director was granted an RSU for 23,893 shares under the Company’s 2010Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under the 2010 Plan was not sufficient for eachdirector’s full RSU grant. The Compensation Committee also granted to each eligible director a contingent grant under our 2020 EquityIncentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU grants, or 929 RSU’s to each eligible director, contingentupon stockholder approval of the 2020 Plan at the Company’s 2020 Annual Meeting of Stockholders, or the Annual Meeting. These grantsare subject to vesting as follows: 50% of the RSUs subject to the grants will vest on December 31, 2020 and 50% of the RSUs will veston March 31, 2021, subject in each case to the continuous service of each director, through such vesting dates, as well as approval ofthe 2020 Plan by the stockholders at the Annual Meeting, which was obtained at the Annual Meeting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2020, 29,866 vested RSUs held by our non-employeedirectors were exchanged into the same number of shares of our common stock. All five non-employee directors elected to return 40% oftheir vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 11,947 of the vestedRSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2020, 29,866 vested RSUs held byour non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors electedto return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Also in September 2020, our stockholders approvedthe 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directors for a total of4,645 RSUs were considered effective and no longer contingent as of that date (See Note 9).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In December 2020, 32,189 vested RSUs held by ournon-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected to return40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 12,876 ofthe vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In March 2021, 32,189 vested RSUs held by ournon-employee directors were exchanged into the same number of shares of our common stock. All five directors elected to return 40% oftheir vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 12,875 of the vestedRSUs being cancelled in exchange for $26,136 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There were no vested RSUs outstanding as of March31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Restricted Stock Grant to Consultant        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In February 2021, our Board of directors approved a restricted stockgrant of 7,758 shares to an investor relations consultant. Those shares were valued at $18,000 based on our closing price on the dateof the approval. The shares will vest quarterly over a twelve month period and were issued under our 2020 Stock Plan. During the twelvemonths ended March 31, 2021, we recorded non-cash stock-based compensation expense of $1,500 related to this grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 82 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            17            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Equity Transactions in the Fiscal Year Ended March 31, 2020.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         December 2019 Public Offering        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 13, 2019, we entered into an underwritingagreement with H.C. Wainwright and Co., or Wainwright, as representative of the several underwriters named therein, relating to the publicoffering, issuance and sale of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stockin lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock, at a public offering price of$1.50 per share and common warrant. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with a commonwarrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, were immediately exercisable,and will expire five years from the date of issuance. The offering closed on December 17, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The gross proceeds of the December 2019 PublicOffering were approximately $5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses andexcluding the exercise of any common warrants and the underwriter's option to purchase additional securities. The net proceeds from theDecember 2019 Public Offering were $4,091,437.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subsequent to the completion of the December 2019Public Offering and prior to March 31, 2020, all of the holders of pre-funded warrants exercised their pre-funded warrants in full.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the event of a Fundamental Transaction (a transferof ownership of the Company as defined in the common warrants issued in the December 2019 Public Offering) within our control, the holdersof the unexercised common stock warrants exercisable for $1.50 per share, are entitled to receive cash consideration equal to a Black-Scholes valuation,as defined in the warrant. If such Fundamental Transaction is not within our control, the warrant holders would only be entitled to receivethe same form of consideration (and in the same proportion) as the holders of our common stock, hence these warrants are classified asa component of permanent equity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         January 2020 Registered Direct Offering andPrivate Placement        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 16, 2020, we engaged Wainwright toact as our exclusive placement agent in connection with the private placement and a concurrent registered direct offering, or together,the Offering, of an aggregate of 1,885,378 shares of our common stock at a purchase price per share of $2.00, or the Shares, for aggregategross proceeds to us of approximately $3.77 million, before deducting fees payable to Wainwright and other estimated offering expensespayable by us. We also entered into a securities purchase agreement, or the Purchase Agreement with certain institutional investors, orthe Purchasers, pursuant to which we agreed to sell and issue to the Purchasers warrants, or the Purchase Warrants, to purchase up toan aggregate of 942,689 shares of our common stock, or the Purchase Warrant Shares. We agreed to pay Wainwright a cash fee of 6.0% ofthe aggregate gross proceeds in the Offering, excluding the proceeds, if any, from the exercise of the Purchase Warrants. We paid Wainwrightan additional 1.0% of the aggregate gross proceeds in the Offering as a management fee and also paid Wainwright an additional $70,000for certain expenses in connection with the Offering. In addition, Wainwright received placement agent warrants on substantially the sameterms as the Purchase Warrants in an amount equal to 3.0% of the aggregate number of Shares sold in the offering, or 56,561 shares ofCommon Stock, at an exercise price of $2.50 per share and a term expiring on January 17, 2025, or the Placement Agent Warrants, and theshares of common stock issuable thereunder, or the Placement Agent Warrant Shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 22, 2020, the Company closed the Offeringand issued the Purchase Warrants to the Purchasers. The Purchase Warrants are exercisable immediately at an exercise price of $2.75 pershare and will expire five and one-half years from the issuance date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The net proceeds from the January 2020 RegisteredDirect Offering and Private Placement were $3,364,878.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 83 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            18            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Common Stock Sales Agreement with H.C. Wainwright        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the fiscal year ended March 31, 2020, we raisedaggregate net proceeds of $896,031 (net of $27,896 in commissions to H.C. Wainwright and $5,929 in other offering expenses) under thisAgreement through the sale of 161,149 shares at an average price of $5.56 per share of net proceeds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Warrant Exercises        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In fiscal year ended March 31, 2020, investorsthat participated in the December 2019 public offering exercised 2,700,000 warrants for aggregate cash proceeds to us of $3,807,162.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Restricted Stock Unit Grants to Non-EmployeeDirectors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In 2012, as amended through October 30, 2020,our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation for personsserving as non-employee directors of the Company. Under this program, each new director receives either stock options or a grant of restrictedstock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs are subject to vesting and representthe right to be issued on a future date shares of our common stock for upon vesting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In April 2019, pursuant to the Non-Employee DirectorsCompensation Program, we issued RSUs with a value of $35,000, in accordance with the terms of the plan, to each of our non-employee directors,as the stock-based compensation element of their overall directors’ compensation, for the fiscal year ending March 31, 2020. Thosegrants were based on the closing price of our common stock on the grant date, or $14.25 per share, resulting in 2,456 RSUs being issuedto each of our five non-employee directors, for a total of 12,280 RSUs. All of the RSUs were subject to vesting in equal quarterly installmentson June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2020, 12,280vested RSUs held by our outside directors were exchanged into the same number of shares of our common stock. As four of our five independentdirectors elected to return 40% of their RSUs in exchange for cash in order to pay their withholding taxes on the share issuances, 3,926of the RSUs were cancelled and we paid $11,230 in cash to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, during the fiscal year ended March31, 2020, 8,793 vested RSUs then held by our executive officers were exchanged into the same number of shares of our common stock. Asour executives elected to net settle a portion of their RSU’s in exchange for the Company paying the related withholding taxes onthe share issuance, 4,657 of the RSUs were cancelled and we issued a net 4,136 shares to our executives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There were no vested RSUs outstanding as of March31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Common Stock for Warrant Cancellation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2020, weagreed with seven accredited investors to issue an aggregate of 3,992 shares of our common stock to these investors in exchange for thecancellation of outstanding warrants then held by the investors to purchase an aggregate of 39,900 shares of our common stock. We measuredthe fair value of the shares issued and the fair value of the warrants exchanged for those shares and recorded a gain of $51,190 on thoseexchanges based on the changes in fair value between the instruments exchanged.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <!-- Field: Page; Sequence: 84 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            19            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        WARRANTS:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We did not issue any warrants during the fiscalyear ended March 31, 2021. During the fiscal year ended March 31, 2020, we issued 4,432,585 warrants in association with our December2019 Public Offering and our January 2020 Registered Direct Financing and associated private placement (see Note 6). All of those warrantshad a five year term and had exercise prices as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid">           Financing          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Warrants Issued          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center; border-bottom: Black 1pt solid">           Exercise Price          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 68%; text-align: left">           December 2019 Public Offering – Investors’ Warrants          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           3,333,334          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 13%; text-align: right">           $1.50          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           December 2019 Public Offering – Placement Agents’ Warrants          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: right">           $1.875          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           January 2020 Registered Direct – Investors’ Warrants          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           942,689          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: right">           $2.75          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           January 2020 Registered Direct – Placement Agents’ Warrants          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           56,562          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: right">           $2.50          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Based on the above assumptions, we valued the warrants issued duringthe fiscal year ended March 31, 2020 as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The 999,251 warrants issued in our January 2020 Registered Direct Financing were valued at $2,388,776 and we classified that fair value as equity.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The 3,433,334 warrants issued in our December 2019 public offering were valued at $3,021,334 and we classified that fair value as equity.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A summary of the aggregate warrant activity for the years ended March31, 2021 and 2020 is presented below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Year Ended March 31,          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Warrants          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Warrants          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 40%; text-align: left">           Outstanding, beginning of year          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 11%; text-align: right">           2,021,368          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           5.21          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 11%; text-align: right">           342,992          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 11%; text-align: right">           27.00          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Granted          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,432,585          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.79          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Adjustment for reverse split          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           73          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Exercised          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (2,700,000          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.50          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           Cancelled/Forfeited          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (29,395          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           91.17          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (54,282          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           91.23          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Outstanding, end of year          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,991,973          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           5.23          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           2,021,368          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           5.21          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Exercisable, end of year          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,991,973          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           5.23          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           2,021,368          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           5.21          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 2.5pt">           Weighted average estimated fair value of warrants granted          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1.22          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following outlines the significant weighted average assumptionsused to estimate the fair value of warrants granted in the fiscal year ended March 31, 2020 utilizing the Binomial Lattice option pricingmodel:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: center">           Fiscal Year Ended          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: center">           March 31, 2020          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 83%; text-align: left">           Risk free interest rate          </td>          <td style="width: 2%">          </td>          <td style="width: 15%; text-align: center">           1.57% - 1.71%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Average expected life          </td>          <td>          </td>          <td style="text-align: center">           5 years          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Expected volatility          </td>          <td>          </td>          <td style="text-align: center">           148.6% - 233.0%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Expected dividends          </td>          <td>          </td>          <td style="text-align: center">           None          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 85 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            20            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The expected volatility was based on the historic volatility. The expectedlife of options granted was based on the “simplified method” as described in the SEC’s guidance due to changes in thevesting terms and contractual life of current option grants compared to our historical grants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The detail of the warrants outstanding and exercisable as of March31, 2021 is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="4" style="text-align: center; border-bottom: Black 1pt solid">           Warrants Outstanding          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: right">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           Warrants Exercisable          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; border-bottom: Black 1pt solid">           Range of           <br/>           Exercise Prices          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Number           <br/>           Outstanding          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Remaining           <br/>           Life (Years)          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Number           <br/>           Outstanding          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 15%; text-align: center">           $2.75 or Below          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           1,732,585          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 15%; text-align: right">           3.80          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           2.23          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           1,732,585          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           2.23          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: center">           $16.50 - $59.25          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           249,985          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: right">           1.43          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           23.24          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           249,985          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           23.24          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: center; padding-bottom: 1pt">           $64.50 - $135.00          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,403          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: right; padding-bottom: 1pt">           0.58          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           $          </td>          <td style="padding-bottom: 1pt; text-align: right">           77.62          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           9,403          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           $          </td>          <td style="padding-bottom: 1pt; text-align: right">           77.62          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,991,973          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="text-align: right; padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,991,973          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        STOCK-BASED COMPENSATION:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        2020 EQUITY INCENTIVE PLAN       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2020, our stockholders approvedthe adoption of the 2020 Plan, to provide incentives to attract, retain and motivate employees, directors and consultants, whose presentand potential contributions are important to our success, by offering them an opportunity to participate in our future performance throughawards of options, the right to purchase common stock, stock bonuses and stock appreciation rights and other awards. We initially authorizeda total of 1,842,556 common shares for issuance under the 2020 Plan pursuant to stock option grants, RSUs or other forms of stock-basedcompensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        2010 STOCK INCENTIVE PLAN       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In August 2010, we adopted the 2010 Stock IncentivePlan, to provide incentives to attract, retain and motivate employees, directors and consultants, whose present and potential contributionsare important to our success, by offering them an opportunity to participate in our future performance through awards of options, theright to purchase common stock, stock bonuses and stock appreciation rights and other awards. We initially authorized a total of 4,667common shares for issuance under the 2010 Stock Incentive Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 26, 2016, our Board of Directors approvedan amendment to the 2010 Stock Incentive Plan to increase the total number of shares of common stock authorized for issuance under theplan to 211,333 shares, subject to amendment of our Articles of Incorporation to increase our authorized common stock. On March 29, 2016,at which our stockholders approved the Amended 2010 Stock Incentive Plan and an amendment of our Articles of Incorporation to increaseour authorized common stock to 30,000,000 shares. On March 31, 2016, we filed a Certificate of Amendment to our Articles of Incorporationto effect the increase in our authorized common stock. As a result of such amendment, the Amended 2010 Stock Incentive Plan became effectiveon March 31, 2016.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Effective October 14, 2019, we completed a 1-for-15reverse stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of commonstock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock remainedat 30,000,000 shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        No future grants will be made under the 2010 StockIncentive Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 86 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            21            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        2012 NON-EMPLOYEE DIRECTORS COMPENSATION PROGRAM       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In 2012, as amended through October 30, 2020,our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation for personsserving as non-employee directors of the Company. Under this program, each new director receives either stock options or a grant of restrictedstock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs are subject to vesting and representthe right to be issued on a future date shares of our common stock upon vesting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 3, 2020, pursuant to the terms of theCompany’s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directors granted RSUs to eachnon-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUs with a grant date fairvalue of $35,000, priced at the average of the closing prices for the five trading days ending on the date of grant, which was $1.41 pershare, so that the total number of RSUs to be granted to each non-employee director for fiscal year 2020 would be 24,822 shares of ourcommon stock. On April 3, 2020, each eligible director was granted an RSU for 23,893 shares under the Company’s 2010Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under the 2010 Plan was not sufficient for eachdirector’s full RSU grant. The Compensation Committee also granted to each eligible director a contingent grant under our 2020 EquityIncentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU grants, or 929 RSU’s to each eligible director, contingentupon stockholder approval of the 2020 Plan at the Company’s 2020 Annual Meeting of Stockholders, or the Annual Meeting. These grantswere subject to vesting as follows: 50% of the RSUs subject to the grants vested on December 31, 2020 and 50% of the RSUs vested on March31, 2021, subject in each case to the continuous service of each director, through such vesting dates, as well as approval of the 2020Plan by the stockholders at the Annual Meeting, which was obtained at the Annual Meeting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2020, 29,866 vested RSUs held by our non-employeedirectors were exchanged into the same number of shares of our common stock. All five non-employee directors elected to return 40% oftheir vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 11,947 of the vestedRSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2020, 29,866 vested RSUs held byour non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors electedto return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Also in September 2020, our stockholders approvedthe 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directors for a total of4,645 RSUs were considered effective and no longer contingent as of that date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In December 2020, 32,189 vested RSUs held by ournon-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected to return40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 12,876 ofthe vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In March 2021, 32,189 vested RSUs held by ournon-employee directors were exchanged into the same number of shares of our common stock. All five directors elected to return 40% oftheir vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting in 12,875 of the vestedRSUs being cancelled in exchange for $26,136 in aggregate cash proceeds to those independent directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There were no vested RSUs outstanding as of March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 87 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            22            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        STAND-ALONE GRANTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From time to time our Board of Directors grantscommon stock or options to purchase common stock or warrants exercisable to common stock to selected officers, employees and consultantsas equity compensation to such persons on a stand-alone basis outside of any of our formal stock plans. The terms of these grants areindividually negotiated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        STOCK OPTION ACTIVITY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From February 2020 through May 2020, our compensationcommittee granted options to purchase 521,476 shares of our common stock that were contingent upon stockholder approval of the 2020 Plan.Upon approval of the 2020 Plan at the Annual Meeting, these option grants were considered effective and no longer contingent as of thatdate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The 2020 Plan approved by our stockholders atthe 2020 Annual Meeting of Stockholders, authorizes up to 1,842,556 shares for issuance pursuant to stock option grants, RSUs or otherforms of stock-based compensation. No future grants will be made under the 2010 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Effective as of October 30, 2020, we issued anoption to purchase  239,122 shares of our common stock pursuant to the 2020 Plan to our Chief Executive Officer, in connection withthe appointment of Dr. Fisher as our Chief Executive Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In connection with the Separation Agreement andpursuant to Dr. Rodell’s employment agreement with the Company, the vesting was accelerated on 50% of outstanding and unvested optionsto purchase shares of our common stock held by Dr. Rodell as of the Separation Date of October 30, 2020, such that the accelerated stockoptions were fully vested and exercisable as of the Separation Date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In December 2020, Dr. Rodell elected to net exercisea portion of his stock options. As a result, we issued Dr. Rodell an aggregate of 15,896 shares of our common stock and we paid the estimatedwithholding taxes of $34,209 related to the net exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Options outstanding that were vested as of March31, 2021 and options that are expected to vest subsequent to March 31, 2021 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Number of           <br/>           Shares          </td>          <td style="padding-bottom: 1pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1pt">          </td>          <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Remaining           <br/>           Contractual           <br/>           Term in           <br/>           Years          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 49%">           Vested          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           58,954          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           20.06          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 15%; text-align: right">           7.35          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Expected to vest          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           785,135          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt; text-align: left">           $          </td>          <td style="padding-bottom: 1pt; text-align: right">           1.79          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="text-align: right; padding-bottom: 1pt">           9.19          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 2.5pt">           Total          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           844,089          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="text-align: right; padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 88 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            23            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following is a summary of the stock optionsoutstanding at March 31, 2021 and 2020 and the changes during the years then ended:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Year Ended March 31,          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Options          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Options          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           Weighted           <br/>           Average           <br/>           Exercise Price          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 32%; text-align: left">           Outstanding, beginning of year          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           51,124          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           44.12          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 13%; text-align: right">           59,111          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           56.85          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Granted          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,011,860          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.71          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Exercised          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (15,896          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.28          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">           Cancelled/Forfeited          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (202,999          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           6.76          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (7,987          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           138.75          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Outstanding, end of year          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           844,089          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           3.07          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           51,124          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           44.12          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Exercisable, end of year          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           58,954          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           20.06          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           25,197          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           70.08          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; padding-bottom: 2.5pt">           Weighted average estimated fair value of options granted          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1.58          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The detail of the options outstanding and exercisable as of March 31,2021 is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td colspan="9" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Options Outstanding           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Options Exercisable           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exercise Prices           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Number            <br/>            Outstanding           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted            <br/>            Average            <br/>            Remaining            <br/>            Life (Years)           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted            <br/>            Average            <br/>            Exercise            <br/>            Price           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Number            <br/>            Outstanding           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted            <br/>            Average            <br/>            Exercise            <br/>            Price           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 1%">          </td>          <td style="width: 18%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $1.28 - $1.68           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            479,814           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9.25 years           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.34           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            --           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $2.45 - $2.52           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            329,766           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9.00 years           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.50           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            24,445           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.45           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $18.75 - $142.50           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            34,509           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.88 years           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32.53           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            34,509           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32.53           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            844,089           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58,954           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We recorded stock-based compensation expense relatedto restricted stock unit issuances and to options granted totaling $779,421 and $843,998 for the fiscal years ended March 31, 2021 and2020, respectively. These expenses were recorded as stock compensation included in payroll and related expenses in the accompanying consolidatedstatement of operations for the years ended March 31, 2021 and 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our total stock-based compensation for fiscalyears ended March 31, 2021 and 2020 included the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Year Ended          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Vesting of restricted stock units          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           175,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           678,028          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Vesting of restricted shares issued for services          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,500          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           –          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Vesting of stock options          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           602,921          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           165,970          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Stock-Based Compensation          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           779,421          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           843,998          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 89 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            24            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We review share-based compensation on a quarterlybasis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjustingthe forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeitureadjustments for the fiscal year ended March 31, 2021 was insignificant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 31, 2021, our outstanding stock optionshad no intrinsic value since the closing price on that date of $2.03 per share was below the weighted average exercise price of our outstandingstock options.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At March 31, 2021, there was approximately $2,668,000of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of4.44 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        6. RELATED PARTY TRANSACTIONS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        DUE TO RELATED PARTIES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Historically, certain of our officers and otherrelated parties have advanced us funds, agreed to defer compensation and/or paid expenses on our behalf to cover working capital deficiencies.There were no such related party transactions during the fiscal year ended March 31, 2021, except that we had accrued unpaid Board feesof $52,000 owed to our outside directors as of March 31, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Due to related parties were comprised of the following items:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Accrued board fees          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           52,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           69,750          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Accrued vacation          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           66,520          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           41,957          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total due to related parties          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           118,520          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           111,707          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        7. OTHER CURRENT LIABILITIES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Other current liabilities were comprised of the following items:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           March 31, 2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Accrued separation expenses for former executive (see Note 11)          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           284,270          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           –          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Accrued professional fees          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           477,366          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           472,420          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total other current liabilities          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           761,636          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           472,420          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        8. INCOME TAXES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the years ended March 31, 2021 and 2020, wehad no income tax expense due to our net operating losses and 100% deferred tax asset valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At March 31, 2021 and 2020, we had net deferredtax assets as detailed below. These deferred tax assets are primarily composed of capitalized research and development costs and tax netoperating loss carryforwards. Due to uncertainties surrounding our ability to generate future taxable income to realize these assets,a 100% valuation allowance has been established to offset the net deferred tax assets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 90 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            25            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Significant components of our net deferred taxassets at March 31, 2021 and 2020 are shown below:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           YEAR ENDED MARCH 31,          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Deferred tax assets:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 66%; text-align: left">           Capitalized research and development          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           3,442,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           3,442,000          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net operating loss carryforwards            <sup>             1            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           19,921,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           18,384,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Stock compensation          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,399,000          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,181,000          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Total deferred tax assets          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24,762,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,007,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 1pt">           Total deferred tax liabilities          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Net deferred tax assets          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           24,762,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           23,007,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Valuation allowance for deferred tax assets          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (24,762,000          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (23,007,000          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Net deferred tax assets          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At March 31, 2021, we had tax net operating loss carryforwards forfederal and state purposes approximating $77 million and $60 million, portions of which began to expire in the year 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The provision for income taxes on earnings subject to income taxesdiffers from the statutory federal rate for the years ended March 31, 2021 and 2020 due to the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 66%; text-align: left">           Income taxes (benefit) at federal statutory rate of 21.00%          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           (1,657,000          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           (1,340,000          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           State income tax, net of federal benefit          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (551,000          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (446,000          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Tax effect on non-deductible expenses and credits          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           122,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           True up items          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           25,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           42,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Expiration of net operating loss carryforwards          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           427,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           222,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Change in valuation allowance          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,755,000          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           1,400,000          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           –          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        ______________       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        (1) Pursuant to Internal Revenue Code Section 382, use of our tax netoperating loss carryforwards may be limited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        ASC 740, “Income Taxes”, clarifiesthe accounting for uncertainty in income taxes recognized in an entity's financial statements, and prescribes recognition thresholds andmeasurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740,the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-notto be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less thana 50% likelihood of being sustained. Additionally, ASC 740 provides guidance on derecognition, classification, interest and penalties,accounting in interim periods, disclosure and transition. Our practice is to recognize interest and/or penalties related to income taxmatters in income tax expense. During the years ended March 31, 2021 and 2020, we did not recognize any interest or penalties relatingto tax matters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At and for the years ended March 31, 2021 and2020, management does not believe the Company has any uncertain tax positions. Accordingly, there are no unrecognized tax benefits at March31, 2021 or March 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our tax returns remain open for examination bythe applicable authorities, generally 3 years for federal and 4 years for state. We are currently not under examination by any taxingauthorities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 91 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            26            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        9. SEGMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We operate our businesses principally throughtwo reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic businessactivities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discretefinancial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisionsabout resources to be allocated to the ESI segment and to assess its performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Aethlon’s revenue is generated primarilyfrom government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead tothe ESI segment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following tables set forth certain information regarding our segments:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">           Fiscal Years Ended March 31,          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2021          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Revenues:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 66%">           Aethlon          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           659,104          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 2%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 13%; text-align: right">           650,187          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Revenues          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           659,104          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           650,187          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Operating Losses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (7,865,967          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (5,899,523          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (23,952          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (30,465          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Operating Loss          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (7,889,919          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (5,929,988          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Net Losses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (7,867,547          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (6,349,576          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (23,952          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (30,465          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Net Loss Before Non-Controlling Interests          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (7,891,499          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           (6,380,041          </td>          <td style="padding-bottom: 2.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Cash:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           9,861,378          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           9,604,583          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           197          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           197          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Cash          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,861,575          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           9,604,780          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Total Assets:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           10,668,719          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           10,387,489          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           197          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           197          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Assets          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,668,916          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           10,387,686          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Capital Expenditures:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           59,881          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           151,665          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Capital Expenditures          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           59,881          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           151,665          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left">           Depreciation and Amortization:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           39,939          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           26,366          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Depreciation and Amortization          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           39,939          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           26,366          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Interest Expense:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td>           Aethlon          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1,580          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           54,232          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt">           ESI          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           –          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total Interest Expense          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           1,580          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           54,232          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 92 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            27            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        10. SUBSEQUENT EVENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management has evaluated events subsequent toMarch 31, 2021 through the date that the accompanying consolidated financial statements were filed with the Securities and Exchange Commissionfor transactions and other events which may require adjustment of and/or disclosure in such financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        SALES UNDER ATM FACILITY       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2021, we raised aggregate net proceedsunder the Agreement described above of $4,947,785, net of $126,922 in commissions to Wainwright and $2,154 in other offering expense throughthe sale of 626,000 shares of our common stock at an average price of $7.90 per share of net proceeds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        REGISTERED DIRECT FINANCING       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2021, we sold an aggregate of 1,380,555shares of our common stock at a purchase price per share of $9.00, for aggregate gross proceeds to us of approximately $12.425 million,before deducting fees payable to Maxim Group LLC, the placement agent and other offering expenses. These shares were sold through a securitiespurchase agreement with certain institutional investors, The shares were issued pursuant to an effective shelf registration statementon Form S-3, which was originally filed with the SEC on March 19, 2020, and was declared effective on March 30, 2020 (File No. 333-237269)and a prospectus supplement thereunder.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        WARRANT EXERCISES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2021, pursuant to the exercise of outstandingwarrants to purchase 531,167 shares of our common stock, we received proceeds in the amount of $820,938 from institutional investors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Also in June 2021, pursuant to the exercise of874,664 outstanding warrants on a cashless basis, we issued 675,554 shares of our common stock. The difference of 199,110 shares of commonstock issuable pursuant to the warrants were cancelled.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        STOCK OPTION EXERCISE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2021, a former employee paid us $22,969to exercise 9,375 stock options.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         RSU GRANTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 1, 2021, pursuant to the terms of theCompany’s 2012 Non-Employee Directors Compensation Program, as amended, or the Directors Plan, the Compensation Committee of theBoard granted RSUs under the Company’s 2020 Plan to each non-employee director of the Company. The Director’s Plan providesfor a grant of $50,000 worth of RSUs at the beginning of each fiscal year, priced at the average for the closing prices for the five dayspreceding and including the date of grant, or $2.06 per share as of April 1, 2021. Each eligible director was granted an RSU in the amountof 24,295 shares under the 2020 Plan. The RSU’s are subject to vesting in four equal quarterly installments on June 30, September30, December 31, 2021, and March 31, 2022, subject to the recipient's continued service with the Company on each such vesting date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        CONTINGENT BONUS AWARDS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to the terms of the Executive Employment Agreement, datedOctober 30, 2020, between the Company and Charles J. Fisher, Jr., M.D., or the Employment Agreement, the Company’s Chief ExecutiveOfficer, Dr. Fisher is entitled to a cash bonus equal to 50% of his annual base salary upon achievement of certain qualified events, ora Qualifying Event, as set forth in the Employment Agreement, as well as a stock option grant of a number of shares of common stock, pursuantto the 2020 Plan, such that Dr. Fisher’s equity holdings in the Company after the additional grant will equal 3% of the Company,on a fully diluted basis. Based on the market capitalization of the Company and the Company’s recent registered direct financing,the Company believes, subject to approval of the Compensation Committee of the Company’s Board of Directors, that in June 2021 aQualifying Event has occurred and that Dr. Fisher has earned the cash bonus award in the amount of $215,000 and an additional stock optiongrant under the terms of the Employment Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 93 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            28            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        11. COMMITMENTS AND CONTINGENCIES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        CONTRACTUAL OBLIGATIONS AND COMMITMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have had the following material changes toour contractual obligations and commitments outside the ordinary course of business during the fiscal year ended March 31, 2021:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SEPARATION AGREEMENT       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 30, 2020, we entered into a SeparationAgreement with Timothy Rodell, M.D., our former Chief Executive Officer, or the Separation Agreement. Under this agreement, we agreedto pay Dr. Rodell a total of $444,729 and to cover his medical insurance costs over a twelve-month period that began on November 1, 2020,all in accordance with the terms of his employment agreement with the Company. We also paid Dr. Rodell accrued vacation in the amountof $20,260 in November 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The total expense accrued at March 31, 2021 relatingto the Separation Agreement, was $284,270 (see Note 7).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        LEASE COMMITMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We currently lease approximately 2,600 squarefeet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego        <i>         ,        </i>        California 92123 under a 39-month gross plusutilities lease that commenced on December 1, 2014 and expires on August 31, 2021. The current rental rate under the lease extension is$8,265 per month.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also rent approximately 1,700 square feet oflaboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $6,148 per month on a one-year leasethat originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extension running from December1, 2020 through the completion date of our construction of our planned new laboratory space which is adjacent to our current laboratory.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Rent expense, which is included in general andadministrative expenses, approximated $192,000 and $178,000 for the fiscal years ended March 31, 2021 and 2020, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Future minimum lease payments under the Granite Ridge Lease as of March31, 2021, are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="width: 83%; padding-bottom: 1pt">           April 1, 2021 through August 31, 2021          </td>          <td style="width: 2%; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">           $          </td>          <td style="width: 13%; border-bottom: Black 1pt solid; text-align: right">           43,670          </td>          <td style="width: 1%; padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1pt">           Less: discount          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (1,127          </td>          <td style="padding-bottom: 1pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">          <td style="text-align: left; padding-bottom: 2.5pt">           Total lease liability          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; text-align: right">           42,543          </td>          <td style="padding-bottom: 2.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the fiscal year ended March 31, 2020, weadopted ASU Topic 842 on April 1, 2019 utilizing the alternative transition method allowed for under this guidance. As a result, we recordedlease liabilities and right-of-use lease assets of $228,694 on our balance sheet as of April 1, 2019. The lease liabilities representthe present value of the remaining lease payments of our corporate headquarters lease, discounted using our incremental borrowing rateas of April 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease liabilities and the cumulative differencebetween rent expense and amounts paid under its corporate headquarters lease. We also elected the short-term lease recognition exemptionfor its laboratory lease. For the laboratory lease that qualified as short-term, we did not recognize right-of-use assets or lease liabilitiesat adoption.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 94 -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            29            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In December 2020, we entered into an agreementto lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space. The agreement carries a term of 63months and we will commence paying rent when we take occupancy of those spaces, which is expected to occur in the third quarter of 2021.Upon taking occupancy of the space, we will record lease liabilities and right-of-use lease assets related to this agreement on our balancesheet. We estimate that the present value of the contractual payments under the lease agreement to be approximately $806,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, the new lease agreement requiredus to post a standby letter of credit in favor of the landlord in the amount of $46,726 in lieu of a security deposit. We arranged forour bank to issue the standby letter of credit in the fiscal year ended March 31, 2021 and transferred a like amount to a restricted certificateof deposit which secured the bank’s risk in issuing that letter of credit. We have classified that restricted certificate of depositon our balance sheet as restricted cash.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        LEGAL MATTERS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From time to time, claims are made against usin the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertaintiesand unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or moreproducts or engaging in other activities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The occurrence of an unfavorable outcome in anyspecific period could have a material adverse effect on our results of operations for that period or future periods. We are not presentlya party to any pending or threatened legal proceedings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 95; Options: Last -->       <div style="margin-top: 6pt; margin-bottom: 6pt">        <table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 33%">           </td>           <td style="width: 34%; text-align: center">            F-            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->            30            <!-- Field: /Sequence -->           </td>           <td style="width: 33%; text-align: right">           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>